Signal Transduction in Cancer Metastasis
Cancer Metastasis – Biology and Treatment VOLUME 15 Series Editors Richard J. Ablin, Ph.D., University of Arizona, College of Medicine and The Arizona Cancer Center, AZ, U.S.A. Wen G. Jiang, M.D., Wales College of Medicine, Cardiff University, Cardiff, U.K. Advisory Editorial Board Harold F. Dvorak, M.D. Phil Gold, M.D., Ph.D. Danny Welch, Ph.D. Hiroshi Kobayashi, M.D., Ph.D. Robert E. Mansel, M.S., FRCS. Klaus Pantel, Ph.D. Recent Volumes in this Series Volume 7: DNA Methylation, Epigenetics and Metastasis Editor: Manel Esteller ISBN 978-1-4020-3641-8 Volume 8: Cell Motility in Cancer Invasion and Metastasis Editor: Alan Wells ISBN 978-1-4020-4008-3 Volume 9: Cell Adhesion and Cytoskeletal Molecules in Metastasis Editors: Anne E. Cress and Raymond B. Nagle ISBN 978-1-4020-5128-X Volume 10: Metastasis of Prostate Cancer Editors: Richard J. Ablin and Malcolm D. Mason ISBN 978-1-4020-5846-2 Volume 11: Metastasis of Breast Cancer Editors: Robert E. Mansel, Oystein Fodstad and Wen G. Jiang ISBN 978-1-4020-5866-7 Volume 12: Bone Metastases: A Translational and Clinical Approach Editors: Dimitrios Kardamakis, Vassilios Vassiliou and Edward Chow ISBN 978-1-4020-9818-5 Volume 13: Lymphangiogenesis in Cancer Metastasis Editors: Steven A. Stacker and Marc G. Achen ISBN 978-90-481-2246-2 Volume 14: Metastasis of Colorectal Cancer Editors: Nicole Beauchemin and Jacques Huot ISBN 978-90-481-8832-1 Volume 15: Signal Transduction in Cancer Metastasis Editors: Wen-Sheng Wu and Chi-Tan Hu ISBN 978-90-481-9521-3
Signal Transduction in Cancer Metastasis Edited by
Wen-Sheng Wu Associated Professor, Institute of Medical Biotechnology, College of Medicine, Tzu-Chi University, Hualien, Taiwan and
Chi-Tan Hu Associated Professor, Research Center for Hepatology, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan
123
Editors Dr. Wen-Sheng Wu Institute of Medical Biotechnology College of Medicine Tzu-Chi University Chung-Yang Rd, Sec 3 701 970 Hualien Taiwan R.O.C.
[email protected]
Dr. Chi-Tan Hu Research Center for Hepatology Department of Medicine Buddhist Tzu-Chi General Hospital Chung-Yang Rd, Sec 3 707 907 Hualien Taiwan R.O.C.
[email protected]
ISSN 1568-2102 ISBN 978-90-481-9521-3 e-ISBN 978-90-481-9522-0 DOI 10.1007/978-90-481-9522-0 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2010936099 © Springer Science+Business Media B.V. 2010 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
Cancer remains to be one of the most devastating diseases world wide since long ago. The poor prognosis of cancer is largely due to metastasis. Metastasis is often depicted as a multistage process in which malignant cells spread from the primary locus to distant organs via circulation. Whereas genetic alterations were suggested to be essential for transformation of primary tumor cells into metastatic phenotype, epigenetic events are equally important, which may be triggered by metastatic factors wherever in the primary tumor locus, blood circulation and the secondary loci. Signal transductions initiated by the metastatic factors are responsible for mediating the molecular and cellular processes leading to metastasis. Blockade of the relevant molecular pathways is one of the most effective strategies for prevention of tumor metastasis. Clinical trials are underway with promising outcome. In this book, we take comprehensive review in regard with this exciting field of cancer research. Chapter 1 takes a brief overview of recently identified signal mechanisms for each step of tumor metastasis including the initiation stage, intravasation, anti-anoikis in blood circulation, homing, extravasation and final survival in the metastatic site. Chapter 2 makes a completed review for the molecular and cellular events involved in initiation of metastasis. Especially, the signaling mechanisms for mediating tumor progression induced by some important metastatic factors are described. In Chapters 3 and 4, the central roles of MAPK and its downstream effectors MAPKAPK play in each step of tumor metastasis are well delineated. Chapter 5 further describes detailedly about how Grb2 and other adaptor proteins, upstream of MAPK cascade, contribute to metastasis. In Chapter 6, the role of reactive oxygen species (ROS) in tumor progression are highlighted. Moreover, the potential contribution of ROS to cross talk between major signaling cascades that lead to sustained MAPK activation are proposed in Chapter 7. Chapter 8 takes an insight into the signaling mechanisms for dynamic trafficking and turnover of focal adhesion proteins in regulation of traction and retraction forces, which are needed for cell locomotion and invasion. Chapter 9 describes the involvement of Notch signaling pathway which is not only essential for embryonic development but also plays important role in tumor progression. Chapter 10 reviewed the recently identified cancer- and metastasis-initiating cells involved in tumor progression. Especially, signal pathways that are frequently deregulated in cancer stem/progenitor cells
v
vi
Preface
during cancer progression are highlighted. Chapter 11 describes the role of lipid rafts, a special component within membrane lipid domain, in signal transduction triggered by growth factor receptors leading to tumor metastasis. Finally, Chapters 12, Chapters 13, and Chapters 14 present the signaling pathways responsible for metastatic progression of specific tumors including ovarian cancer, uveal melanoma and hepatoma, respectively. We thank all the contributors of every Chapter in the book including Jia-Ru Wu, Chi-Tan Hu, Laure Voisin, Stéphanie Duhamel, Sylvain Meloche, Alexey Shiryaev, Marijke Van Ghelue, Ugo Moens, Alessio Giubellino, Praveen R. Arany, Moulay A. Alaoui-Jamali, Krikor Bijian, Panagiota Toliopoulos, Pingyu Zhang, Patrick A. Zweidler-McKay, Murielle Mimeault, Surinder K. Batra, Samir Kumar Patra, Lydia W. T. Cheung, Carman K. M. Ip, Alice S. T. Wong, Cécile Laurent, Jérôme Couturier, Xavier Sastre-Garau, Laurence Desjardins, Emmanuel Barillot, Sophie Piperno-Neumann, Simon Saule and Rajagopal N. Aravalli. We hope this book might stimulate more cancer biologists to emphasize this field which benefits devising more effective molecular targeting strategies for prevention of cancer metastasis. Hualien, Taiwan
Wen-Sheng Wu Chi-Tan Hu
Contents
1 Overview of Signal Transduction in Tumor Metastasis . . . . . . . Wen-Sheng Wu and Jia-Ru Wu
1
2 Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor via Multiple Signal Pathways . . . . . . . . . . Wen-Sheng Wu and Chi-Tan Hu
9
3 The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis . . . . . . . . . . . . . . . . . . . . . . Laure Voisin, Stéphanie Duhamel, and Sylvain Meloche
25
4 Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis . . . . . . . . . . . . . . . . . . . . . . . . . Alexey Shiryaev, Marijke Van Ghelue, and Ugo Moens
41
5 Grb2 and Other Adaptor Proteins in Tumor Metastasis . . . . . . Alessio Giubellino and Praveen R. Arany
77
6 The Role of ROS Signaling in Tumor Progression . . . . . . . . . . Wen-Sheng Wu and Jia-Ru Wu
103
7 Signal Cross Talks for Sustained MAPK Activation and Cell Migration Mediated by Reactive Oxygen Species: The Involvement in Tumor Progression . . . . . . . . . . . . . . . . Chi-Tan Hu, Jia-Ru Wu, and Wen-Sheng Wu 8 Insights into the Dynamics of Focal Adhesion Protein Trafficking in Invasive Cancer Cells and Clinical Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Moulay A. Alaoui-Jamali, Krikor Bijian, and Panagiota Toliopoulos 9 Notch Signaling in Cancer Metastasis . . . . . . . . . . . . . . . . . Pingyu Zhang and Patrick A. Zweidler-McKay
119
137
157
vii
viii
10
11
Contents
New Concepts on the Critical Functions of Cancerand Metastasis-Initiating Cells in Treatment Resistance and Disease Relapse: Molecular Mechanisms, Signaling Transduction Elements and Novel Targeting Therapies . . . . . . . Murielle Mimeault and Surinder K. Batra Involvement of Lipid Rafts in Growth Factor Receptors-Mediated Signaling for Cancer Metastasis . . . . . . . . Samir Kumar Patra
12
Cadherin-Catenin Signaling in Ovarian Cancer Progression . . . . Lydia W.T. Cheung, Carman K.M. Ip, and Alice S.T. Wong
13
PTP4A3, a Signal Molecule Deregulated in Uveal Melanoma Metastasis . . . . . . . . . . . . . . . . . . . . . . . . . Cécile Laurent, Jérôme Couturier, Xavier Sastre-Garau, Laurence Desjardins, Emmanuel Barillot, Sophie Piperno-Neumann, and Simon Saule
14
175
209 225
255
Signal Transduction Pathways Involved in Hepatocarcinogenesis and Metastasis of Hepatoma . . . . . . . . Rajagopal N. Aravalli
265
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
283
Contributors
Moulay A. Alaoui-Jamali Faculty of Medicine, Departments of Medicine and Oncology, Segal Cancer Center of the Jewish General Hospital, McGill University, Montreal, Canada,
[email protected] Praveen R. Arany Harvard University, 49 Oxford Street, 415 ESL, Cambridge, MA 02138, USA,
[email protected] Rajagopal N. Aravalli Department of Radiology, University of Minnesota Medical School, Minneapolis, MN 54455, USA,
[email protected] Emmanuel Barillot Institut Curie, Paris F-75248, France; INSERM, U900, Paris F-75248, France; Ecoles des Mines ParisTech, Fontainebleau F-77300, France,
[email protected] Surinder K. Batra Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha 68198-5870, Nebraska, USA,
[email protected] Krikor Bijian Faculty of Medicine, Departments of Medicine and Oncology, Segal Cancer Center of the Jewish General Hospital, McGill University, Montreal, Canada,
[email protected] Lydia W.T. Cheung School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong,
[email protected] Jérôme Couturier Département Biologie des Tumeurs, Institut Curie, Hôpital, Paris F-75248, France,
[email protected] Laurence Desjardins Département d’Ophtalmologie, Institut Curie, Hôpital, Paris F-75248, France,
[email protected] Stéphanie Duhamel Institut de Recherche en Immunologie et Cancérologie, Université de Montréal, Montreal, Quebec H3C 3J7, Canada; Departments Molecular Biology, Université de Montréal, Montreal, Quebec H3C 3J7, Canada,
[email protected]
ix
x
Contributors
Xavier Sastre-Garau Département Biologie des Tumeurs, Institut Curie, Hôpital, Paris F-75248, France,
[email protected] Marijke Van Ghelue Department of Medical Genetics, University Hospital of North Norway, N-9038 Tromsø, Norway,
[email protected] Alessio Giubellino National Cancer Institute, National Institutes of Health, 10 Center Drive, Bldg. 10-CRC, Rm. 1W-5832, Bethesda, MD 20892, USA,
[email protected] Chi-Tan Hu Research Center for Hepatology, Department of Medicine, Buddhist Tzu Chi General Hospital, School of Medicine and Graduate Institute of Clinical Medicine, Tzu Chi University, Hualien, Taiwan,
[email protected];
[email protected] Carman K.M. Ip School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong,
[email protected] Cécile Laurent Institut Curie, Paris F-75248, France; CNRS, UMR3347, Orsay F-91405, France; INSERM, U1021, Orsay F-91405, France; Université Paris-Sud 11, Orsay F-91405, France; INSERM, U900, Paris F-75248, France; Ecoles des Mines ParisTech, Fontainebleau F-77300, France,
[email protected] Sylvain Meloche Institut de Recherche en Immunologie et Cancérologie, Université de Montréal, Montreal, Quebec H3C 3J7, Canada; Departments of Pharmacology, Université de Montréal, Montreal, Quebec H3C 3J7, Canada; Departments Molecular Biology, Université de Montréal, Montreal, Quebec H3C 3J7, Canada,
[email protected] Murielle Mimeault Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha 68198-5870, Nebraska, USA,
[email protected] Ugo Moens Medical Faculty, Department of Medical Biology, University of Tromsø, N-9037 Tromsø, Norway,
[email protected] Sophie Piperno-Neumann Département D’oncologie Médicale, Institut Curie, Hôpital, Paris F-75248, France,
[email protected] Samir Kumar Patra Department of Life Science, National Institute of Technology, Rourkela, Orissa, India,
[email protected];
[email protected] Simon Saule Institut Curie, Paris F-75248, France; CNRS, UMR3347, Orsay F-91405, France; INSERM, U1021, Orsay F-91405, France,
[email protected] Alexey Shiryaev Medical Faculty, Department of Medical Biology, University of Tromsø, N-9037 Tromsø, Norway,
[email protected]
Contributors
xi
Panagiota Toliopoulos Faculty of Medicine, Departments of Medicine and Oncology, Segal Cancer Center of the Jewish General Hospital, McGill University, Montreal, Canada,
[email protected] Laure Voisin Institut de Recherche en Immunologie et Cancérologie, Université de Montréal, Montreal, Quebec H3C 3J7, Canada,
[email protected] Alice S.T. Wong School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong,
[email protected] Jia-Ru Wu Department of Medical Technology, Graduate Institute of Medicine, Tzu Chi University, Hualien, Taiwan,
[email protected] Wen-Sheng Wu Department of Medical Technology, Graduate Institute of Medicine, Tzu Chi University, Hualien, Taiwan; Institute of Medical Biotechnology, College of Medicine, Tzu Chi University, Hualein, Taiwan,
[email protected] Pingyu Zhang Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA,
[email protected] Patrick A. Zweidler-McKay Division of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA,
[email protected]
Chapter 1
Overview of Signal Transduction in Tumor Metastasis Wen-Sheng Wu and Jia-Ru Wu
Abstract The signal transductions mediating each stage of tumor metastasis are gradually unraveled. A lot of growth factors and cytokines secreted in the tumor environment may trigger epithelial–mesenchymal transition (EMT), migration and invasion of the primary tumor via integration of multiple pathways. Further, TGF-β1/Smad signaling may switch the tumor cell from cohesive to single cell movement that facilitates the invasive tumor to enter blood circulation (intravasation). In the circulation, tumor cell may survive in an anchorage independent manner by developing signals counteracting the apoptotic machinery responsible for anoikis. In the extravasation stage, tumor cells that express higher selectin ligands my bind to platelet via P-selectin which facilitates the formation of tumor-platelet-leukocyte emboli. The arrested emboli may promote the E-selectinmediated activation of ERK(MAPK) to trigger transendothelial passage. Moreover, various chemokine receptor/ligand pairs such as CCR4/CXCL12 can act to achieve organ preference in metastatic colonization. Distinct signaling pathways may also be responsible for determining the destination of tumor cells. The final change faced by the metastatic tumor cells is how to survive in the secondary loci. Recently, Srcmediated signaling was found to be responsible for metastatic breast cancer cells to survive in the bone marrow microenvironment. Blockade of the aforementioned molecular pathways for each stage of tumor progression could be one of the most effective strategies for prevention of metastasis. Keywords Tumor metastasis · Signal transductions · EMT · Migration · Invasion · Intravasation · Extravasation · MAPK · TGF-β · Src
W.-S. Wu (B) Department of Medical Technology, Tzu Chi-University, No. 701, Chung Yang Rd, Sec. 3, Hualien 970, Taiwan, Republic of China e-mail:
[email protected]
W.-S. Wu, C.-T. Hu (eds.), Signal Transduction in Cancer Metastasis, Cancer Metastasis – Biology and Treatment 15, DOI 10.1007/978-90-481-9522-0_1, C Springer Science+Business Media B.V. 2010
1
2
W.-S. Wu and J.-R. Wu
Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . Signaling for the Initiation of Tumor Metastasis . . . . . . . . . . . Signaling for Intravasation . . . . . . . . . . . . . . . . . . . . Signaling for Tumor Progression in Circulation . . . . . . . . . . . 1.4.1 Anti-Anoikis of Circulating Tumor Cell . . . . . . . . . . . 1.4.2 Signaling for Extravasation . . . . . . . . . . . . . . . . . 1.5 Signaling for Homing and Survival of the Tumor in the Metastatic Loci 1.6 Conclusion and Perspective . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.1 1.2 1.3 1.4
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
2 2 3 3 3 5 5 6 7
1.1 Introduction Metastasis is a complicated pathological processes consisting of several stages [1]. Initially, the primary tumor cell exhibit epithelial–mesenchymal transition (EMT) followed by migration and invasion to the surrounding tissues. Subsequently, the tumor cells may penetrate the endothelium to enter blood circulation (intravasation). The tumor cells that survive in the blood may move out of blood vessel (extravasation) and finally proliferate in the secondary loci. In addition, angiogenesis may support the growth of the tumor cells. During these processes, the tumor cells may be endowed with increasingly metastatic capability by a lot of environmental factors. The signal transductions mediating each stage of tumor metastasis are gradually unraveled and will be briefly overviewed in this Chapter.
1.2 Signaling for the Initiation of Tumor Metastasis The microenvironment in the primary tumor locus is rather complicated. A variety of the stromal cells, inflammatory cells, and tumor cell itself may interact with each other to constitute a microenvironment in favor of tumor progression. A lot growth factors and cytokines including hepatocyte growth factor (HGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), stromal cell-derived factor (SDF) and transforming growth factor-β (TGFβ), which can be secreted during tumor-stromal and/or tumor-macrophage interactions [2–4], can trigger EMT, migration and invasion of primary tumor cells. Various signal pathways such as Ras-Raf-MAPK [5], PKC [6], PI3K/AKT [7, 8] and integrinrelated pathway [9] were involved in these processes. A detailed review for tumor progression at this stage can be found in next Chapter.
1
Overview of Signal Transduction in Tumor Metastasis
3
1.3 Signaling for Intravasation It is a general concept that most of the metastatic factors in the tumor environment can trigger the invasion of tumor cell not only toward the surrounding tissue but also across the endothelium into blood circulation. However, the detailed cellular and molecular events of intravasation are not clearly established yet. A recent study [10] suggested that the modes of cell movement determine whether tumor cells can penetrate blood vessel. During spreading of breast cancer cells, collective and single-celled movement can be observed. Interestingly, single cell motility is essential for tumor cells to enter blood circulation (intravasation) whereas cells restricted to collective movement were capable of lymphatic invasion. Moreover, TGF-β1, one of the most important metastatic factors, may switch tumor cells from cohesive to single cell motility through Smad 2/4-dependent pathway. This may lead to upregulation of various signal components such as EGFR, Nedd9, M-RIP, FARP and RhoC facilitating intravasation. The involvement of MAPK-dependent pathway in intravasation of breast tumor cell was implicated in a recent study for Raf kinase inhibitory protein (RKIP), a negative regulator of MAPK [11]. The Ras-Raf-1-MEK-ERK cascade initiated by Erb2 may relieve the negative regulation of a chromatin remodeling protein HMGA2 by let-7 microRNA, resulting in activation of pro-invasive and prometastatic genes, including Snail. The blockade of Ras-MAPK-Snail axis by RIPK suppressed intravasation of breast tumor cell.
1.4 Signaling for Tumor Progression in Circulation Following intravasation, tumor cells undertake a dangerous voyage in the hostile environment of the blood circulation. Importantly, anchorage-independent growth (anti-anoikis) is required for survival of tumor cell in circulation, mediated by specific signal pathways.
1.4.1 Anti-Anoikis of Circulating Tumor Cell 1.4.1.1 The Basic Concept for Anoikis Cell to matrix adhesion is a key factor for cellular homeostasis and disruption of such interaction has adverse effects on cell survival. It leads to a specific type of apoptosis known as ‘‘anoikis’’. The molecular mechanisms governing anoikis have been well reviewed [12]. Essentially, loss of the integrin signaling is the most critical cause for anoikis. Various type of integrins can sense mechanical forces arising from the matrix, converting these stimuli to diverse signals responsible for modulating a variety of cellular behaviors including adhesion, migration and survival
4
W.-S. Wu and J.-R. Wu
[for review 13]. Without adhesion on ECM, the integrin-mediated survival signaling will be lost and the cells enter apoptosis. The BH3-only family proteins such as Bid and Bim are the most critical pro-apoptotic proteins executing anoikis. Bim is sequestered in the dynein complex until the loss of integrin engagement resulting in its release and translocation to mitochondria. Activation of Bid and Bim rapidly promote the assembly of channel protein Bax-Bak oligomers within the outer mitochondrial membrane followed by release of cytochrome C. Cytochrome C may trigger the caspase cascade resulting in activation of the effector caspase3. Caspase-3 then cleaves a lot of molecules including signaling molecules like focal adhesion-kinase (FAK), Cas, and paxillin, which are key components in integrin-mediated signal transduction for adhesive survival. 1.4.1.2 Signal Mechanism for Anti-Anoikis of Tumor Cell in Circulation In the circulation, tumor cell may escape anoikis by several ways. The basic strategy is to develop a constitutive survival signals counteracting the apoptotic machinery responsible for anoikis. Changing the Pattern of Integrin Expression One way for cancer cells to avoid anoikis is to change the pattern of integrin expression so that the incorrect survival signals may be received continually. Several integrins (α1β1, α2β1, α3β1, α5β1, α6β1, α6β4, and αvβ3) have profound impact on cell survival without engagement with ECM [14]. One recent report [15] demonstrated that overexpression of αvβ3 in tumor cell can substantially increase anchorage-independent cell survival in vitro and metastasis in vivo. These effects were mediated by the activation of the non-receptor tyrosine kinase Src and its down stream signal components including ERK and PI3K/Akt , which are capable of phosphorylating Bim, leading to its proteasome-dependent degradation [12]. Constituting Autocrine Growth Factor Loops Another way for the tumor cell to achieve anti-anoikis is constituting the autocrine growth factor loops which sustainedly activates the survival pathways. For example, overexpression of TrkB, a neurotrophic tyrosine kinase receptor, greatly activates the PI3K/Akt pathway and Twist-Snail transcriptional apparatus rendering the tumor cell anoikis-resistant [16, 17]. The Role of ROS Reactive oxygen species (ROS) are recently recognized to be critical mediators of signal transduction. The role of ROS in tumor migration and invasion is detailed in Chapter 6. Interestingly, Giannoni et al. [18] demonstrated that ROS, produced upon integrin engagement and activation of the small GTPase Rac-1, play essential role in transducing the pro-survival signal for protection from anoikis. In particular,
1
Overview of Signal Transduction in Tumor Metastasis
5
ROS are responsible for the redox mediated activation of Src, leading to the ligand-independent trans-phosphorylation of EGFR. The redox-dependent EGFR activation switches both ERK and PKB/Akt pathways, resulting in degradation of Bim.
1.4.2 Signaling for Extravasation Extravasation of cancer cells, also called diapedesis, is the passage of circulating tumor cells out of blood vessel. Essentially, tumor cells ought to adhere to the endothelium followed by trans-endothelial migration and invasion. This process can be facilitated by interaction of the tumor cells with circulating platelets and leukocytes, resulting in the formation of emboli capable of binding to endothelial cells. Platelet is the most adhesive component in the blood. One of the previous reports demonstrated that activation of αvβ3 integrin promoted the interaction of metastatic human breast cancer cells with platelet and supported adhesion of cancer cell within the vasculature [19]. On the other hand, leukocytes are the most invasive blood cell, capable of infiltrating to inflammatory tissue loci when ever needed. It was proposed that extravasation of tumor cell follows that of infiltration of leukocytes [20, 21]. Moreover, selectin, which is the adhesion receptors on the platelet and endothelium are essential mediator of extravasation [for review 22]. Tumor cells express higher selectin ligands for binding to platelet via P-selectin (on the platelet) which facilitate the formation of tumor-platelet-leukocyte emboli. The arrested emboli may then induce signals that further promote the E-selectin (on the endothelium)mediated transendothelial passage including the opening of endothelial cell junctions [23]. The intracellular signal pathway mediating extravasation has not been fully established. Two important signal molecules, Rho GTPases [24] and MAPK [23] which are well known to be critical for regulation of cytoskeletal rearrangements and motility, were found to be involved. Tremblay et al. indicated that E-selectindependent paracellular extravasation requires the activation of ERK(MAPK) downstream of E-selectin [23]. In addition, the critical role of p38 (MAPK) in adhesion of tumor cell to endothelial cells [25] was demonstrated by Matsuo et al. They found platelets and lung endothelial cells of p38α(+/−) mice were poorly bound to tumor cells compared with those of WT mice suggesting that p38alpha plays an important role in the early step of extravasation.
1.5 Signaling for Homing and Survival of the Tumor in the Metastatic Loci The final stages of tumor metastasis include the homing of tumor cell to specific organs. The underlying mechanisms for this intriguing process are largely unexplored but are highlighted in several recent studies. One plausible mechanism
6
W.-S. Wu and J.-R. Wu
for organ preference in metastatic colonization is the communication between the circulating tumor cells and the target host tissue via interaction of chemokine receptors and their ligands. This is reminiscent of the homing process of circulating leukocytes and stem cells to specific organs. Of the chemokine receptor/ligand pairs involved in the homing of metastatic tumors, CCR4 and CXCL12 are the most well studied [for review 26, 27]. The intracellular signaling for the organ preference in metastatic colonization has not been clearly delineated yet. One recent study [28] raised the possibility that distinct signaling pathways may determine the destination of metastatic tumor cells. They found that human prostate cancer cell DU145 can be triggered by oncogenic Ras for metastasis to multiple organs, including bone and brain. Interestingly, Raf/ERK, one of the effector pathways of Ras, determine colonization of the brain, whereas the other that mediated by RalGEF is responsible for metastasis to bone, the most common organ site for prostate cancer metastasis. After reaching the target tissue, the final challenge faced by the tumor cells is how to survive in the secondary loci, which is totally different from where they are derived. This may be revealed by variable latency in metastasis of different tumors. In some types of cancer, metastasis occurs soon after a primary tumor develops, whereas in others it emerges years after the primary tumor is removed. It has also been proposed that in order to achieve the final stage of metastasis, primary tumors must produce factors that induce the formation of a suitable and appropriate environment in the organ where metastatic cells will be seeded. Recently, the signal mechanisms that support the survival of disseminated breast cancer cells in bone marrow was investigated by Zhang et al. [29]. In a clinical approach, they found association between Src pathway and late-onset bone metastasis. In vitro studies further demonstrated that Src was required for the prosurvival pathway triggered by CXCL12 coupled with its G protein-coupled receptor CXCR4 and down stream effector AKT. On the other hand, c-Src signaling may confer resistance to the apoptotic effect of TNF-related apoptosis-inducing ligand (TRAIL). Both pathways support the survival of breast cancer cell in the bone marrow microenvironment.
1.6 Conclusion and Perspective Metastasis is a long process during which the tumor cell develops increasingly metastatic potential in order not only to migrate and invasion but also to face the subsequent challenges for surviving in unfavorable environments outside of their original loci. The signal transduction triggered by the metastatic factors in the primary locus, blood circulation and the secondary loci mediate each stage of tumor progression (Fig. 1.1). Blockade of the relevant molecular pathway could be one of the most effective strategies for prevention of tumor metastasis. Clinical trials are underway with promising outcomes as will be mentioned in the later Chapters of this book.
1
Overview of Signal Transduction in Tumor Metastasis
7
Phenotypical Changes in Tumor Microenvironment HGF/cMet; TGFβ/Smad; Integrin and other signals
Invasion
Mi
gra
tio
n
Primary Tumor EM
Intravasation
T
(Single Cell Movement)
TGF-β1 / Smad
An
ti-a
noi
kis
Altered integrin expression, autocrine growth factor loops integrin-Rac-ROS signaling
Survive in secondary loci Src-mediated signaling
Extravasation E-selectin-mediated activation of MAPK
Fig. 1.1 Signal pathway triggering tumor metastasis. In the tumor environment phenotypical changes including epithelial–mesenchymal transition (EMT), migration and invasion can be triggered by TGF-β, HGF-cMet, integrin-mediated signaling. In the intravasation stage, TGF-β1/Smad signaling may switch the tumor cell from cohesive to single cell movement facilitating the invasive tumor to enter blood circulation. In the circulation, tumor cell may survive in an anchorage independent growth fashion by developing several signaling strategy (as indicated) to counteract the apoptotic machinery responsible for anoikis. In the extravasation stage, tumor cells may develop E-selectin-mediated ERK (MAPK) signals that trigger the E-selectin-mediated transendothelial passage. Finally, Src-mediated signaling was responsible for metastatic cancer cells (such as breast cancer) to survive in the secondary loci (such as bone marrow microenvironment)
References 1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679–695. 2. Nakamura T, Matsumoto K, Kiritoshi A, et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997; 57: 3305–3313. 3. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br. J. Cancer 2001; 85: 255–260. 4. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 2000; 6: 3530–3535. 5. Leicht DT, Balan V, Kaplun A, et al. Raf kinases: function, regulation and role in human cancer. Biochim. Biophys. Acta 2007; 1773: 1196–1212. 6. Oka M, Kikkawa U. Protein kinase C in melanoma. Cancer Metastasis Rev. 2005; 24: 287–300. Review.
8
W.-S. Wu and J.-R. Wu
7. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumor 2004; 90: 2–8. Review. 8. Sheng S, Qiao M, Pardee AB. Metastasis and AKT activation. J. Cell Physiol. 2009; 218: 451–454. Review. 9. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010; 10: 9–22. Review. 10. Giampieri S, Manning C, Hooper S, et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 2009; 11: 1287–1296. 11. Dangi-Garimella S, Yun J, Eves EM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009; 28: 347–358. 12. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 2008; 76: 1352–1364. 13. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004; 5: 816–826. 14. Alahari SK, Reddig PJ, Juliano RL. Biological aspects of signal transduction by cell adhesion receptors. Int. Rev. Cytol. 2002; 220: 145–184. 15. Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin αvα3–c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat. Med. 2009; 15: 1163–1170. 16. Lagadec C, Meignan S, Adriaenssens E, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009; 28: 1960–1970. 17. Smit MA, Geiger TR, Song JY, et al. A Twist-Snail axis critical for TrkB-induced epithelialmesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol. Cell Biol. 2009; 29: 3722–3737. 18. Giannoni E, Buricchi F, Grimaldi G, et al. Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival. Cell Death Differ. 2008; 15: 867–878. 19. Felding-Habermann B, O’Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. PNAS 2001; 98: 1853–1858. 20. Petri B, Bixel MG. Molecular events during leukocyte diapedesis. FEBS J. 2006; 273: 4399–4407. 21. Johnston B, Butcher EC. Chemokines in rapid leukocyte adhesion triggering and migration. Semin. Immunol. 2002; 14: 83–92. 22. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis 2008; 27: 19–30. 23. Tremblay PL, Huot J, Auger FA. Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res. 2008; 68: 5167–5176. 24. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin. Exp. Metastasis 2008; 25: 335–344. 25. Matsuo Y, Amano S, Furuya M, et al. Involvement of p38alpha mitogen-activated protein kinase in lung metastasis of tumor cells. J. Biol. Chem. 2006; 281: 36767–36775. 26. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metastasis 2008; 25: 345–356. Review. 27. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267: 226–244. 28. Yin J, Pollock C, Tracy K, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol. Cell Biol. 2007; 27: 7538–7550. 29. Zhang XHF, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Srcdependent survival signals. Cancer Cell 2009; 16: 67–78.
Chapter 2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor via Multiple Signal Pathways Wen-Sheng Wu and Chi-Tan Hu
Abstract In the tumor microenvironment, the primary tumor cells may recruit and interact with stromal cells and inflammatory cells including macrophages, mast cells and neutrophiles. A great multitude of growth factors, cytokines, chemokines and growth/motility factors may be secreted by aforementioned cells in the microenvironment to trigger epithelial-mesenchymal transition (EMT), migration and invasion of tumor cells and facilitate neovasculation and modifications of the ECM. Multiple signal pathway induced by various metastatic factors may be integrated to establish an amplified and sustained driving force for tumor progression. The first part of this review focus on the cellular and molecular processes occurring in the microenvironment that are fundamental for triggering the initiation stage of tumor metastasis. In the second part, altered signal pathways induced by several critical metastatic factors such as HGF, TGFβ and that elicited by integrin-ECM engagement are delineated. In the future, more effective cancer therapy can be developed by targeting the critical signal molecules responsible for the initiation stage of tumor metastasis. Keywords Tumor metastasis · Signal transductions · EMT · Migration · Invasion · MAPK · HGF · TGF-β · Integrin
Contents 2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.2 Phenotypical Changes of Tumor Cells in the Initial Stage of Tumor Metastasis: EMT, Migration and Invasion of Primary Tumor . . . . . . . . . . 2.2.1 Epithelial–Mesenchymal Transition: the Initiation Step of Tumor Metastasis 2.2.2 Microenvironment in the Primary Tumor Locus . . . . . . . . . . . . .
.
10
. . .
10 10 12
C.-T. Hu (B) Division of Gastroenterology, Department of Medicine, Buddhist Tzu Chi Hospital and University, Section 3, No.707, Chung-Yan Road, Hualien, Taiwan e-mail:
[email protected];
[email protected]
W.-S. Wu, C.-T. Hu (eds.), Signal Transduction in Cancer Metastasis, Cancer Metastasis – Biology and Treatment 15, DOI 10.1007/978-90-481-9522-0_2, C Springer Science+Business Media B.V. 2010
9
10
W.-S. Wu and C.-T. Hu
2.3 Signal Transduction Triggered by Metastatic Factors Within Microenvironment 2.3.1 HGF/c-Met . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.3.2 TGF-β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.3.3 The Integrin-ECM Engagement . . . . . . . . . . . . . . . . . . . 2.4 Conclusion and Perspective . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . .
. . . . . .
14 14 15 17 19 20
2.1 Introduction Cancer metastasis, or dissemination of the primary tumor to distant body sites, is one of the most complicated pathological processes [1]. It is also the major determinant of mortality in cancer patients. The critical steps in tumor metastasis include (a) detachment of the primary cancer cells followed by migration and invasion to adjacent tissues, (b) penetrating the extracellular matrix (ECM) and blood vessels (intravasation) and then (c) penetrating out of the vessels (extravasation) and finally proliferate in a secondary site. The microenvironment in the primary tumor locus is rather complicated [2]. Various types of cells including the primary tumor itself may secret a lot growth factors and cytokines to trigger phenotypical changes in tumor cells responsible for the initiation of tumor metastasis. This review focus on the molecular and cellular events occurred in this critical stage. Especially, the signal transduction pathways involved in tumor metastasis will be focused.
2.2 Phenotypical Changes of Tumor Cells in the Initial Stage of Tumor Metastasis: EMT, Migration and Invasion of Primary Tumor The phenotypical changes which eventually endow tumor cells with metastatic ability are epithelial-mesenchymal transition (EMT) followed by migratory and invasive properties.
2.2.1 Epithelial–Mesenchymal Transition: the Initiation Step of Tumor Metastasis The conversion of epithelial cells to mesenchymal cells is fundamental for embryonic development during which cell–cell adhesion and cell polarity are lost accompanied with the acquisition of fibroblastoid morphology with motile and invasive properties [3]. Transcriptional reprogramming during EMT resulted in combined loss of epithelial cell junction proteins (e.g., E-cadherin, catenins and mucin-1) and the appearance of mesenchymal markers (e.g., fibronectin, vitronectin, vimentin and smooth muscle actin).
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
11
As described by a recent review [4], the significance of EMT during cancer progression and even its relevance in human cancer tissues have remained a matter of debate until very recently. EMT is now proved to be a fundamental step in tumor progression and metastasis in a lot of studies. For example, in colon carcinoma, EMT occurs at the invasive front and produces migratory cells that lose E-cadherin expression [5]. Moreover, direct in vivo imaging has also yielded evidence of EMT in cancer progression [6]. 2.2.1.1 Tumor Migration: The Essential Driving Force for Metastasis After EMT, tumor cells acquire higher migratory ability to move to the surrounding tissue. Cell movement is a complex and tempo-spatially controlled process involving the coordinated activity of hundreds of different proteins [7]. The cytoskeletal network consisting of actin, myosin and many proteins associated with them is essentially responsible for the typical morphological changes observed in cell migration. In the initial stage of cell migration, the leading edge of a cell is pushed forward by the extension of the internal cytoskeleton leading to the formation of a large, flat structure that is often termed the lamellipodium. The leading edge is then attached to the surface by adhesion molecules such as integrins. This allows the rest of the cell body to be pulled forward. Integrins, the cytoskeleton-associated cell surface receptor can bind to the ECM including laminins, fibronectin and proteoglycans, which is responsible for adhesion and de-adhesion during cell migration. Moreover, engagement of integrins with ECM may stimulate intracellular signal transduction mediating a lot of cellular effects including migration. The integrinmediated signaling may integrate with those from other metastatic factors in the tumor microenvironment, endowing tumor cells with sustained migratory capability which is the essential driving force for tumor metastasis. 2.2.1.2 Tumor Invasion in Metastasis Invasion is another essential step for tumor progression during which tumor cells follow a chemoattractive path across the ECM and basement membrane of tissue boundary, which are the structural barriers against tumor invasion. Degradations of the basement membrane and ECM are fundamental for tumor cell invasion [8]. A chorioallantoic membrane invasion assay has been used to demonstrate proteolysis in the invasive process [9]. Tumor cells and most of the cells in the tumor environment may overexpress and secret one or more of the matrix degradation enzymes (proteinases) which can be divided into four groups: (1) the matrix metalloproteinases (MMPs), a family of secreted and membrane-anchored proteinases, (2) the adamalysin-related membrane proteinases, (3) the bone morphogenetic protein-1-type metalloproteinases, and (4) tissue serine proteinases, including tissue plasminogen activator, urokinase, thrombin and plasmin [10]. The activities of these enzymes are tightly regulated by a series of activation steps and specific inhibitors. One of the principle matrix degradation enzymes is matrix metalloproteases (MMPs). MMPs are a family of neutral metalloenzymes secreted as latent
12
W.-S. Wu and C.-T. Hu
proenzymes, requiring activation through proteolytic cleavage of the amino-terminal domain in the presence of zinc and calcium [11, 12]. Five MMP subclasses were grouped according to substrate specificity: interstitial collagenases, gelatinases, stromelysins, membrane type-MMPs (MT-MMPs), and elastases [13]. Increased MMP activity has been detected and shown to correlate with invasion and metastatic potential in a wide range of cancers, including ovary, lung, prostate, breast, and pancreas cancers [11, 14, 15].
2.2.2 Microenvironment in the Primary Tumor Locus The formation of a clinically progressing tumor requires interactions with the surrounding normal stroma. The tumor-stroma compartment as a whole constitutes the tumor microenvironment. Recent evidence indicates that the microenvironment not only maintains the survival of cancer stem cells/cancer initiating cells but also promotes cancer cells metastasis. Furthermore, inflammatory cells and immunomodulatory mediators present in the tumor microenvironment polarize host immune response toward specific phenotypes favoring tumor progression. A lot of studies demonstrate a positive correlation between poor prognosis with angiogenesis, carcinoma-associated fibroblasts, and the effect of inflammation on tumor progression. Thus, the dynamic interactions between tumor cells and cells of the tumor microenvironment are critical to tumor metastasis [2]. 2.2.2.1 The Constitution of Tumor Microenvironment The concept of tumor microenvironment as an integrated and essential part of the cancer tissue has been proposed decades ago. However, not until recent years, the cellular and molecular components of tumor microenvironment were identified, and the mechanisms for how they affect tumor progression were delineated. The constitution of tumor microenvironment (Fig. 2.1) comprises the primary tumor itself which may recruit and interact with stroma through production and secretion of stimulatory growth factors and cytokines [16, 17]. A variety of cell types populate the stromal compartment, including smooth muscle cells, myofibroblasts, carcinoma associated fibroblasts, vascular cells (such as lymph-endothelial, vascular-endothelial cells and pericytes) and immune cells including lymphocytes, tumor associated monocytes/macrophages and dendritic cells [16, 17]. The interactions between tumor cells and stroma cells lead to secretion of growth factors and cytokines for neovasculation and modifications of the ECM, which greatly support growth and survival of tumor cells [16, 17] (Fig. 2.1). 2.2.2.2 The Effect of Inflammation on Tumor Progression It has been proposed since 1863 by Rudolf Virchow that cancer originates at sites of chronic inflammation. This notion was further strengthened by recent studies demonstrating that chronic inflammation is critical for cancer progression [18].
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
13
Angiogenesis
ell
s
Pericyte
om al c str te d/ ac tiv at ed
MyoFi
un m
im TAM
MSC
Growth factors Cytokines Proteinases
Re
s
ell
CAFi
ec
cr ui
DC
d ite
EC EC
SMC
u cr Re
Lymph vessel
Fi Cancer cell
ECM EC Epithelial cell
Fi
Basement membrane Hypoxic/necrotic cancer cell
PMC
SMC
IC
IC
EMT/migration/invasion
Fig. 2.1 The constitution of tumor microenvironment. Transition to invasive carcinoma is preceded by the interaction/cross-talk among the premalignant cells (PMC) and stromal cells such as fibroblasts (Fi), smooth muscle cells (SMC), endothelial cells (EC), or immune cells (IC) (dashed lined zones). Cancer cells further modify directly or indirectly (tumor or tissue hypoxia/necrosis) the microenvironment by activating other stromal cells, such as tumor associated monocytes/macrophages (TAM), dendritic cells (DC) or carcinoma associated fibroblasts (CAFi) (solid blue arrows; dashed blue arrows represent differentiation). In turn, growth factors, cytokines and proteinases released from cancer cells, immune cells and the activated stromal cells (dashed red arrows) promote tumor growth, epithelial-mesenchymal transition (EMT), migration, invasion (by degradating the ECM and basement membrane) of primary cancer cells, and angiogenesis (solid red arrows). MSC mesenchymal stem cell, MyoFi myofibroblast
Inflammatory responses within the microenvironment can be triggered by tumor hypoxia and necrosis secondary to excessive tumor cell proliferation. The inflammatory cytokines, including colony stimulating factor (CSF)-1, granulocyte–monocyte (GM)-CSF, transforming growth factor (TGF)-β, and chemokines (e.g., CCL2, CCL7, CCL3, CCL4) [19] are chemoattractive for monocytes and macrophages. The recruited macrophages in turn secrete growth factors, cytokines, chemokines and growth/motility factors that affect tumor cell behavior (e.g., induction of motility and invasiveness). These include vascular endothelial growth factor (VEGF)-A and -C, basic fibroblast growth factor (bFGF), tumor necrosis factor (TNF), hepatocyte growth factor (HGF), epidermal growth factor (EGF) family members, platelet-derived growth factor (PDGF), and chemokines such as CXCL12 and
14
W.-S. Wu and C.-T. Hu
interleukin (IL)-8. These factors may also promote the recruitment of additional inflammatory cells, such as mast cells and neutrophils which also secret tumorpromoting cytokines, growth factors and proteases, thus amplifying the initial inflammatory reaction [20] and facilitating tumor progression including EMT, migration, invasion of the tumor cells coupled with angiogenesis for supporting the growth of cancer tissue (Fig. 2.1).
2.3 Signal Transduction Triggered by Metastatic Factors Within Microenvironment As described above, a variety of growth factor/cytokine and extracellular matrix may be secreted by tumor cells, stromal cells and inflammatory cells. These factors have great impacts on the initiation of tumor progression and may be collectively called as the “metastatic factors”. Of these, TGF-β [21], HGF [22], EGF [23], and insulin-like growth factor (IGF) [24] have been demonstrated to be capable of inducing EMT and migration of tumor cells. Also, HGF, EGF and TGF-β released from the degraded matrix may guide the path in front of tumor cells. The signal transductions responsible for tumor progression induced by some of these factors are well established as described in the following sections.
2.3.1 HGF/c-Met Hepatocyte growth factor (HGF), or so called scatter factor (SF) was capable of inducing scatter (i.e., dissociation) of epithelial cells and stimulating proliferation of hepatocytes. SF/HGF is synthesized by mesenchymal cells as a paracrine effector of epithelial cells. The HGF-induced cell scatter may endow the cell with increasing motility and invasiveness, effects that are physiologically required for embryonic development [for review 25, 26] and also pathologically involved in tumor metastasis [27, 28]. 2.3.1.1 The HGF-cMet Signaling The cellular receptor of HGF is the tyrosine kinase receptor c-Met. C-Met receptor consists of a disulphide-linked heterodimeric complex containing an extracellular portion for ligand binding, a membrane spanning segment, a juxtamembrane domain, a catalytic domain, and a C-terminal docking site [29]. Binding of HGF to c-Met triggers autophosphorylation of its cytoplasmic domain. The phosphorylation at two tyrosine residues in the catalytic domain, Y1234 and Y1235, is crucial for kinase activity, while phosphorylation at Y1349 and Y1356 in the C-terminal docking site is essential for recruiting adaptor proteins. Many adaptor proteins such as Shc [30], Src, Grb2, the p85 regulatory subunit of PI3K [29] and Gab1 [31] may bind directly or indirectly with the c-Met receptor. Most of them contain a Src
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
15
homologous2 (SH2) domain interacting with c-Met receptor and a Src homologous3 (SH3) domain that binds to downstream signal molecules. Several down stream signal pathways were well known to be triggered by HGF/ c-Met, including Raf-ERK (MAPK) [32, 33], p38 (MAPK) [34, 35], and PI3KAkt/PKB [33, 36] pathways. HGF/c-Met can also crosstalk with integrin-initiated signal cascade leading to activation of FAK-Src-paxillin, Ras-Rac1/Cdc42-PAK and Gab1-Crk-C3G-Rap1 cascades. In addition, by activation of the PKC isozyme ε, c-Met may recruit ERK1/2 to focal adhesion complex to phosphorylate and activate the migration-related signal components [for review 37]. 2.3.1.2 The Role of HGF/SF-Met Signaling in Tumor Progression All of the aforementioned HGF/c-Met signalings are known to be provital for cytoskeletal rearrangement, cell scattering, migration, invasion and angiogenesis. Thus, elevated activation of HGF-cMET signaling may lead to eventual metastasis. In the animal studies, cells which over-express either c-MET or HGF are extremely metastatic when implanted into nude mice [38]. Consistently, transgenic mice for either MET or HGF develop metastatic tumors [39]. A lot of patho-physiological evidences demonstrated that c-MET can be constitutively activated by establishment of ligand-receptor autocrine loops, or activating point mutations [for review 40]. Moreover, altered HGF secretion has been reported in both solid and hematologic malignancies. In the past decades, mounting studies have demonstrated the critical role of HGF/c-Met in malignant progression of a lot of tumors [for review 41, 42, 43, 44]. These include small cell lung cancer [45], melanoma cells [35], ovarian cancer [46], colorectal carcinoma [47], human stomach cancer [32] prostate adenocarcinoma cells [48], breast cancer [36, 49], pancreatic cancer [34], head and neck squamous cell carcinoma [33], oral squamous cell carcinoma [50] and renal carcinoma cells [51]. 2.3.1.3 Blockade of HGF/c-Met for Prevention of Tumor Metastasis The use of HGF as a target for prevention of metastasis has been intensively studied [for review 52]. Previously, NK4, a competitive antagonist of HGF/c-Met was employed to block HGF-induced invasion and metastasis of hepatocellular carcinoma. NK4 is an internal fragment of HGF and able to bind to but not activate the c-Met receptor, thereby competitively suppressing the biological activities of HGF [for review 53]. Recently, a single-agent and combination therapeutic strategies to inhibit HGF/c-Met signaling for prevention of cancer progression was proposed [54].
2.3.2 TGF-β The transforming growth factor-β (TGF-β) superfamily of growth factors consist of TGF-βs, activins and bone morphogenetic proteins (BMPs). In physiological
16
W.-S. Wu and C.-T. Hu
context, TGF-β is involved in the proliferation and differentiation of cells, embryonic development, angiogenesis, and wound healing. Previously, TGF-β was known to be a regulatory molecule that signals cell cycle arrest [55]. However, later studies demonstrated that members of the TGF-β family produce different cellular effects, either growth promoting or antiproliferative, depending on the types and states of cells [for review 56].
2.3.2.1 TGF-β/Smad Signaling The signal pathway for the action of TGF-β was well established [for review 57]. The membrane receptors of TGF-β consist groups of serine/threonine kinase family of which the type I and type II TGF-β receptors may form heteromeric complexes responsible for intracellular signaling. Ligand binding of TGF-β receptors may activate its cytoplasmic mediators, the Smads. The mammalian Smad family consists of 8 members, which can be divided into 3 groups according to their functions: receptor-activated Smads (R-Smads), common-mediator Smads (Co-Smads) and inhibitory Smads (I-Smads) [58]. After receptor activation, Smad2 and Smad3, which belong to the group of R-Smads, can be phosphorylated in their C-terminus and associated with Smad 4, one of the Co-Smad. This Smad complex translocates into the nucleus and associate with transcriptional coactivators or corepressors to regulate the transcriptional activation of various TGF-β responsive genes. Several reports demonstrated that TGF-β/Smad can crosstalk with MAPK cascade for regulation of growth, survival and motility of cells [59]. The MAPK family proteins including ERK1 and ERK2; JNK1 and JNK2; and the four p38 isoforms, p38α, p38β, p38γ and p38δ can be activated by TGF-β and have been implicated as upstream regulators of Smad. For example, all three MAPK can phosphorylate Smad3 in the linker region and facilitate both activation and nuclear accumulation of Smad3 [60]. On the other hand, Smads can act upstream of MAPKs and mediate their activation [59]. These studies suggested that a sustained signal circuit may be established by crosstalk of both TGF-β/Smad and MAPK pathway.
2.3.2.2 The Role of TGF-β in Tumor Progression The potential involvement of TGF-β in cancer has been noted by cancer biologists decades ago. Previously, it was suggested that TGF-β play as a tumor suppressor and cancer cells may acquire genetic alterations involved in the TGF-β signaling pathway to bypass the antiproliferative action of TGF-β. Moreover, the role of TGF-β1 itself as a potent inducer of tumor progression was highlighted in recent studies. TGF-β is among the prevalent growth factors overproduced in tumor microenvironment exerting autocrine or paracrine action on the tumor cells. TGF-β may induce EMT, migration and invasion of tumor cell in cultured condition [21, 61, 62]. TGF-β can also enhances proteinase expression by tumor cells which in turn leads to degradation of the ECM with a consequent release of stored TGF-β. Moreover, excess TGF-β production is associated with poor prognosis of a lot of cancer including breast tumor, lung cancer, hepatocarcinoma and prostate carcinoma [63].
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
17
2.3.2.3 TGF-β/Smad Signaling for Tumor Progression Both Smad and MAPK signaling has been implicated in mediating the tumor progressive effects of TGF-β on cancer cells. For example, overexpression of Smad3 had prometastatic effects on breast cancer cell lines [64], and Smad signaling is required for TGF-β-induced bone metastasis of breast cancer cells [65]. Also, Smad signaling mediates the invasive phenotype of head and neck squamous carcinoma cells by regulating their collagenase production [66]. In addition, TGF-β-stimulated invasion of head and neck SCC cells is mediated via p38 (MAPK) of which p38α and p38 δ isotypes are the most important [66]. 2.3.2.4 Blockade of TGF-β Signal for Prevention of Tumor Metastasis Due to its important role in tumor progression, the TGF-β signaling were regard as promising targets for anti-metastasis. Large molecular inhibitors, such as TGF-β antibodies and antisense oligonucleotides, have been used quite widely in preclinical and clinical studies [67, 68]. Also, small molecular inhibitors were developed to target TGF-β receptor kinases. However, because of the multifunctional activities of TGF-β, complete loss of TGF-β signaling would eventually be detrimental, such as promotion of inflammation, development of autoimmune diseases and even enhancement of tumor growth in situations where cancer cells are still responsive to the antiproliferative effects of TGF-β.
2.3.3 The Integrin-ECM Engagement In addition to aforementioned growth factors and cytokines, the extracellular matrix (ECM) is another potent metastatic factors in the tumor microenvironment. The ECM serve as the scaffold for the organization of cells in tissues exerting an extraordinary control on cell growth, survive migration and invasion. The interaction between tumor cells and stromal cells may lead to altered secretion and/or modifications of extracellular matrix which greatly facilitate tumor progression. The effects of the ECM on cells are mainly mediated by integrins, a large family of cell-surface receptors that bind and mediate adhesion to ECM components. Each integrin consists of two type-I transmembrane subunits: α and β. In mammals, 18α and 8β subunits associate in various combinations to form 24 integrins that can bind to distinct, although partially overlapping, subsets of ECM ligands. Engagement of integrin with ECM lead to clustering of integrins at the focal adhesion site which impart polarity to the cell and remodel its cytoskeleton. Moreover, the focal adhesion site serves as a platform for signal transduction mediating a lot of cellular effects including proliferation, adhesion, migration and eventually metastasis [69, 70, 71, 72]. 2.3.3.1 The Integrin-Mediated Signaling A lot of signal cascades can be activated by integrin engagement, of which the mitogen activated protein kinase (MAPK) is the most relevant to tumor
18
W.-S. Wu and C.-T. Hu
progression. Integrins can activate extracellular signal-regulated kinase (ERK)/(MAPK) through Shc or FAK. Whereas FAK signaling is necessary for directional cell movement, Shc promotes random cell motility [73]. The Shc-dependent pathway may trigger the conventional Ras-Raf-MEK cascade for ERK activation. In the FAK-dependent pathway, FAK may autophosphorylate at Y397 for binding to SH2 domain of Src followed by phosphorylation on multiple residues resulting in elevation of its kinase activity. Activated FAK/Src may phosphorylate the adaptor protein P130CAS and scaffold protein paxillin. Paxillin may be phosphorylated at tyrosine residue 31 and 118 between its N-terminal LD1 and LD2 motif generating docking site for P130CAS. This may facilitate the recruitment of another SH2/SH3 adaptor CRK and trigger activation of GTPases Rac via guanidine exchange factor (GEF) DOCK180 leading to JNK(MAPK) activation. The effects of integrin-triggered ERK and JNK (MAPK) activation in cell migration has two-fold. One is the phosphorylation of cytoskeletal components, the other is the regulation of gene expression. ERK(MAPK) may phosphorylate and activate the myosin light chain (MLC) kinase (MLCK), which induces the contraction of actomyosin fibres through phosphorylation of MLC [74]. On the other hand, ERK and JNK (MAPK) also control cell migration through induction of activator protein-1(AP-1)-dependent gene expression. Interestingly, after integrin engagement, MAPK are not only activated but also recruited to focal adhesion complex to induce phosphorylation of paxillin. Paxillin phosphorylation might further promote the turnover of focal adhesions facilitating cell migration [75]. Another important down stream component of integrin signal cascade is Rho family protein. The RhoGTPases mediate many of the integrin-dependent modifications of the actin cytoskeleton that are necessary for cell migration [76]. Whereas Cdc42 and Rac promote actin polymerization at the leading edge, and thereby the formation of filopodia and lamellipodia, Rho induces the assembly and contraction of the actomyosin fibres, which contributes to pulling the trailing edge forwards. 2.3.3.2 Altered Integrin Signaling Promotes Tumor Progression There are several mechanisms for integrin signaling to contribute tumor metastasis. One of them is altered expression of integrin, the other is integration of integrin signaling with that triggered by other metastatic factors. Pathological studies of human cancer have provided evidence that tumor cells switch expression of their integrins. These changes are complex and depend on the tissue origin of the tumor, its histological type, and the stage of progression of the disease [77, 78, 79].One example is that elevated levels of integrins α6β4 can be observed in metastatic breast tumor cell. Consistently, introduction of β4 to β4-negative breast carcinoma cells activates signaling from phosphatidylinositol 3-kinase (PI3K) to Rac and increases the invasive ability of these cells [79]. In addition, one recent report [80] demonstrated that overexpression of αvβ3 in tumor cell can substantially increases anchorage-independent cell survival in vitro and metastasis in vivo.
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
19
2.3.3.3 Crosstalk of Integrin Signaling With Other Pathway Since many growth factors and ECM are located in the tumor microenvironment as described in the above section, it is tempting to speculate that integrin signaling might crosstalk with others to enhance tumor progression. Indeed, a lot of evidences have indicated that deregulated joint integrin–RTK signaling contributes to tumor metastasis. For example, αvβ3 integrin combines with several RTKs, including the receptors for EGF, PDGF, insulin and vascular endothelial growth factor (VEGF), and cooperates with them to promote cell migration [81, 82]. In addition, αvβ6 and αvβ8 might promote EMT by contributing to the activation of TGF-β [83]. The mechanisms underlying the crosstalk of integrin with RTK or other signal cascade have been intensively studied. Guo et al. indicated that both the EGF receptor and c-Met induce phosphorylation of β4 and enhance Shc activity by disrupting hemidesmosomes. These suggested that RTKs may decrease the ability of α6β4 to mediate stable adhesion while increase its function in signaling [70]. On the other hand, one of the studies demonstrated that the integrin β4 tail may serve as an adaptor for amplification of pro-invasive signals elicited by HGF/c-met [84]. Recently, Wu et al. suggested that integrin may crosstalk with RTK and PKC by establishing a signal circuit in the focal adhesion complex mediated by reactive oxygen species (ROS), resulting in sustained ERK activation and cell migration [85]. The detailed mechanisms are described in Chapter 6. One recently highlighted mechanisms for sustained integrin and RTK signaling involved the endocytic-exocytic cycling of both receptors [86, 87]. Interestingly, Caswell et al. reported that α5β1 and EGFR recycle to the plasma membrane in complex with one another, resulting in enhanced cell migration and invasion. This is associated with enhanced signaling from EGFR to the proinvasive kinase, AKT [86]. Moreover, coordination of α5β1 and EGFR trafficking depend on their association with the Rab11 effector Rab-coupling protein (RCP, Rab11-FIP1) [86]. The role of Rab-GTPases and its down stream effector as central regulators of integrin traffics and tumor progression are well reviewed in Chapter 8 of this book. 2.3.3.4 Targeting Integrin Signaling for Prevention of Tumor Progression Since the role of integrin signaling in migration and invasion of cell are so provital, it become one of the most promising targets for prevention of tumor metastasis. One recent review [87] indicated that the use of integrin antagonists for cancer therapy have shown encouraging outcome. One of the drug cilengitide, which is an inhibitor of αvβ3 and αvβ5, is currently being tested in a Phase III trial for patients with glioblastoma.
2.4 Conclusion and Perspective Growth factors and cytokines secreted by tumor cells, stromal cells and inflammatory cells in the complicated tumor microenvironment can induce signal transductions for eliciting phenotypical changes required for tumor progression (Fig. 2.1).
20
W.-S. Wu and C.-T. Hu
Moreover, there is significant overlap between the pathways induced by each metastatic factors resulting in crosstalk of signal transduction. In the future, more effective cancer therapy can be developed by targeting the critical signal molecules responsible for the initiation stage of tumor metastasis.
References 1. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127(4): 679–695. 2. Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 2008; 130: 1091–1103. 3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119: 1420–1428. 4. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890. 5. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50: 151–162. 6. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007; 67: 2649–2656. 7. Parsons JT, Horwitz AR. Cell migration: integrating signals from front to back. Science 2003; 302: 1704–1709. 8. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 1991; 51: 5054s–5059s. 9. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353–362. 10. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439–442. 11. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem. Biol. 1996; 3: 895–904. 12. Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, Chu WS. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin. Exp. Metastasis 1998; 16: 501–512. 13. Chambers AF, Matrisian LM. Changing views of the role of matrix mettaloproteinases in metastasis. J. Natl. Cancer Inst. 1997; 89: 1260–1270. 14. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976; 36: 889–894. 15. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–68. 16. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375–379. 17. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 2000; 6: 324–329. 18. Rüegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J. Leukoc. Biol. 2006; 80: 682–684. 19. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv. Cancer Res. 2005; 93: 159–187. 20. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436–444.
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
21
21. Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764–5774. Review. 22. Savagner P, Yamada KM, Thiery JP. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J. Cell Biol. 1997; 137: 1403–1419. 23. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007; 67: 9066–9076. 24. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O’Regan RM. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008; 68: 2479–2488. 25. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998; 8: 404–410. Review. 26. Van der Voort R, Taher TE, Derksen PW, Spaargaren M, vander Neut R, Pals ST. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv. Cancer Res. 2000; 79: 39–90. Review. 27. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell Physiol. 2007; 213: 316–325. Review. 28. Lesko E, Majka M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci. 2008; 13: 1271–1280. 29. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261–271. 30. Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 1995; 10: 1631–1638. 31. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384: 173–176. 32. Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: a potential therapeutic target for human stomach cancer. Korean J. Intern. Med. 2006; 21: 20–27. 33. Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D, Wang CY. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J. Biol. Chem. 2002; 277: 25203–25208. 34. Lee KH, Hyun MS, Kim JR. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin. Exp. Metastasis 2003; 20: 499–505. 35. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002; 21: 1000–1008. 36. Gallego MI, Bierie B, Hennighausen L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 2003; 22: 8498–8508. 37. Kermorgant S, Parker PJ. c-Met signalling: spatio-temporal decisions. Cell Cycle 2005; 4: 352–355. 38. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA 1994; 91: 4731–4735. 39. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. Diverse tumorigenesis associated with aberrant development in mice
22
40. 41. 42. 43.
44.
45.
46. 47.
48.
49.
50.
51.
52. 53. 54. 55. 56. 57. 58. 59.
60.
W.-S. Wu and C.-T. Hu overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA 1997; 94: 701–706. Lu X, Yao W, Newton RC, Scherle PA. Targeting the c-Met signaling pathway for cancer therapy. Expert. Opin. Investig. Drug 2008; 17:997–1011. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003; 4: 915–925. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 1996; 74: 505–513. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Cytokine Growth Factor Rev. 2002; 13: 41–59. Review. Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J. Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp. 1997; 212: 119–130; discussion 130–132, 148–154. Review. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br. J. Cancer 2007; 97: 368–377. Zhou HY, Pon YL, Wong AS, HGF/MET signaling in ovarian cancer. Curr. Mol. Med. 2008; 8: 469–480. Herynk MH, Zhang J, Parikh NU, Gallick GE, Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J. Exp. Ther. Oncol. 2007; 6: 205–217. MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate 2005; 64: 139–148. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Transforming growth factor-beta signalingdeficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol. Cancer Res. 2008; 6: 1521–1533. Kitajo H, Shibata T, Nagayasu H, Kawano T, Hamada J, Yamashita T, Arisue M. Rho regulates the hepatocyte growth factor/scatter factor-stimulated cell motility of human oral squamous cell carcinoma cells. Oncol. Rep. 2003; 10(5): 1351–1356. Nakamura T, Kanda S, Yamamoto K, Kohno T, Maeda K, Matsuyama T, Kanetake H. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation. Oncogene 2001; 20: 7610–7623. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006; 12: 3657–3660. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003; 94: 321–327. Toschi L, Jänne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin. Cancer Res. 2008; 14: 5941–5946. Review. Massagué J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998; 67: 753–791. Review. Akhurst RJ, Derynck R. TGF-beta signaling in cancer – a double-edged sword. Trends Cell Biol. 2001; 11: S44–S51. Review. Leivonen SK, Kähäri VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int. J. Cancer 2007; 121: 2119–2124. Review. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogenactivated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005; 24: 5742–5750. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-b-mediated transcription. J. Biol. Chem. 1999; 274: 37413–37420.
2
Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor
23
61. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 1994; 127: 2021–2036. 62. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996; 10: 2462–2477. 63. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, and Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37: 19–29. 64. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006; 66: 2202–2209. 65. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 2005; 102: 13909–13914. 66. Leivonen SK, Alaaho R, Koli K, Grenman R, Peltonen J. Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene 2006; 25: 2588–2600. 67. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr. Opin. Investig. Drugs 2006; 7: 513–521. 68. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signaling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 2004; 3: 1011–1022. 69. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028–1032. 70. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004; 5: 816–826. 71. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002; 2: 91–100. 72. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673–687. 73. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, Yamada KM. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 1999; 146: 389–403. 74. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 1997; 137: 481–492. 75. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature 2003; 424: 219–223. 76. Raftopoulou M, Hall A. Cell migration: rho GTPases lead the way. Dev. Biol. 2004; 265: 23–32. 77. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W. Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 1995; 108: 2241–2251. 78. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the αvβ3 integrin: adhesion mechanism for transformed glial cells. J. Clin. Invest. 1991; 88: 1924–1932. 79. Mercurio AM, Rabinovitz I. Towards a mechanistic understanding of tumor invasion – lessons from the α4β4 integrin. Semin. Cancer Biol. 2001; 11: 129–141. Review. 80. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ, Cheresh DA. An integrin αvα3–c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat. Med. 2009; 15: 1163–1169. 81. Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu. Rev. Cell Dev. Biol. 2003; 19: 173–206. 82. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat. Cell Biol. 2002; 4: E83–E90.
24
W.-S. Wu and C.-T. Hu
83. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 2001; 29: 117–129. 84. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for α6β4 integrin in the control of HGFdependent invasive growth. Cell 2001; 107: 643–654. 85. Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev. 2008; 27: 303–314. Review. 86. Caswell P, Norman J. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol. 2008; 18: 257–263. 87. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010; 10(1): 9–22.
Chapter 3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis Laure Voisin∗ , Stéphanie Duhamel∗ , and Sylvain Meloche
Abstract The extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein (MAP) kinase module is a conserved signaling pathway that plays a major role in the control of cell proliferation, survival and differentiation. This pathway is typically turned on by engagement of growth factor receptors, which leads to the activation of the small GTPase Ras and to sequential phosphorylation and activation of Raf, MEK1/MEK2 and ERK1/ERK2 protein kinases. ERK1 and ERK2 are multifunctional Ser/Thr kinases that phosphorylate a panoply of substrates involved in multiple cellular processes. Hyperactivation of the ERK1/2 pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or by gain-of-function mutations in RAS or RAF genes. This dysregulation is believed to provide a proliferation and survival advantage to cancer cells. Accumulating evidence suggest that the ERK1/2 signaling pathway also contributes to the increased motility, invasiveness and dissemination of tumor cells. In this chapter, we review the role of ERK1/2 MAP kinase signaling in the pathogenesis of tumor metastasis. Keywords Adhesion · Angiogenesis · Anoikis · Apoptosis · Cancer · Cell survival · E-cadherin · Epithelial-mesenchymal transition (EMT) · Extracellular matrix (ECM) · Extracellular signal-regulated kinase 1/2 (ERK1/2) · Extravasation · Immune-system evasion · Integrins · Invasion · Invasiveness · Intravasation · Matrix metalloproteinases (MMPs) · Mitogen-activated protein kinase (MAPK) · Metastasis · Micrometastases · Motility · Polarity · Proteases · Ras/ Raf/MEK/ERK1/2 pathway · Rho GTPases · Signaling pathway · Snail · Tumorigenesis · Tumor · Urokinase-type plasminogen-activated receptor (uPAR)
S. Meloche (B) Institut de Recherche en Immunologie et Cancérologie, Université de Montréal, 2950, Chemin de Polytechnique, Montreal, Quebec, Canada H3C 3J7 e-mail:
[email protected] ∗ These
authors contributed equally to this work
W.-S. Wu, C.-T. Hu (eds.), Signal Transduction in Cancer Metastasis, Cancer Metastasis – Biology and Treatment 15, DOI 10.1007/978-90-481-9522-0_3, C Springer Science+Business Media B.V. 2010
25
26
L. Voisin et al.
Contents 3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.2 Hyperactivation of the Ras-ERK1/2 MAP Kinase Pathway in Cancer . 3.3 The ERK1/2 MAP Kinase Pathway in Cancer Metastasis . . . . . . 3.3.1 Loss of Cellular Contacts, Detachment From the Primary Tumor and Local Invasion . . . . . . . . . . . . . . . . . . . . . 3.3.2 Intravasation and Dissemination to Distant Organ Sites . . . . 3.3.3 Extravasation, Formation of Micrometastases and Outgrowth of Secondary Tumors . . . . . . . . . . . . 3.4 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . .
26 26 27
. . . . . . . . . . . .
27 31
. . . . . . . . . . . . . . . . . .
32 34 35
3.1 Introduction Mitogen-activated protein (MAP) kinase pathways are evolutionarily conserved protein kinase cascades that play a key role in signal transduction [58]. These pathways process information from a wide variety of extracellular stimuli and cellular perturbations to control multiple physiological processes required to maintain normal cellular and tissue homeostasis [16, 47, 58]. Furthermore, deregulated activity of MAP kinase pathway components has been linked to many diseases, including cancer, inflammatory disorders, diabetes and cardio-facio-cutaneous syndromes [49]. These enzymes are therefore viewed as attractive targets for novel targeted therapies. Among the best-characterized MAP kinase pathways is the Ras-dependent extracellular signal-regulated kinase (ERK) 1/2 pathway, which conveys signals from mitogenic factors, cytokines and differentiation cues. Typically, ligand binding to growth factor receptors leads to the activation of the small GTPase Ras, which allows the recruitment of Raf to the membrane and mediates the sequential phosphorylation and activation of Raf, MEK1/MEK2 and ERK1/ERK2 protein kinases [67]. Once activated, the multifunctional kinases ERK1/ERK2 phosphorylate a vast array of substrates, including membrane receptors, cytoskeletal proteins, transcriptional regulators and signaling enzymes, to impact on cell growth, cell cycle progression, survival, adhesion and motility [99]. Not surprisingly, the ERK1/2 MAP kinase pathway is found commonly deregulated in cancer.
3.2 Hyperactivation of the Ras-ERK1/2 MAP Kinase Pathway in Cancer Hyperactivation of the Ras/Raf/MEK/ERK1/2 pathway by aberrant activation of receptor tyrosine kinases or by gain-of-function mutations in RAS or RAF genes is a highly prevalent event in human cancer. Gene amplification and mutational activation of members of the HER (human EGF receptor) family of receptors are
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
27
frequently observed in human epithelial tumors and gliomas [37]. Activating mutations in RAS genes, most frequently in KRAS, occur in ∼30% of cancers and are often acquired early in the tumorigenic process [26, 76]. Although Ras is known to regulate multiple effector pathways, the discovery that BRAF is mutated in ∼20% of all cancers and in 44% of melanomas has provided genetic evidence for the involvement of the Raf/MEK/ERK1/2 effector branch in oncogenic signaling [19, 26]. Raf relays its oncogenic signals mainly via the MAP kinase kinases MEK1 and MEK2. Several studies have shown that expression of activated alleles of MEK1 or MEK2 is sufficient to deregulate the proliferation and transform immortalized fibroblast and epithelial cell lines [17, 52, 55, 63, 90]. In vivo, orthotopic transplantation of mammary or intestinal epithelial cells expressing activated MEK1/MEK2 into mice induces the formation of metastatic tumors [63, 90]. Transgenic expression of activated MEK1 in mouse skin induces hyperproliferative and inflammatory lesions and inhibits epidermal differentiation, mimicking features of squamous cell carcinomas [35, 74]. Although mutations in MEK1/MEK2 genes are rare in cancer [53], numerous studies have documented the hyperactivation of MEK1/MEK2 and ERK1/ERK2 in solid tumor and leukemia clinical specimens [36, 79]. Consistent with its physiological involvement in the regulation of cell proliferation and survival, aberrant activation of the ERK1/2 pathway is expected to relax the growth factor dependency and enhance the survival of cancer cells. In addition, accumulating evidence suggest that this signaling pathway also contributes to the increased motility and invasiveness of tumor cells, another hallmark of cancer [33]. In this chapter, we discuss the evidence for a role of ERK1/2 MAP kinase signaling in the pathogenesis of cancer metastasis.
3.3 The ERK1/2 MAP Kinase Pathway in Cancer Metastasis Metastasis is a complex process by which tumor cells spread from a primary site to form new tumors in distant organs [14, 28]. The metastatic process consists of a series of sequential and rate limiting steps that can be defined as follows: (1) detachment from the primary tumor and local invasion; (2) intravasation into the lymphatic or blood circulation; (3) transport to distant anatomical sites and arrest in microvessels; (4) extravasation into the surrounding tissue; (5) formation of micrometastases; and (6) colonization and formation of large clinically detectable metastases. The outcome of the metastatic process is dependent on both the intrinsic properties of the cancer cells and the host response.
3.3.1 Loss of Cellular Contacts, Detachment From the Primary Tumor and Local Invasion 3.3.1.1 The Epithelial-Mesenchymal Transition (EMT) One of the first steps in the metastasis process involves changes in the intercellular adhesion properties of cancer cells. Carcinoma cells undergo a drastic modification
28
L. Voisin et al.
known as epithelial-mesenchymal transition (EMT), whereby epithelial cells switch to a fibroblast-like mesenchymal phenotype, enabling their detachment from epithelial sheets within the primary tumor and favoring their motility and invasiveness [32, 42]. EMT is characterized by morphological changes, loss of apical-basal polarity and alterations in gene expression profiles. A major determinant of the reduced intercellular adhesion observed during EMT is the loss of the epithelial adherens junction protein E-cadherin [61]. Various mechanisms can lead to silencing of E-cadherin expression during tumor progression, but transcriptional repression has emerged as a fundamental mechanism. Several transcriptional repressors, including Snail, ZEB and bHLH factors (E47/E2A, Twist), have been found to inhibit the expression of the E-cadherin gene and to induce EMT [60]. Multiple signaling pathways can induce EMT, including transforming growth factor-β (TGF-β), Wnt, NF-kB, Notch, phosphoinositide 3-kinase and ERK1/2 MAP kinase [60, 83]. Early studies have shown that expression of activated MEK1 in MDCK cells results in morphological transformation and conversion to invasive mesenchymal-like cells [34, 55, 75]. Other studies also documented the essential role of the ERK1/2 pathway in hepatocyte growth factor (HGF)/scatter factorinduced scattering of epithelial cells [34, 65, 82]. The role of Ras effector pathways in epithelial plasticity was analyzed in EpH4 mammary epithelial cells using Ras effector mutants and signaling inhibitors. These experiments revealed that hyperactivation of the ERK1/2 pathway cooperated with TGF-β to induce a full EMT in these cells [38]. Treatment with the MEK1/2 inhibitor PD98059 completely prevented and reversed EMT. Similarly, in TGF-β-responsive pancreatic cancer cells bearing activating KRAS mutations, TGF-β1 treatment caused an EMT that was reduced or abolished by pretreatment with the MEK1/2 inhibitor [23]. More recently, we have reported that expression of activated forms of MEK1 or MEK2 induces a partial EMT in IEC-6 intestinal epithelial cells, characterized by loss of epithelial polarity, adoption of a fibroblastoid morphology and downregulation of E-cadherin expression [90]. No induction of the mesenchymal proteins vimentin and smooth muscle α-actin was observed in IEC-6 cells. These results suggest that constitutive ERK1/2 signaling, while disrupting normal epithelial morphology and polarization, is not sufficient to induce a full EMT. In agreement with this idea, conditional activation of Raf was shown to induce an EMT in MDCK cells, but this was dependent on the operation of an autocrine loop producing TGF-β [51]. Activation of the ERK1/2 pathway can also contribute to the induction of TGF-β1 by TGF-β3 in epithelial cells [100]. One mechanism by which ERK1/2 signaling contributes to EMT execution is through induction of the Snail family of transcriptional repressors. In MDCK cells, treatment with PD98059 was found to decrease basal Snail promoter activity and to abolish Snail induction in response to TGF-β or activated Ras [59]. HGF-induced Snail expression and cell scattering is also dependent on ERK1/2 activation in hepatocytes [31]. Notably, the upregulation of Snail by HGF requires the activity of the zinc finger transcription factor Egr-1, a known target of ERK1/2 MAP kinases. Activation of the ERK1/2 pathway by receptor tyrosine kinases also leads to the induction of Slug and to repression of E-cadherin transcription in colon carcinoma
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
29
cells [15]. Another mechanism by which oncogenic Ras-mediated ERK1/2 activation decreases intercellular adhesion in lung epithelial cells is through induction of metalloproteinase (MMP)-9 and proteolytic cleavage of E-cadherin, resulting in partial disruption of adherens junctions [92]. Interestingly, a recent study has identified RSK1 and RSK2 as key effectors of the ERK1/2 pathway for eliciting cell scattering and mesenchymal gene expression in epithelial cell lines of diverse origins [21]. RSK activity is also important for Raf-induced secretion of TGF-β in MDCK cells.
3.3.1.2 Extracellular Proteases and Invasiveness The most characteristic trait of malignant cells is their ability to invade normal adjacent tissues. Dissemination of cancer cells involves the breakdown and remodeling of extracellular matrix (ECM) components by extracellular proteases to allow movement of individual or collective mass of cells into new passage ways. Several classes of proteases contribute to ECM remodeling, but the most important are probably the MMPs, a family of zinc-dependent proteinases that can degrade all components of the ECM [20, 40]. The role of MMPs is not limited to tumor cell invasion, as these enzymes can proteolytically process a large number of growth factors, cytokines, adhesion molecules and precursor of biologically active proteins to impact on tumor initiation, angiogenesis and immune surveillance [22]. Cancer cells frequently upregulate MMP expression, but the bulk of these proteases are secreted by host-derived cells like fibroblasts, endothelial cells or inflammatory cells that contribute to the tumor microenvironment. It should be noted that individual tumor cells can switch to an amoeboid mode of movement and invade local tissue in the absence of extracellular proteolysis [73]. The ERK1/2 MAP kinase pathway plays a major role in inducing proteolytic enzymes and promoting tumor cell invasiveness. Numerous studies have reported that pharmacological inhibition of MEK1/2 markedly decreases the invasiveness of various carcinoma cells in vitro [39, 68, 78, 80]. Importantly, constitutive activation of MEK1 or MEK2 is sufficient to upregulate the expression of ECM proteases and to increase the invasive capacity of mammary and intestinal epithelial cells [63, 90]. Biochemical studies and transcriptional profiling experiments have revealed that the ERK1/2 pathway regulates the expression of several MMP genes, such as MMP-1, MMP-3, MMP-7, MMP-9, MMP-10, MMP-11, MMP-13, MMP-14, MMP-19 and MMP-25 [21, 45, 68, 89, 90]. ERK1/2 signaling also coordinately enhances the expression of α2-integrin and CD44, which act as receptors for MMP-1 and MMP-9, respectively [21]. Compelling evidence that these MMPs regulate tumor progression and metastasis was provided by genetic studies employing engineered mouse models [20]. Another protease that plays a crucial role in tumor cell invasion and metastasis is the serine protease urokinase-type plasminogen activator (uPA) [9, 48]. Activated uPA bound to its cell surface receptor uPAR on tumor cells converts the zymogen plasminogen into the active protease plasmin, which in turn cleaves pro-MMPs into MMPs and latent TGF-β1 into its active form. Hyperactivation of ERK1/2 MAP
30
L. Voisin et al.
kinases was shown to upregulate the expression of uPA and of its receptor uPAR in a variety of stromal and tumor cell types [1, 21, 48, 63, 90]. 3.3.1.3 Tumor Cell Motility The acquisition of cell motility is essential for tumor cells to invade surrounding tissues and enter into the blood or lymphatic circulation. Cancer cells can move by at least three distinct mechanisms: mesenchymal motility, amoeboid motility and collective motility [73]. Studies with cultured cells and gene expression profiling have provided strong evidence for the involvement of the ERK1/2 signaling pathway in mesenchymal motility of epithelial cells [21, 88]. The cell motility cycle consists of the following steps: formation of protrusions at the leading edge, integrin-mediated adhesion to the underlying substrate, cell contraction and disassembly of adhesions at the rear [70]. The Rho GTPases Cdc42 and Rac, which are key regulators of actin dynamics, control the formation of protrusions (filopodia and lamellipodia) at the front of the moving cell [66]. Rho, on the other hand, regulates the assembly of stress fibers and focal adhesions assembly and is required for cell body contraction. One of the mechanisms by which the ERK1/2 pathway promotes cell motility is by regulating the activity of Rho family GTPases. In colon carcinoma cells, ERK1/2 signaling was shown to coordinately modulate the activity of Rho and Rac via transcriptional upregulation of the Fra-1 transcription factor and uPAR [87]. Induction of Fra-1 inactivates β1-integrin signaling by an unknown mechanism, resulting in the repression of Rho-GTP levels and reduced activation of the Rho effector ROCK. This prevents the formation of excessive stress fibers and focal adhesions, allowing Rac-induced membrane ruffles to be extended into protrusions. Elevated expression of uPAR drives the activation of Rac and membrane ruffling by a Fra1-independent mechanism. Active ERK1/ERK2 MAP kinases localize to cell adhesions [25] and several studies have shown that local ERK1/2 activity is required for focal adhesion disassembly and migration [43, 94, 97]. Various molecular mechanisms have been proposed to explain how ERK1/2 signaling affects adhesion, including stimulation of calpain 2 activity and proteolysis of FAK, downregulation of ROCKI/II expression or activity, and induction of Rnd3 expression [12, 30, 43, 57, 72]. A more recent study reported that oncogenic Ras-mediated ERK1/2 activation induces tyrosine dephosphorylation and inhibition of FAK activity, resulting in decreased adhesion and enhanced migration and metastasis [101]. Another target of ERK1/2 MAP kinases involved in the regulation of cell motility is myosin light chain kinase (MLCK). Together with ROCK, MLCK regulates actinmyosin contractility by phosphorylating the regulatory light chain of myosin II. A study showed that ERK1/2 directly phosphorylate MLCK leading to increased myosin light chain phosphorylation and enhanced cell migration [44]. It has been suggested that ERK1/2-mediated activation of MLCK is required to generate the traction force necessary for pseudopodial protrusion formation at the side of the cell facing the chemotactic gradient [11]. Rho activity, on the other hand, facilitates pseudopodia retraction. It should also be emphasized that mesenchymal motility
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
31
is dependent upon proteolytic degradation of the ECM, which is regulated by the ERK1/2 pathway as discussed above.
3.3.2 Intravasation and Dissemination to Distant Organ Sites 3.3.2.1 Intravasation Metastasising cells that detach from the primary tumor must enter into the bloodstream and survive in the circulation until they can arrest at a secondary site. Both active and passive mechanisms have been proposed to explain how tumor cells enter the vasculature [10]. Interestingly, a recent study reported that expression of the Raf/MEK/ERK1/2 pathway inhibitor RKIP in the metastatic breast cancer cell line MDA-MB-231 inhibits cell intravasation in a murine orthotopic model [18]. 3.3.2.2 Surviving Anoikis Following intravasation, tumor cells undertake a dangerous voyage in the hostile environment of the blood circulation, where they are devoided of contact with the ECM and are threatened by high shear stress. Epithelial cells, as well as other cell types, that lose appropriate contact with the matrix or neighboring cells undergo a form of apoptosis known as anoikis [29]. Surviving anoikis, therefore, is a prerequisite for cancer progression and establishment of metastases. An early study revealed that transformation of MDCK epithelial cells with oncogenic Ras confers resistance to anoikis, although the downstream effectors mediating this response were not characterized at that time [27]. Subsequently, several studies reported that activation of the ERK1/2 MAP kinase pathway is both necessary and sufficient to protect against cell detachment-induced apoptosis in fibroblast, endothelial and epithelial cell models [5, 41, 50, 71, 77, 95]. One of the main mechanisms by which ERK1/2 signal anoikis survival is repressing the expression or activity of pro-apoptotic Bcl-2 family proteins such as Bim, and inducing the expression of pro-survival members like Bcl-2 and Mcl-1 [7]. In a pioneer study, Reginato et al. [69] have shown that expression of H-RasV12 , Raf-CAAX or MEK2DD in the mammary epithelial cell line MCF-10A completely inhibits the upregulation of Bim expression in suspension and prevents anoikis. Other mechanisms such as upregulation of c-FLIP expression [5] or autocrine production of EGF receptor ligands [77] may also contribute to the survival effect of the ERK1/2 pathway. 3.3.2.3 Escape From Immune Response In addition to surviving anoikis, tumor cells in the circulation must also escape recognition and destruction by the immune system. Although the role of the ERK1/2 MAP kinase pathway in immune-mediated antitumor responses has not been studied extensively, recent reports suggest that ERK1/2 may also control the escape of tumor cells from immune surveillance. The expression of major histocompatibility complex (MHC) class II genes is necessary for presentation of antigens to CD4+ lymphocytes and induction of an effective immune response. Both the
32
L. Voisin et al.
constitutive and inducible expression of MHC class II proteins is regulated by the transcriptional activator class II transactivator (CIITA) [81]. Studies have shown that ERK1/2 signaling negatively regulates the expression and function of CIITA in dendritic cells and macrophages [91, 98]. Interestingly, a recent study identified the Ig superfamily membrane glycoprotein CD200 as a transcriptional target of the Raf/MEK/ERK1/2 pathway in melanoma cells [62]. Expression of CD200 mRNA is higher in melanoma than in other tumors and correlates with progression from nevi to melanoma. Importantly, the authors showed that melanoma cell lines expressing high CD200 repressed primary T cell activation by dendritic cells, an effect abrogated by RNAi silencing of CD200 expression. These findings suggest that hyperactivation of ERK1/2 in metastatic melanomas attenuates the host antitumor immune response. Another study reported that stimulation of human keratinocytes with EGF or expression of oncogenic Ras activates ERK1/2 and markedly decreases expression of the skin-associated chemokine CCL27, which regulates the recruitment of T cells to the skin during immune surveillance [64]. Treatment of keratinocytes with the MEK1/2 inhibitor U0126 was found to abrogate the suppression of CCL27 expression. This suggests that skin tumors may evade T cell-mediated antitumor response by downregulating CCL27 expression through activation of the Ras-ERK1/2 pathway.
3.3.3 Extravasation, Formation of Micrometastases and Outgrowth of Secondary Tumors 3.3.3.1 Extravasation Once at the secondary site, tumor cells must adhere to the endothelium and transmigrate across endothelial cells by a process known as diapedesis. Expression of the adhesion molecule E-selectin, which is induced by proinflammatory cytokines, appears to play an important role in the homing of cancer cells [96]. Early studies have shown that metastatic Ras-transformed NIH 3T3 fibroblasts and parental nontransformed cells extravasate with the same kinetics in the chick chorioallantoic membrane model or after injection in the mouse mesenteric vein [46, 86]. However, a recent study has suggested that the ERK1/2 MAP kinase pathway may play an active role in diapedesis [85]. Indeed, it has been reported that activation of E-selectin by the binding of circulating colon cancer cells triggers the activation of ERK1/2, and that inhibition of ERK1/2 signaling with PD98059 or by adenoviral expression of a dominant-negative ERK1/2 mutant inhibits E-selectin-mediated transendothelial migration. 3.3.3.2 Establishment and Outgrowth of Micrometastases Into Macrometastases The outgrowth of single extravasated cells into micrometastases and eventually macrometastases is a very inefficient step of the metastatic cascade [14, 28]. Tumor cells must adapt to their new microenvironment, resist to immune attack, survive
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
33
apoptosis, and start proliferating. Early observations have shown that cancer cells do not colonize tissues randomly but have a predilection to form macrometastases in specific organs. This compatibility between disseminated tumor cells and host tissues has led to the formulation of the “seed and soil” hypothesis [24]. Several mechanisms have been proposed to explain the tropism of metastasizing cells. Many evidence point to a role of the ERK1/2 MAP kinase pathway in the outgrowth of micrometastases. Webb et al. [93] compared the ability of Ras effector domain mutants expressed in NIH 3T3 fibroblasts to mediate tumorigenic and metastatic phenotypes in nude mice. While all Ras effector mutants displayed comparable tumorigenic properties, only the V12S35 mutant that activates the Raf/MEK/ERK1/2 pathway was able to induce the formation of lung metastases when injected intravenously. To confirm this finding, the authors further showed that expression of the Mos oncogene, a strong activator of MEK1/MEK2, or activated MEK1 also confer metastatic properties to the cells. These results suggest that constitutive activation of the ERK1/2 pathway is necessary and sufficient to promote the last steps of the metastatic cascade. Another study showed that Ras does not enhance the ability of NIH 3T3 cells to extravasate from liver sinusoids or to initiate proliferation of cells to form micrometastases in a liver metastasis model [86]. However, only micrometastases formed by Ras-transformed cells persisted to form macrometastases by day 14, whereas most NIH 3T3 micrometastases disappeared from liver. Ras signaling was able to shift the balance between apoptosis and cell division in favor of proliferation in this model. Interestingly, an elegant series of in vivo studies using the chick chorioallantoic membrane model and nude mice has highlighted the importance of the ERK1/2 and p38 MAP kinase pathways in regulating metastasis dormancy [2–4]. These studies showed that the ratio of ERK1/2-to-p38 activity dictates cell proliferation or growth arrest and dormancy in various cancer cell lines. High expression of uPAR, by interacting with and activating α5β1 integrin, initiates a signaling cascade that leads to sustained activation of ERK1/2 and cell proliferation. High ERK1/2 activity is maintained by a positive feedback loop that induces uPA and uPAR expression (see above). Downregulation of uPAR expression decreases ERK1/2 activity and increases p38 activity, inducing dormancy of carcinoma cells. ERK1/2 signaling may contribute to metastasis outgrowth via several molecular mechanisms. The central role of ERK1/2 in cell cycle progression and cellular survival is well documented and has been the subject of recent reviews [6, 7, 13, 54, 84]. In addition, growing metastases like primary tumors are critically dependent on the recruitment of new blood vessels (angiogenesis) or on co-option of existing vessels to provide the cells with the nutrients and oxygen necessary to reach a clinically detectable size [8]. This angiogenic switch is controlled by a balance between pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), and anti-angiogenic factors like thrombospondin. Activation of the ERK1/2 pathway can stimulate angiogenesis by upregulating VEGF expression through the regulation of Sp1 and HIF-1 transcription factors [56]. Finally, ERK1/2 signaling may also contribute to metastasis expansion by favoring immune-system evasion.
34
L. Voisin et al.
3.4 Concluding Remarks The ERK1/2 MAP kinase signaling pathway has gained notoriety for its role in cell cycle progression and cell proliferation. However, later work has provided convincing evidence for the involvement of this pathway in other cellular processes that are essential hallmarks of cancer. In vitro studies of cancer cell lines and in vivo findings from animal models have highlighted the role of ERK1/2 signaling in cell survival, motility, invasiveness and angiogenesis. Through its various effects, the ERK1/2 pathway may contribute to every step of the metastatic process, from the early escape of cancer cells from the primary tumor loci to the late step of metastatic colonization (Fig. 3.1). Indeed, expression of activated forms of MEK1 or MEK2 in intestinal epithelial cells is sufficient to induce the formation of intestinal tumors and to promote tumor progression and metastasis in a mouse orthotopic transplantation model [90]. These pre-clinical studies suggest that blockade of the ERK1/2 pathway with small-molecule inhibitors of Raf or MEK1/2 should prove effective not only in shrinking the primary tumor but also in restraining metastatic dissemination, which is the major cause of cancer-associated mortality.
Fig. 3.1 The ERK1/2 MAP kinase signaling pathway in cancer metastasis. Schematic diagram illustrating how ERK1/2 signaling may contribute to every step of the metastatic process, from the early escape of cancer cells from the primary tumor to the late steps of metastatic colonization. See text for details
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
35
Acknowledgments Work in the author’s laboratory was supported by grants from the National Cancer Institute of Canada and the Cancer Research Society. S. Duhamel is recipient of a studentship from the Canadian Institutes for Health Research. S. Meloche holds the Canada Research Chair in Cellular Signaling.
References 1. Aguirre-Ghiso JA, Alonso DF, Farias EF, Gomez DE, de Kier Joffe EB. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur. J. Biochem. 1999; 263: 295–304. 2. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 2001; 12: 863–879. 3. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003; 63: 1684–1695. 4. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 2004; 64: 7336–7345. 5. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J. Cell Biol. 2001; 152: 633–643. 6. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001; 12: 397–408. 7. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009; 16: 368–377. 8. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003; 3: 401–410. 9. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 2002; 3: 932–943. 10. Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol. 2007; 8: 444–448. 11. Brahmbhatt AA, Klemke RL. ERK and RhoA differentially regulate pseudopodia growth and retraction during chemotaxis. J. Biol. Chem. 2003; 278: 13016–13025. 12. Carragher NO, Westhoff MA, Fincham VJ, Schaller MD, Frame MC. A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src. Curr. Biol. 2003; 13: 1442–1450. 13. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. ERK implication in cell cycle regulation. Biochim. Biophys. Acta 2007; 1773: 1299–1310. 14. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002; 2: 563–572. 15. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze’ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J. Cell. Biol. 2003; 163: 847–857. 16. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim. Biophys. Acta 2007; 1773: 1376–1387. 17. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77: 841–852. 18. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009; 28: 347–358.
36
L. Voisin et al.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954. 20. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25: 9–34. 21. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR, Winther O, Taunton J, Hansen SH, Frodin M. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 2009; 35: 511–522. 22. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 2: 161–174. 23. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001; 61: 4222–4228. 24. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 2003; 3: 453–458. 25. Fincham VJ, James M, Frame MC, Winder SJ. Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBO J. 2000; 19: 2911–2923. 26. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR. Cosmic 2005. Br. J. Cancer 2006; 94: 318–322. 27. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 1994; 124: 619–626. 28. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim. Biophys. Acta 2009; 1796: 293–308. 29. Gilmore AP. Anoikis. Cell Death Differ. 2005; 12(Suppl 2): 1473–1477. 30. Glading A, Chang P, Lauffenburger DA, Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem 2000; 275: 2390–2398. 31. Grotegut S, von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 2006; 25: 3534–3545. 32. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003; 4: 657–665. 33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70. 34. Herrera R. Modulation of hepatocyte growth factor-induced scattering of HT29 colon carcinoma cells. Involvement of the MAPK pathway. J. Cell Sci. 1998; 111(Pt 8): 1039–1049. 35. Hobbs RM, Silva-Vargas V, Groves R, Watt FM. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J. Invest. Dermatol. 2004; 123: 503–515. 36. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813–822. 37. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005; 5: 341–354. 38. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGF-β cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 2002; 156: 299–313.
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
37
39. Janulis M, Silberman S, Ambegaokar A, Gutkind JS, Schultz RM. Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. J. Biol. Chem. 1999; 274: 801–813. 40. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006; 25: 35–43. 41. Jost M, Huggett TM, Kari C, Rodeck U. Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway. Mol. Biol. Cell 2001; 12: 1519–1527. 42. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119: 1420–1428. 43. Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol. Biol. Cell 2008; 19: 498–508. 44. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 1997; 137: 481–492. 45. Komatsu K, Buchanan FG, Otaka M, Jin M, Odashima M, Horikawa Y, Watanabe S, Dubois RN. Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol. Cancer 2006; 5: 63. 46. Koop S, Schmidt EE, MacDonald IC, Morris VL, Khokha R, Grattan M, Leone J, Chambers AF, Groom AC. Independence of metastatic ability and extravasation: metastatic rastransformed and control fibroblasts extravasate equally well. Proc. Natl. Acad. Sci. USA 1996; 93: 11080–11084. 47. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001; 81: 807–869. 48. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006; 5: 1760–1771. 49. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, Chen W, Cobb MH. The roles of MAPKs in disease. Cell Res. 2008; 18: 436–442. 50. Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol. Biol. Cell 2000; 11: 1103–1112. 51. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 2000; 14: 2610–2622. 52. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994; 265: 966–970. 53. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008; 68: 5524–5528. 54. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007; 26: 3227–3239. 55. Montesano R, Soriano JV, Hosseini G, Pepper MS, Schramek H. Constitutively active mitogen-activated protein kinase kinase MEK1 disrupts morphogenesis and induces an invasive phenotype in Madin-Darby canine kidney epithelial cells. Cell Growth Differ. 1999; 10: 317–332. 56. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors. Cardiovasc. Res. 2005; 65: 564–573.
38
L. Voisin et al.
57. Pawlak G, Helfman DM. Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts. Mol. Biol. Cell 2002; 13: 336–347. 58. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001; 22: 153–183. 59. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 2003; 278: 21113–21123. 60. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 2007; 7: 415–428. 61. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190–193. 62. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J. Clin. Invest. 2007; 117: 3922–3929. 63. Pinkas J, Leder P. MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res. 2002; 62: 4781–4790. 64. Pivarcsi A, Muller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, Seeliger S, Kubitza R, Pippirs U, Meller S, Gerber PA, Liersch R, Buenemann E, Sonkoly E, Wiesner U, Hoffmann TK, Schneider L, Piekorz R, Enderlein E, Reifenberger J, Rohr UP, Haas R, Boukamp P, Haase I, Nurnberg B, Ruzicka T, Zlotnik A, Homey B. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl. Acad. Sci. USA 2007; 104: 19055–19060. 65. Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 1998; 9: 2185–2200. 66. Raftopoulou M, Hall A. Cell migration: rho GTPases lead the way. Dev. Biol. 2004; 265: 23–32. 67. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100–3112. 68. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003; 22: 395–403. 69. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK, Brugge JS. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 2003; 5: 733–740. 70. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. Cell migration: integrating signals from front to back. Science 2003; 302: 1704–1709. 71. Rosen K, Rak J, Leung T, Dean NM, Kerbel RS, Filmus J. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J. Cell Biol. 2000; 149: 447–456. 72. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001; 20: 755–766. 73. Sahai E. Mechanisms of cancer cell invasion. Curr. Opin. Genet. Dev. 2005; 15: 87–96. 74. Scholl FA, Dumesic PA, Khavari PA. Mek1 alters epidermal growth and differentiation. Cancer Res. 2004; 64: 6035–6040. 75. Schramek H, Feifel E, Healy E, Pollack V. Constitutively active mutant of the mitogenactivated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells. J. Biol. Chem. 1997; 272: 11426–11433.
3
The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis
39
76. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007; 7: 295–308. 77. Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 2001; 15: 981–994. 78. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999; 5: 810–816. 79. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004; 4: 937–947. 80. Simon C, Juarez J, Nicolson GL, Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. Cancer Res. 1996; 56: 5369–5374. 81. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135–146. 82. Tanimura S, Chatani Y, Hoshino R, Sato M, Watanabe S, Kataoka T, Nakamura T, Kohno M. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene 1998; 17: 57–65. 83. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2: 442–454. 84. Torii S, Yamamoto T, Tsuchiya Y, Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 2006; 97: 697–702. 85. Tremblay PL, Huot J, Auger FA. Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res. 2008; 68: 5167–5176. 86. Varghese HJ, Davidson MT, MacDonald IC, Wilson SM, Nadkarni KV, Groom AC, Chambers AF. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res. 2002; 62: 887–891. 87. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4: 67–79. 88. Viala E, Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. N. Y. Acad. Sci. 2004; 1030: 208–218. 89. Vincenti MP, Brinckerhoff CE. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J. Cell Physiol. 2007; 213: 355–364. 90. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, Rodrigue-Gervais IG, Gaboury L, Lamarre D, Basik M, Meloche S. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 2008; 8: 337. 91. Voong LN, Slater AR, Kratovac S, Cressman DE. Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator. J. Biol. Chem. 2008; 283: 9031–9039. 92. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol. Biol. Cell 2009; 20: 791–800. 93. Webb CP, Van Aelst L, Wigler MH, Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA 1998; 95: 8773–8778. 94. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat. Cell Biol. 2004; 6: 154–161. 95. Welch DR, Sakamaki T, Pioquinto R, Leonard TO, Goldberg SF, Hon Q, Erikson RL, Rieber M, Rieber MS, Hicks DJ, Bonventre JV, Alessandrini A. Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res. 2000; 60: 1552–1556.
40
L. Voisin et al.
96. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008; 27: 19–30. 97. Xie H, Pallero MA, Gupta K, Chang P, Ware MF, Witke W, Kwiatkowski DJ, Lauffenburger DA, Murphy-Ullrich JE, Wells A. EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCgamma signaling pathway. J. Cell Sci. 1998; 111(Pt 5): 615–624. 98. Yao Y, Xu Q, Kwon MJ, Matta R, Liu Y, Hong SC, Chang CH. ERK and p38 MAPK signaling pathways negatively regulate CIITA gene expression in dendritic cells and macrophages. J. Immunol. 2006; 177: 70–76. 99. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24: 21–44. 100. Yue J, Mulder KM. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J. Biol. Chem. 2000; 275: 30765–30773. 101. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, Gao X, Zhou XZ, Aldape K, Cobb MH, Xie K, He J, Lu Z. FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol. Cell 2009; 35: 11–25.
Chapter 4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis Alexey Shiryaev, Marijke Van Ghelue, and Ugo Moens
Abstract Cancer is characterized by cells that disobey the stringent control mechanisms of cellular processes such as division and growth, survival, homeostasis, motility, and tissue invasion. Signalling pathways, including the mitogenactivated protein kinase (MAPK) signalling pathways, regulate these cellular processes. Not unexpectedly, cancer cells display defects in signalling pathways due to mutations in genes encoding signal transduction proteins. The typical MAPK pathways transmit, amplify and translate signals through consecutive phosphorylation events engaging a MAPK kinase kinase, a MAPK kinase, and a MAPK, which finally phosphorylates substrates. These substrates can be non-protein kinases or protein kinases. The latter are referred to as MAPK-activating protein kinases. Escalating evidence exists that the MAPK signal transduction pathways can be implicated in metastasis. This review focuses on the specific roles of MAPKactivating protein kinases in metastasis and summarizes potential small inhibitors against MAPK-activating protein kinases that may find their way in cancer therapy. Keywords MAPK-activating protein kinases · Inhibitors · Metastasis · Cytoskeleton · Gene expression Abbreviations AMPK BRSK2 CaMKK CHK2 CK DYRK EPCG ERK8
AMP-activated protein kinase brain-specific kinase 2 calmodulin-dependent kinase checkpoint kinase 2 casein kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase Epigallocatechin gallate extracellular-signal-regulated kinase 8
U. Moens (B) Medical Faculty, Department of Medical Biology, University of Tromsø, N-9037 Tromsø, Norway e-mail:
[email protected]
W.-S. Wu, C.-T. Hu (eds.), Signal Transduction in Cancer Metastasis, Cancer Metastasis – Biology and Treatment 15, DOI 10.1007/978-90-481-9522-0_4, C Springer Science+Business Media B.V. 2010
41
42
GSK3β HIPK IKK LCK MARK3 MELK MST2 PDK1 PHK PIM PKA PKBα PKCα PRK2 ROCK-II SGK1 Src SRPK1 S6K1
A. Shiryaev et al.
glycogen synthase kinase 3β homeodomain-interacting protein kinase 2 IkappaB kinase lymphocyte cell-specific protein tyrosine kinase microtubule-affinity-regulating kinase maternal embryonic leucine-kinase mammalian homologue Ste20-like kinase 2 3-phosphoinositide-dependent protein kinase phosphorylase kinase provirus integration site for Moloney murine leukaemia virus protein kinase A/cAMP-dependent protein kinase protein kinase B isoform α protein kinase C isoform α protein kinase C-related kinase 2 Rho-dependent kinase II serum- and glucocorticoid-induced kinase 1 sarcoma kinase serine-arginine protein kinase 1 p70 ribosomal protein S6 kinase 1
Contents 4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2 MAPKAPK and Cancer . . . . . . . . . . . . . . . . . . . . . 4.2.1 Mutations in the MAPKAPK-encoding Genes in Cancer Tissue 4.2.2 MAPKAPK Expression Levels in Cancers . . . . . . . . . . 4.2.3 MAPKAPK and Cell Cycle . . . . . . . . . . . . . . . . . 4.2.4 MAPKAPK and Cell Survival . . . . . . . . . . . . . . . 4.3 MAPKAPK and Metastasis . . . . . . . . . . . . . . . . . . . . 4.3.1 MAPKAPK and Regulation of the Cytoskeleton . . . . . . . 4.3.2 MAPKAPK and Gene Regulation . . . . . . . . . . . . . . 4.4 Role of MAPKAPK in Tumour Angiogenesis Triggered by VEGF . . 4.5 MAPKAPK Inhibitors . . . . . . . . . . . . . . . . . . . . . . 4.6 Future Perspectives . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . . .
42 45 45 47 47 50 50 51 56 62 63 63 64
4.1 Introduction Many cellular processes such as proliferation, differentiation, apoptosis, development, gene expression, and cell motility are governed by signal transduction pathways. Such pathways often consist of protein kinases that transmit and convert signals through a relay of protein phosphorylation events [131, 156]. One of
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
43
the major signalling pathways in mammalian cells is the mitogen-activated protein kinase (MAPK) pathway. Seven distinct mammalian MAPK pathways have been identified that mediate cellular responses to a wide variety of extracellular signalling molecules (Fig. 4.1). The typical MAPK pathways, represented by the ERK1/2, ERK5, JNK, and p38 modules consist of a cascade of three consecutive phosphorylation events exerted by a MAPK kinase kinase (MAPKKK or MAP3K), a MAPK kinase (MAPKK or MAP2K), and a MAPK. The atypical MAPKs ERK3, ERK4, ERK7, and ERK8 comprise the less characterized MAPK pathways [36, 37, 89, 94, 112, 167, 180, 218, 235]. MAPKs not only target substrates without kinase activity, but also phosphorylate other protein kinases designated as MAPK-activated protein kinases (MAPKAPK). The MAPKAPK include the ribosomal-S6-kinases (RSK1–4 or MAPKAPK1a-d), the MAPK-interacting kinases (MNK1 and 2), the mitogenand stress-activated kinases (MSK1 and 2), and the MAPKAPK (MK2, 3 and 5) subfamilies [4, 5, 18, 59, 157, 177]. The first MAPKAPK to be isolated was ribosomal S6 kinase (RSK), a 90 kDa protein kinase that phosphorylated the 40S ribosomal subunit protein S6 in Xenopus laevis oocytes [53]. This family of serine/threonine kinase consists of four human isoforms referred to as RSK1–4 (p90Rsk1−4 ) or MAPKAPK1a-d that share 65–73% amino acid identity [4, 23]. RSKs regulate cell growth, cell proliferation, cell survival, transcriptional and translational regulation, and cell motility [4, 23].
MEKK1-4 MEKK1-4 MLK2/3 MLK2/3 ASK1 TAO1/2 TAK1 TAK1 ASK1/2
MAPKKK
RAF1/A/B C-MOS
???
MEKK 2/3
???
MAPKK
MEK 1/2
ERK3K
MEK5
???
MEK 4/7
MEK 3/6
MAPK
ERK 1/2
ERK 3/4
ERK5
ERK 7/8
JNK 1/2/3
p38 α/β/γ/δ
MAPKAPKs (MKs)
RSKs
MNKs
MSKs
MK5
MK2/3
Fig. 4.1 Schematic presentation of the mammalian MAPK pathways. The classical MAPK pathways, represented by the MEK/ERK, JNK, p38 MAPK, and MEK5/ERK5 pathways, consist of a module of three kinases that subsequently phosphorylate and activate each other. The MAPK kinase kinase (MAPKKK or MAP3K) phosphorylates MAPK kinase (MAPKK or MAP2K), which in turn phosphorylates MAPK. Downstream of MAPK are substrates including other protein kinases referred to as MAPK-activated protein kinases (MAPKAPK or MK). The atypical pathways include ERK3, ERK4, ERK7, and ERK8. MAPKs can converge to different MAPKAPK as shown in this figure. ERK7/8 and the JNKs 1–3 do not seem to activate MAPKAPK
44
A. Shiryaev et al.
Studies with knockout mice revealed that Rsk1−/− and Rsk3−/− were viable with no obvious phenotype, while Rsk2−/− mice had impaired learning and cognitive functions, poor coordination, suffered of osteopaenia, and had a specific loss of white adipose tissue. Mutations in the human rsk2 gene are associated with the X-linked mental retardation Coffin-Lowry syndrome [203]. Remarkably, the triple Rsk1−/− /Rsk2−/− /Rsk3−/− knockout mice were viable, while reports on Rsk4−/− mice are lacking so far [4]. The MAPK-interacting or MAPK signal-integrating kinases 1 and 2 (MNK1 and MNK2) were originally identified by screening ERK substrates, but later it was shown that they are activated in vivo by both ERK and p38 MAPK. Two C-terminal different human MNK1 (MNK1a and MNK1b) and two human MNK2 (MNK2a and MNK2b) isoforms, have been identified in human and mouse [18]. The exact in vivo functions of MNK1 and MNK2 are not known because mice deficient in MNK1, MNK2, or both appear normal (reviewed in Gerits et al. [63]). A recent study reported that transgenic mice expressing a constitutive active MNK1 mutant developed tumours rapidly compared to control mice, suggesting that MNK1 can act as an oncogene [216]. MNK1 and MNK2 seem to be involved in anti-apoptotic signalling in response to serum withdrawal as MNK1−/− /MNK2−/− mouse embryonic fibroblasts more readily undergo apoptosis after removal of serum compared to wild-type cells [29]. Identification of substrates proposed the possible involvement of MNK in transcriptional and translational regulation, inflammatory responses, proliferation and survival [18, 61]. Mitogen- and stress-activated protein kinases 1 and 2 (MSK-1 and MSK-2, also termed RSK-B) play a versatile role in transcription and translational regulation, and therefore they can affect inflammatory responses and neuronal processes [5, 205]. The exact physiological roles of MSKs remain obscure as MSKs seem dispensable for mammalian development, and knockout mice do not exhibit an obvious phenotype under normal conditions (reviewed in Gerits et al. [63]). Perturbed MSK activity was reported in two clinical conditions. Enhanced MSK1 and MSK2 activity was detected in lesional psoriatic epidermis compared to non-lesional skin [58], while a deficit in MSK-1 expression was monitored in the striatum of post-mortem Huntington’s disease patients [181]. The molecular mechanisms for MSKs in these disorders are, however, not understood. Mitogen-activated protein kinase-activated protein kinases 2 (MK2) and MK3 possess 75% sequence identity and are directly activated by p38 MAPK (reviewed in Gaestel [59] and Ronkina et al. [176]). Although both enzymes are ubiquitously expressed, the protein and activity levels of MK2 are more prominent than MK3 [176, 177]. MK2 knockout mice are fertile, viable, of normal size and depict no specific behavioural defects, but these animals display increased stress resistance and survive LPS-induced endotoxic shock [109]. Additional studies revealed that MK2 participates in cytokines production, endocytosis, cytoskeleton architecture, cell migration, cell cycle control, cell survival, and transcriptional regulation (reviewed in Gaestel [59] and Ronkina et al. [177]). Moreover, MK2 may play a
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
45
contributing role in infections and in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and asthma [61]. MK3 deficient mice are viable, fertile and possess an apparent wild-type phenotype under normal condition [176]. However, studies in a MK2-deficient background indicated that MK3 can compensate for the loss of MK2 [176]. This suggests that MK2 and MK3 are functionally closely related enzymes. Unexpectedly, MK2/MK3 double knock-out mice showed no obvious embryonic defects and are viable [176]. Mitogen-activated protein kinase-activated protein kinase 5 (MK5) and its human homologue p38-regulated/activated protein kinase (PRAK) were originally described as in vitro p38 substrates that could be activated by p38 through phosphorylation of Thr-182 [143, 144]. However, MK5 seems to be mainly activated by the atypical ERK3 and ERK4 MAPK [1, 99, 186, 188], while the connection with p38 remains controversial [59]. The biological functions of MK5 are poorly understood, as MK5 knockout mice bred onto different backgrounds display either no obvious phenotype or are embryonic lethal [59]. Recent studies demonstrated that PRAK/MK5 is involved in ras-induced senescence, tumour suppression, inhibition of cell proliferation, rearrangements of the cytoskeleton, and anxiety-related behaviour [64, 65, 108, 116, 198].
4.2 MAPKAPK and Cancer A causative role for several components of the MAPK signalling pathways in cancer is well documented [36, 43, 44, 124, 173, 220]. Far less investigation has been performed on the putative contribution of MAPKAPK in oncogenesis, but these kinases contain properties of either oncogenes or tumour suppressors. In this section we will briefly outline some of these oncogenic properties of the MAPKAPK, while in Section 4.3 we will focus on the implications of MAPKAPK in metastasis.
4.2.1 Mutations in the MAPKAPK-encoding Genes in Cancer Tissue Screening the human kinome, i.e. the complete set of protein kinase genes in the genome, for somatic mutations in different cancers, including breast, lung, colorectal, gastric, testicular, ovarian, renal, melanoma, glioma, and acute lymphoblastic leukaemia revealed single nucleotide substitutions in the genes for the MAPKAPs (see Table 4.1). The impact of these mutations on the functions of the MAPKAPK enzymes and the prevalence of these mutants in cancer tissue have not been investigated in detail, nor has a causative role in tumorigenesis or metastasis been established.
RPS6KA1 RPS6KA3
RPS6KA2
RPS6KA6
RPS6KA5 RPS6KA4
RPS6KA5 MKNK1 MKNK2 MAPKAPK2 MAPKAPK3
MAPKAPK5 12q24.12-q24.13
RSK1 RSK2
RSK3
RSK4
MSK1 MSK2, RSKB
MSK1 MNK1 MNK2 MAPKAPK-2, MK2 MAPKAPK-3, MK3
MAPKAPK-5, MK5, PRAK
None c.1246A>G c.1822C>T (hom) c.1448A>G c.931G>A c.1280C>G c.1581+1G>A (IVS16+1 G>A) c.2195G>A c.772T>A c.419A>G none c.707C>T c.1137_1138GG>TT None None None None c.82C>T c.314A>C None
Mutation
P28S p.E105A
p.S236L p.L379_E380>Lstop
p.R732Q p.S258T p.Y140C
p.I416V p.L608F p.Y483C p.E311K p.S427stop
Amino acid change
Brain Ovary
Breast Lung
Breast Brain Stomach Skin Lung Ovary Large intestine LUNG Lung
Cancer tissue
[70, 86] [70, 86]
[70, 193] [70]
[225] [70, 86] [70] [70] [39, 70] [70] [70] [39, 70] [39, 70]
Reference
Nucleotide changes are represented as “c.” indicating that nucleotide +1 in the coding DNA reference sequence is the A of the ATG translation initiation codon. A “p.” is used to indicate description of amino acid change at the protein level, meaning that the translation initiator Methionine is numbered as +1. Amino acid changes are indicated by the one letter code. “Stop” represents nonsense mutation.
14q31-q32.1 1p33 19p13.3 1q32 3p21.3
14q31-q32.1 11q11-q13
Xq21.1
6q27
1p Xp22.2-p22.1
Gene name
Protein
Chromosome location
Table 4.1 Somatic mutations in genes encoding MAPKAPK
46 A. Shiryaev et al.
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
47
4.2.2 MAPKAPK Expression Levels in Cancers RSK1 and 2 protein levels are often upregulated in prostate and breast cancer compared to normal tissues [32, 192]. On the other hand, RSK3 expression is reduced or absent in ovarian tumours and cell lines, suggesting a role as tumour suppressor [14]. The activities of MNK1 and MNK2 are enhanced in certain breast cancer cell lines that overexpress HER2 [30]. Increased phosphoMK2 and phosphoMK3 levels have also been reported in thyroid carcinomas compared to normal tissue [162], while the expression level of MK5 in ovary, prostate and stomach tumour tissue was elevated compared to levels in normal tissue [66]. The biological implication of anomalous MAPKAPK expression in these cancers remains unclear.
4.2.3 MAPKAPK and Cell Cycle One hallmark of cancer cells is uncontrolled cell cycle regulation [75]. Some MAPKAPK have the potential to interfere with the cell cycle. Inhibition of RSK by the specific inhibitor SL0101 and depletion of RSK1 or RSK2 produced a block in the G1 phase of the cell cycle in mammalian cells [23, 192], while rsk2−/− mouse embryonic fibroblasts accumulate at the G1 phase [28]. RSK3 can reduce cell proliferation and cause G1 arrest in ovarian cancer cells, suggesting a role as tumour suppressor [14]. Depletion of RSK4 strongly reduced the mRNA levels of p21Cip1 and abolished p53-dependent G1 cell arrest induced either by conditional activation by p53 or by DNA damage via ionizing irradiation [11]. On the other hand, Thakur et al. [201] reported that overexpression of RSK4 in the human breast cancer cell line MDA-MB-231 suppressed cell proliferation, triggered accumulation in G0 /G1 phase, and enhanced expression of p21Cip1 . RSK can affect the cell cycle progression through several mechanisms, including controlling the activity of the cell cycle regulator proteins Bub1, Emi2, Cdc25, LKB1, c-FOS, cyclindependent kinase (CDK) inhibitor p27Kip1 and Myt1 through direct phosphorylation, and through stimulation of cyclin B synthesis (reviewed in Kostenko et al. [107]). A role for MSK in cell proliferation derives from studies using the MSK inhibitor Ro31-8220 [185] or knockdown of MSK1 [103], but the molecular mechanisms remain elusive. A few reports suggest a possible involvement of MNKs in cell cycle regulation and cancer. Treatment of the AU565 breast cancer cell lines, which displays enhanced MNK activity, or prostate PC3 cells with the MNK inhibitor CGP57380 (see Table 4.2) prevented colony formation or decreased the rate of proliferation [13, 30], while dominant negative MNK1 restrained the growth of leukaemia cells [30]. Mice transplanted with hematopoietic stem cells expressing activated MNK1 displayed accelerated tumorigenesis compared to mice reconstituted with cells expressing kinase-dead MNK1 [216]. Another group found that overexpression of a dominant negative MNK1 inhibited cell proliferation [216, 226]. All these observations point to a role of MNK in cell cycle regulation, but the
MSK IC50 = 8 nM IC50 = 8.3 μM for MSK1 IC50 = 5 μM for MSK1 60% inhibition with 50 μM 91% inhibition with 0.1 μM IC50 = 1.8 nM
Ro 318220 Y 27632 HA1077 Flavokavain A
A-443654
(1H-Imidazo [4,5-c]pyridin-2-yl)-1,2, 5-oxadiazol-3-ylamine compound 27
IC50 = 2.8 mM for RSK2 IC50 = 3 mM for RSK2 IC50 = 19 μM for RSK2 IC50 = 15 μM for RSK2 60% inhibition at 10 μM
H89 Ro 318220 Y 27632 HA1077 SB415286 IC50 = 120 nM
73% at 10 μM
SU 6656
H89
Aurora B, PIM3 Lck, Src, S6K1 Aurora B, PLK1, MELK, MST2 AMPK, Aurora B, Aurora C, BRSK2, CaMKKα, CaMKKβ, CHK2, DYRK1A, LCK, MST2, PHK, Src, SRPK1 PKA S6K1,MSK1, PKCα MSK MSK1,ROCK-II,PRK2 CaMKKβ, ERK8, GSK3β, DYRK1A, HIPK2, PIM3, SRPK1 PKA, S6K1, ROCK-II, PKBα, RSK2 S6K1, RSK2, PKCα RSK2 RSK2, ROCK-II, PRK2 Aurora B, Dyrk1A, IKKβ, MK3, MK5 DYRK1A, PKA, PKBα, PKBβ, PRK2 Not tested
IC50 = 89 nM IC50 = 15 nM 99% at 0.1 μM
SL0101 Fmk BI-D1870
RSK
Other targets
Inhibitory activity
Compound
MAPKAPK
Table 4.2 MAPKAPK inhibitors, their specificities, and use in clinical trial
No
No
No No No No
No
No No No No No
No
No No No
Clinic trials
[9]
[7]
[38] [38] [38] [57]
[5, 38]
[5, 38] [38] [38] [38] [7]
[7]
[7, 192] [7, 34] [7, 183]
References
48 A. Shiryaev et al.
MK5
MK3
MK2
IC50 = 2.5–10 μM 96% inhibition with 50 μM
Pyrranopyridine derivative Flavokavain A IC50 = 1.9 μM 90% inhibition with 10 μM 91% inhibition with 50 μM
Rottlerin EGCG
Flavokavain A
Aurora B, Dyrk1A, IKKβ, MK3, MSK1
MK3 and MK5 at 10x higher concentrations Not tested Aurora B, Dyrk1A, IKKβ, MK5, MSK1 MK2 DYRK1A
IC50 = 5.4 μM Not tested IC50 < 10 nM
BX 795
Rottlerin MK2i (KKKALNRQLGVAA peptide) Pyrrolopyridine derivatives
65% inhibition with 1 μM (MNK1)
CGP 57380 (4-amino-5-(4-fluoroanilino)pyrazolo[3,4-d]pyrimidine) CK1–7 AMPK,CK1δ, ERK8, PIM1, PIM3, SGK1 Aurora B, Aurora C, ERK8, IKKε, TBK1, MARK3, PDK1 MK5 Not tested
81% inhibition with 1 μM
Compound C
74% inhibition with 25 μM (MNK1) 81% inhibition with 0.1 μM (MNK2)
AMPK, CaMKKα, CaMKKβ, CK2, DYRK2, DRK3, ERK8, HIPK2, PIM2, PIM3, AMPK, DYRK1A, DYRK2, DYRK3, ERK8, HIPK2, MELK, PIM2, PIM3 BRSK2, CK1δ
90% inhibition with 1 μM
ST0609
MNK
Other targets
Inhibitory activity
Compound
MAPKAPK
Table 4.2 (continued)
No Phase Ib, Phase II No
No No
No
No No
No
No
No
No
No
Clinic trials
[57]
[38] [6, 33]
[40] [57]
[3]
[38] [125]
[7]
[7]
[7, 104]
[7]
[7]
References
4 Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis 49
50
A. Shiryaev et al.
precise molecular mechanism by which MNK affects the cell cycle is not known. However, phosphorylation of eIF4E by MNK was required for cell cycle progression [13, 216], indicating the involvement of eIF4E. Therefore, overexpression of a dominant negative MNK1 that lacks kinase activity may result in insufficient eIF4E phosphorylation and cell cycle arrest, while cells displaying enhanced MNK activity prevail over cell cycle control. Moreover, inhibition of MNK1 with CPG57380 resulted in selective downregulation of mRNAs encoding proteins involved in cell cycle progression such as CDK2, CDK8 and CDK9 [13], underscoring a role for MNK in cell cycle regulation. Early observations revealed that growth-factor induced proliferation coincided with strong increase in MK2 activity, while MK2 could inhibit Ras-induced proliferation of NIH3T3 cells, suggesting a role for MK2 in cell cycle progression [25, 129, 168]. Cells treated with siRNA targeting MK2 eliminated G1 arrest and G2 /M and S phase checkpoints [130]. MK2 interferes with cell cycle progression through phosphorylation of Cdc25 and as such controlling the activity of check point kinases Chk1 and Chk2 [122, 130, 170, 227] or by modulating the stability of p53 by phosphorylating MDM2 [215]. Overexpression of MK3 resulted in de-repression of the gene encoding p14/p19ARF , which induced both G1 and G2 arrest, and slowed down cell cycling [210]. Wild-type MK5, but not a kinase dead mutant could prevent p21RAS -induced proliferation in NIH3T3 cells [25]. MK5-mediated inhibition of proliferation may depend on MK5’s ability to phosphorylate and thereby stimulate the transcriptional activity of p53, and as a consequence increase the expression of the cyclin-dependent protein kinase inhibitor p21Cip1/Waf1 , a target gene of p53 [116, 198].
4.2.4 MAPKAPK and Cell Survival RSKs positively regulate cell survival in different cell types by phosphorylation/inactivation of pro-apoptotic proteins such as BAD and DAPK (reviewed in Anjum and Blenis [4]). Also MSK and MNK are involved in cell survival, but the mechanisms are incompletely understood (reviewed in Arthur [5] and Buxade et al. [18]). MK2 deficient mouse cell show increased apoptosis after UV irradiation [215], while neurons from MK2−/− mice were more resistant to lipopolysaccharideinduced apoptosis [202]. A plausible role of MK3 and MK5 in apoptosis has not been described so far.
4.3 MAPKAPK and Metastasis Metastasis is a complicated process that allows tumour cells to abandon their place of origin and to colonize at distant organs. MAPKAPK may contribute to metastasis by affecting cell motility through regulating the activity of cytoskeleton modelling proteins in a phosphorylation-dependent manner. Moreover, MAPKAPK have been
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
51
shown to regulate the expression of several proteins implicated in metastasis. These two mechanisms will be discussed in this section.
4.3.1 MAPKAPK and Regulation of the Cytoskeleton The cytoskeleton of human cells is composed of three classes of proteins comprising actin microfilaments, tubulin microtubules, and intermediate filaments [68, 151, 152]. Reorganization of the cytoskeleton is required in many cellular processes including alteration of cell shape, movement of organelles, endo- and exocytosis, cell division, extracellular matrix assembly, and cell migration [115, 118, 160, 208]. The latter process occurs during embryogenesis, immune response, and tissue repair and regeneration. However, abnormal cell migration contributes to disease progression such as cancer invasion and metastasis and requires reorganization of the cytoskeleton, including the formation of protrusive structures such as filopodia, lamellipodia and invadopodia [101, 128, 230]. 4.3.1.1 HSP27 Actin remodelling, including variety of length and spatial conformation is conferred by the action of actin-binding proteins [194]. The MAPKAPK MK2, MK3, and MK5 all seem to be able to affect actin remodelling and cell migration by targeting actin-binding proteins. The mechanisms by which these MAPKAPK affect actin rearrangements will be outlined here. Actin filaments consist of growing ends (so called barbed or “+” ends) and pointed or “−“ ends (Fig. 4.2a). One of the actin-binding proteins is the small heat shock protein 27 (HSP27) [135]. In its unphosphorylated form, HSP27 binds to barbed ends of polar actin microfilaments thereby inhibiting actin polymerization (Fig. 4.2b). Phosphorylation of HSP27 results in release of HSP27 from the barbed ends and concomitantly enhances reorganization of F-actin [117]. MK2, MK3 and MK5 are genuine HSP27 kinases that are implicated in F-actin remodelling and cell motility (reviewed in Kostenko and Moens [106]). Interestingly, HSP27 and phosphoHSP27 levels are enhanced in many tumours compared to healthy tissue [20], suggesting that increased (phospho)HSP27 levels may be implicated in invasiveness. MK5 can also affect HSP27-mediated F-actin polymerization and cell migration through an indirect mechanism requiring 14-3-3 proteins [199]. The group of Gaestel showed that phosphorylated HSP25, the murine homologue of HSP27, can interact with the seven known isoforms of 14-3-3 proteins (β, γ, ε, ν, σ, η, and ζ) in vitro [206]. This may protect phosphoHSP27 against protein phosphatases. Overexpression of MK5 in HeLa cells stimulated motility. This MK5-induced cell migration was inhibited by overexpression of 14-3-3ε protein which was shown to bind MK5 in vivo and to inactivate MK5 [199]. Hence, MK5 can extricate 14-3-3ε from phosphoHSP27 resulting in free phosphoHSP27 which can be dephosphorylated by protein phosphatases. Non-phosphorylated HSP27 will bind the barbed ends of F-actin and prevent polymerization.
52
A. Shiryaev et al. G-actin monomer
A
B
HSP27
barbed or “+” ends
PP2A
MK2,MK3,MK5
HSP27 P F-actin
pointed or “–” ends
cofilin-mediated severing
C
polymerization at barbed ends
D ARP2/3-mediated branching
cofilin G-actin monomer MK2
ARP2/3
P ARP2/3
polymerization at barbed ends
E
MK5 MK5 14-3-3ε
14-3-3ε
cofilin
kinases
14-3-3ε
P
P
cofilin
cofilin
phosphatases
14-3-3ε
F-actin severing
P
P
HSP27
HSP27
+ MK5
MK5 14-3-3ε
Fig. 4.2 (continued)
MK2, MK3, MK5
HSP27
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
53
F F-actin polymerization
no F-actin polymerization P P
CapZIP CapZ
MK2
CapZIP
CapZIP CapZ
CapZ
barbed or “+” ends
pointed or “–” ends
Fig. 4.2 Regulation mechanisms of actin polymerization. (a) New G-actin monomers are added at the barbed or plus end of the growing filamentous F-actin chain, while depolymerisation occurs at the pointed or minus ends. (b) Spontaneous assembly of actin in vivo is prevented by monomer sequestering proteins and capping proteins. HSP27 behaves in its unphosphorylated form as an actin cap-binding protein and can inhibit actin polymerization. Phosphorylation of HSP27, e.g. by the MAPKAPK MK2, MK3, or MK5, increases the rate and extent of actin polymerization. Protein phosphatase 2A has been shown to act as an in vivo HSP27 phosphatase (reviewed in Kostenko and Moens [106]). (c) Cofilin can increase the number of barbed ends by severing existing filaments. (d) The ARP2/3 complex allows branching of actin filaments. MK2 can phosphorylate the p16-Arc subunit of the ARF2/3 complex. (e) MK5, HSP27 and cofilin can all bind 14-3-3ε. Phosphorylated cofilin and phosphorylated HSP27 bind 14-3-3ε which protects them from dephosphorylation. MK5 may usurp 14-3-3ε, releasing 14-3-3ε from cofilin and HSP27 and subsequently allowing dephosphorylation of these proteins. Dephosphorylation of cofilin leads to activation and hence severing of F-actin, while dephosphorylation of HSP27 will prevent F-actin polymerization as depicted in (b). (f) The CapZ-CapZIP complex prevents F-actin polymerization by binding the barbed ends. MK2-mediated phosphorylation of CapZIP releases the CapZ–CapZIP complex from F-actin allowing polymerization to occur
4.3.1.2 Cofilin Another actin-binding protein whose activity may be regulated by MAPKAPs is cofilin. Cofilins are small proteins (15–20 kDa) that in their unphosphorylated (i.e. active) state increase actin dynamics by depolymerizating filaments from their pointed ends (Fig. 4.2c). They are essential regulators of actin dynamics during cell migration by severing existing actin filaments. This increases the number of available barbed (+) ends allowing rapid actin polymerization and enhances the rate of F-actin depolymerization, allowing recycling of G-actin [42, 101, 152]. Inhibition of cofilin activity in carcinoma cells either by siRNA-mediated depletion or by constitutive phosphorylation due to overexpression of the cofilin kinase LIM domain kinase (LIMK) prevented cell motility, while increased cofilin levels are detected in invasive subpopulations of tumour cells (reviewed in Wang et al. [212], Yamaguchi and Condeelis [230], and Kelley et al. [101]). These finding underscore that cofilin activity is required for invasion. The activity of cofilin is regulated by
54
A. Shiryaev et al.
phosphorylation. Phosphorylation of cofilin leads to inactivation of the protein and decreases its association with actin. In its phosphorylated state, cofilin can bind 14-3-3 proteins, thereby protecting itself from protein phosphatases (Fig. 4.2e). Phosphorylated cofilin 1 and cofilin 2 were found to interact with 14-3-3ε [123], and this prevents dephosphorylation by protein phosphatases [67]. Although cofilin 1 and 2 are not direct substrates for MAPKAPK, they may be indirectly controlled by MK5. MK5 is able to bind 14-3-3ε in vivo [199] and may thus usurp 14-3-3ε, allowing dephosphorylation and activation of cofilin 1 and 2, along with F-actin rearrangements (Fig. 4.2e). In conclusion, abnormal MK5 expression or activity in neoplastic cells may stimulate dynamic F-actin remodelling and promote cell migration through direct phosphorylation of HSP27 or/and through affecting the phosphorylation/activity state of the F-actin remodelling proteins HSP27 and cofilin by sequestering 14-3-3ε. 4.3.1.3 Arp2/3 Several other proteins involved in F-actin architecture are substrates for MAPKAPK. MK2 interacts and phosphorylates the A isoform of the p16 subunit (p16-Arc) of the actin-related protein-2/3 (Arp2/3) complex at Ser-77 [191]. As this complex controls actin nucleation and branching (Fig. 4.2d), and actin-based motility by driving the formation of lamellipodia [161, 127], MK2 may affect metastasis through phosphorylation of p16-Arc A. However, further studies are necessary in order to unequivocally determine if phosphorylation of p16-Arc by MK2 regulates cellular functions dependent on the actin cytoskeleton [191]. 4.3.1.4 CapZIP CapZ, a heterodimer composed of two subunits CapZa and CapZb, is thought to regulate actin filament assembly and organization by binding the barbed ends of the filaments [21]. CapZ-interacting protein (CapZIP) can be phosphorylated at Ser-179 and Ser-244 by MK2 or MK3 in vitro, while phosphospecific antibodies confirmed MK2/MK3-mediated phosphorylation of Ser-179 in cell culture [54]. CapZIP may thus in a phosphorylation dependent manner affect the ability of CapZ to remodel actin filament (Fig. 4.2f). Indeed, phosphorylation of CapZIP terminates actin filament elongation [194]. Hence, perturbed CapZIP phosphorylation by aberrant MK2 or MK3 activity may influence the cytoskeleton and cell migration. Experimental proof comes from studies with chemokines. These are cytokine-like proteins that regulate leukocyte transport by mediating adhesion of leukocytes to endothelial cells, initiation of transendothelial migration, angiogenesis, and tissue invasion [17, 22, 238]. Several results indicate that tumour cells during the process of metastasis might use chemokine-mediated mechanisms that are similar to those for regulating leukocyte transport [136, 137]. In particular, Muller and colleagues have shown that leukocyte chemoattractant receptor CXC chemokine receptor 4 (CXCR4) and its ligand CXC chemokine ligand 12 (CXCL12 or stromalcell-derived factor 1; SDF-1) govern the pattern of breast-cancer metastasis in a
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
55
mouse model. Binding of CXCL12 to CXCR4 receptor activates several signalling cascades, including the p38 MAPK pathway [97, 174]. Rousseau et al. [179] delineated the p38 MAPK-dependent pathway by which chemotactic agents stimulate cell migration. They found that ligand binding to the CXCR4 receptor elicits the sequential activation of PAK1/PAK2, p38α MAPK and MK2, which then may phosphorylate several substrates like CapZIP, HSP27 (3.1.1), and LSP1 (see Section 4.3.1.5). Signalling of two other chemokines, CXCL4 and CXCL10, via the CXCR3-B receptor increased the enzymatic activity of p38 MAPK and coincided with MK2-mediated phosphorylation of HSP27. The CXCR3-B isoform is the chemokine receptor responsible for inhibition of microvascular cell growth [121], and p38 MAPK is a signalling pathway downstream of CXCR3-B, that contributes to mediating the angiostatic effects of CXCL10 and CXCL4 [159]). The biological relevance of CXCL4/10-CXCR3-B-p38MAPK-MK2-HSP27 connection for metastasis remains unexplored. 4.3.1.5 Lymphocyte-Specific Protein 1 The F-actin bundling cytoskeletal protein lymphocyte-specific protein 1 (LSP1) is involved in cell migration and is a genuine MK2 substrate [95]. The gene encoding LSP1 is a breast cancer susceptibility gene [62], but whether anomalous LSP1 phosphorylation by MK2 may be a contributing event in breast cancer metastasis merits investigation. 4.3.1.6 Filamin A The cytoskeletal protein filamin A, a membrane-associated protein that cross-links actin filaments, is essential for cell locomotion [55]. Previous studies demonstrated that filamin A phosphorylation at serine-2152 is required for p21-activated kinase 1 (Pak1)-mediated membrane ruffling as mutation of this residue into alanine prevented cell shape changes. RSK1 and RSK2 can also phosphorylate filamin A at serine-2152 in vivo and elicit migration of human melanoma cells [224]. Strikingly, inhibition of RSK caused a 60% decrease in filamin A-dependent migration of human melanoma cells, while human melanoma cell lines that do not express detectable filamin A levels did not migrate [19, 224]. Hence RSK may play an essential role in cell motility and aberrant RSK expression or activation may be implicated in tumour cell invasiveness. 4.3.1.7 5-Lipoxygenase 5-lipoxygenase (5-LO) is a key enzyme in the biosynthesis of proinflammatory leukotrienes [165]. 5-LO can form complexes with cytoskeletal proteins, including actin [98] and coactosin-like protein, which is a member of the ADF/cofilin group of actin-binding proteins [166]. MK2 and probably MK3 can phosphorylate 5-lipoxygenase in vitro, and this modification potentiated the enzymatic activity of
56
A. Shiryaev et al.
5-LO [217]. However, a possible relationship between MK2/3-mediated phosphorylation of 5-LO and its interactions with the cytoskeleton, effect on cell motility, and metastasis in malignant conditions has not been established yet. 4.3.1.8 Vimentin Vimentin, a major intermediate filament protein, acts as an organizer of proteins involved in migration and cell adhesion [91]. Vimentin levels are upregulated in several tumours and RNA interference studies or the use of inhibitors and dominant-negative vimentin mutants that disrupt vimentin filaments support a role for vimentin in metastasis [79, 219]. Phosphorylation induces disassembly of vimentin and structural changes of the intermediate filament network. Although phosphorylation of vimentin may be involved in invasiveness and metastasis, the exact molecular mechanisms remain to be elucidated [90, 92, 190]. MK2 can phosphorylate vimentin at Ser-38, Ser-50, Ser-55, and Ser-82, but while phosphorylation by other kinases correlated with disassembly of vimentin filaments, phosphorylations by MK2 retained vimentin’s ability to form filament, at least in vitro [26]. The authors suggested that MK2 might work synergistically with other kinases to disrupt intermediate filaments. Whether MK2-mediated phosphorylation of vimentin kindles the invasiveness of neoplastic cells remains to be determined. Vimentin has also been shown to interact with 14-3-3ε, but the functional importance is not completely solved [184]. Hypothetically, MK5 may sequester 14-3-3ε, but the consequence for vimentin’s role in metastasis remains elusive. 4.3.1.9 Myosin Myosins are a family of motor proteins that hydrolyse ATP to drive movements along actin filaments. Myosins typically contain light chains (MLC) and heavy chains [111, 145, 187]. The MLC of myosin type II has been shown to be in vitro substrates of MK5 [144], and RSK-2 [197]. Phosphorylation of the MLC is a key mechanism for regulation of actin-myosin contractility and anomalous MLC phosphorylation may contribute to metastasis (reviewed in Olson and Sahai [149]). However, a biological implication of MK5- or RSK-2-mediated phosphorylation of MLC in metastasis remains to be determined In conclusion, aberrant activity of MAPKAPK may interfere with reorganization of the cytoskeleton and cell motility, and hence promote cell migration/metastasis.
4.3.2 MAPKAPK and Gene Regulation Some of the MAPKAPK substrates are transcription factors [5, 18, 23, 59, 205], enabling MAPKAPK to influence the expression of genes, including genes whose products are implicated in metastasis of tumour cells. MAPKAPK not only exert their effect at the transcriptional level by modulating the activity of transcription
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
57
factors, but can also regulate at the post-transcriptional levels by affecting the stability of mRNA. Examples of both mechanisms are discussed below. 4.3.2.1 E-cadherin In many primary tumours with invasive properties, intercellular adhesion is reduced, often because of the loss of E-cadherin, a critical component of cell-cell adhesive interactions [158]. E-cadherin is a calcium-dependent transmembrane protein (for recent review see Baranwal and Alahari [10]). The cytoplasmic tail of E-cadherin is tethered, via α-catenin and β-catenin, to the actin cytoskeleton. Loss of E-cadherin expression is a requisite for cell de-adhesion and migration during the epithelial to mesenchymal transition and is common in carcinomas [200]. One of the regulatory pathways of the E-cadherin expression involves MSK1. Ordóñez-Morán and colleagues have shown by the use of chemical inhibitors, dominant-negative mutants and small interfering RNA, that the activity of RhoA-ROCK, and p38MAPKMSK1 activation is necessary for the induction of CDH1/E-cadherin transcription and acquisition of an adhesive epithelial phenotype, and moreover, for the inhibition of β-catenin-TCF transcriptional activity by 1,25(OH)2 D3 (active vitamin D metabolite). They have confirmed that 1,25(OH)2 D3 increased the level of active, phosphorylated p38MAPK and MSK1 without affecting their total cellular content in colon cancer cells [150]. Furthermore, 1,25(OH)2 D3 increased phosphorylation of the transcription factors cAMP response element-binding protein (CREB) and activating transcription factor 1 (ATF1), that are MSK1 substrates [221]. Finally, the finding that knockdown of MSK1 or MSK2 by siRNA decreased the induction of E-cadherin is further evidence that these kinases mediate 1,25(OH)2 D3 action [150]. Additional studies are necessary to identify the particular role of transcription factors CREB and ATF1 in transcription of E-cadherin. 4.3.2.2 CD44 CD44 is a transmembrane glycoprotein that binds hyaluronic acid and that mediates adhesion of leukocytes and activation of T-cells [76, 141, and references therein]. CD44 is also the receptor for matrix metalloproteinase 9 (see Section 4.3.2.4) and plays an important role among other cell-cell and cell-ECM adhesion molecules employed by cancer (for review see Jothy [96]). Originally described as a protein associated with the activation and homing of lymphocytes, CD44 became relevant to metastasis by the study showing its involvement in the metastatic dissemination of pancreatic cancer cells in a rat model [71] and due to its involvement in both cell-cell and cell-ECM adhesion processes [15, 138]. Many cancer cell types as well as their metastases express high levels of CD44 [213, 232]. Robbins and coworkers proposed that in androgen-independent prostate cancer cells the ERK1/2 and p38 pathways converge to MNK1, which enhances transcription of CD44 [172]. This suggests that MNK1 may play a role in metastasis of certain prostate cancers through stimulating the expression of CD44. Further efforts are needed to describe the full pathway of CD44 transcription regulation.
58
A. Shiryaev et al.
4.3.2.3 Urokinase Plasminogen Activator The serine protease urokinase plasminogen activator (uPA), when bound to its specific cell surface receptor uPAR, initiates the activation of metalloproteinases and efficiently converts plasminogen to the active serine protease plasmin. Activated plasmin in turn initiates the destruction of various extracellular matrix proteins [154]. In particular, uPA was shown to be involved in tissue remodelling events in non-pathological conditions. For instance, a coordinated expression of uPA and uPAR is required for trophoblast implantation [102]. Substantial evidence has been obtained that uPA and uPAR are overexpressed in malignancies including breast, ovary, and prostate tumours, and this is associated with disease progression, metastasis and poor prognosis [50, 80]. MK2 can increase the expression of uPA at the post-transcriptional level [74, 83]. In their work, Huang and colleagues showed that p38 MAPK activity had little effect on uPA and uPAR promoter activities, suggesting that p38 MAPK signalling pathway is not required for uPA and uPAR transcription. However, administration of the potent p38 MAPK inhibitor SB203580 reduced the half-life of uPA and uPAR transcripts from over 12 h to 2–3 h in BT549 cells, demonstrating that p38 MAPK activity is required for the stability of uPA and uPAR mRNA [83]. It is well known that adenosine/uridine-rich elements (ARE) in 3 -untranslated region (UTR) of mRNAs can affect the stability of transcripts significantly [49]. The 3 -UTR of uPA mRNA contains a minimum ARE consensus sequence [140] and previous studies have pointed to a role of MK2 in stabilization of cytokine mRNA stability through phosphorylation/inactivation of the ARE-destabilizing protein tristetraprolin [81, 142, 223]. Using β-globin reporter gene constructs containing uPA mRNA 3 -UTR or ARE-deleted 3 -UTR, it was demonstrated that p38 MAPK/MK2 signalling pathway regulates uPa mRNA stability through a mechanism involving the ARE [74]. In conclusion, anomalous MK2 activity in tumour cells may cause enhanced uPA protein levels due to stabilization of uPA transcripts and this may promote metastasis. The observation that inhibition of p38 MAPK concomitantly reduced VEGF-induced migratory ability of human umbilical embryonic cells and uPA expression underscores the MK2-uPA link in metastasis [234]. The expression of uPA seems also to be regulated by MSK1. MSK1-induced expression occurs at the transcriptional level as a result of chromatin remodelling induced by histone H3 phosphorylation by MSK1 [195].
4.3.2.4 Matrix Metalloproteinases 2 and 9 Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that play a major role in remodelling of the extracellular matrix [134]. Aberrant MMP activity is associated with pathogenic processes, including invasion and metastasis [41]. Indeed, overexpression of many MMPs, including MMP-1, -2, -7, -9, -13, and -14 is positively associated with tumour progression and metastasis [41]. Zhang and colleagues reported that VEGF binding to its receptor Flt-1 (VEGFR-1) but not KDR (VEGFR-2) triggered the expression of MMP2 and MMP9 through the p38 MAPK/MK2 signalling pathway [236]. The fine mechanism by which MK2
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
59
influences MMP2 and MMP9 expression was not addressed, but as a consequence tumour cells with perturbed MK2 activity may be more invasive. 4.3.2.5 Transforming Growth Factor β Transforming growth factor β (TGFβ), a 25 kDa homodimeric extracellular cytokine, is an important regulator of cell adhesion and motility in a variety of cell types [189]. It contributes to tumour progression by inducing an epithelial to mesenchymal transition (EMT) and cell migration [8]. Work by Xu and coworkers showed that TGFβ signals through p38 MAPK and MK2. TGFβ-activated MK2 can phosphorylate HSP27 (see Section 4.3.1.1) and subsequently stimulate MMP2 (see Section 4.3.2.4), and promoted cell invasion in human prostate cancer [229]. The precise mechanism of MMP2 activation by HSP27 remains to be solved, but it is tempting to speculate that signal transducer and activator of transcription 3 (STAT3) is involved. STAT3 is known to be implicated in cell invasion and migration and to upregulate MMP2 transcription via direct interaction with the MMP2 promoter [228]. Moreover, HSP27 physically interacts with STAT3 [175]. A plausible scenario could be following: TGFβ activated the p38MAPK/MK2 pathway resulting in HSP27 phosphorylation. Phospho-HSP27 binds to and potentiates the transcriptional activity of STAT3, which increases MMP2 expression. Similarly, the p38 MAPK/MK2/HSP27 pathway was described for growth arrestspecific gene 6 (GAS6)-induced cytoskeletal reshuffling and migration. GAS6, which binds to the Ark (adhesion-related kinase) receptor, has growth-factor like properties [72]. Stimulation of immortalized gonadotropin-releasing hormone neuronal cells with GAS6 resulted in increased MK2 activity, HSP27 phosphorylation, and actin cytoskeletal reorganization and migration, while inhibition of p38MAPK with SB203580 or overexpression of dominant negative p38α blocked GAS6/Ark-mediated migration of cells [2].
4.3.2.6 Chemoattractant Receptors Thakur and colleagues discerned that overexpression of RSK4 in highly invasive and metastatic MDS-MB-231 breast cancer cell line resulted in significantly reduced chemotaxis against CXCL12 as well as a significantly reduced chemoinvasion together with suppression of soft agar colony formation [201]. Even more important, when RSK4-overexpressing cells or vector control cells were injected into the mammary fat pads of female SCID mice, animals injected with RSK4-overexpressing cells showed much smaller tumour size with pseudocapsule, indicative of noninvasive growth, whereas mice with vector control cells had higher volume and weight and showed penetrating growth in stromal tissue. The precise mechanism of RSK4 inhibition of invasion is not clear, but overexpression of RSK4 led to reduced expression of CXCR4 and increased expression of Claudin2 (CLDN2) proteins and vice versa after silencing of RSK4 [201]. CLDN2 is a transmembrane protein essential for tight junctions of epithelial tissue, and loss or reduced expression of it has been
60
A. Shiryaev et al.
implicated in EMT and metastasis [146]. RSK4-mediated CLDN2 expression may therefore hamper metastasis. Another chemokine receptor, CCR7, is important for lymphatic invasion of cancer cells and is overexpressed in metastatic breast cancer cells [136]. MSK1 has been shown to regulate the expression of CCR7 and to reverse the inhibitory effect of the plant steroidal lactone tubocapsanolide A on migration of MDA-MB-231 cells [153].
4.3.2.7 Human Epidermal Growth Factor Receptor 2 Human epidermal growth factor receptor 2 (HER2; also known as ErbB-2 or c-neu) is amplified and/or overexpressed in ∼20–30% of breast cancer patients [82]. Patients having elevated HER2 protein levels exhibit poor prognosis as overexpression of HER2 is associated with aggressive tumour growth and metastatic activity [88, 237]. Increased phosphorylation and activity of the MNKs correlate with HER2 overexpression in certain breast cancer cell lines, and inhibition of the MNKs reduces colony formation in soft agar suggesting that MNKs may have a role in proliferation or invasiveness of breast cancer [30]. The exact role of MNK in metastasis of HER2 positive tumours and the mechanism by which MNK regulates HER expression necessitates further investigation.
4.3.2.8 Cyclooxygenese-2 Cyclooxygenase (COX) is the rate-limiting enzyme for the production of prostaglandins and thromboxanes from free arachidonic acid. Two COX isoenzymes have been described: COX-1, which is constitutively and ubiquitously expressed, and the inducible COX-2 [100]. Mounting evidence documents increased levels of COX-2 in carcinomas of the colon, stomach, breast, oesophagus, lung, liver, and pancreas [24, 87, 147, 182]. In contrast, the levels of COX-1 are mostly similar in normal and tumour tissues [182]. Elevated expression of COX-2 and its main product prostaglandin E2 has been shown to increase tumour invasiveness and enhance metastatic potential [47, 48, 222, 233]. COX-2 is regulated by both transcriptional and post-transcriptional mechanisms. ARE within the 3 -UTR of COX2 mRNA can affect both mRNA stability and protein translation [45]. It was originally shown that COX-2 mRNA stability is regulated in part by p38MAPK pathway [78, 93]. Later studies suggest that p38MAPK-induced stabilization of the COX-2 transcripts is mediated by MK2 [196] and probably involves a similar mechanism as for uPA (described in Section 4.3.2.3). The RNA-binding protein heterogeneous nuclear ribonucleoprotein A0 (hnRNP A0) can be phosphorylated by MK2 at Ser84 in vitro and this residue became phosphorylated in LPS-stimulated cells leading to its binding to ARE and stabilization of specific mRNAs, including COX-2 [178]. Alternatively, HSP27 may be involved in COX-2 mRNA stabilization, as β-globinCOX-2 transcripts were partially stabilized by constitutively active MK2 or by a phosphomimicking HSP27 mutant [120].
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
61
Both RSK and MSK can stimulate COX-2 expression at the transcription level [52, 155]. Eliopoulos et al. showed that LPS enhanced COX-2 mRNA levels in an RSK1- and MSK1-dependent manner, while Pathal et al. demonstrated upregulation of COX-2 transcript by activation of the Toll-like receptor 2 (TLR2), and subsequent signalling through ERK and p38 MAPK which both converge to MSK1. MSK phosphorylates CREB [5], which is a key modulator of COX-2 transcription [204]. The TRL-MSK-COX-2 pathway may be relevant for metastasis because TRLs are expressed on a wide variety of tumours and TLRs activation not only promotes tumour cell proliferation and resistance to apoptosis, but also enhances tumour cell invasion and metastasis. The latter processes involves upregulating MMPs and integrins (for recent review see Huang et al. [84]), but might also involve MAPKAPK-regulated transcription of the cox-2 gene [52]. 4.3.2.9 p75NTR The p75NTR neurotrophin receptor is a member of the tumour necrosis factor family and has been identified as a metastasis suppressor [113]. Expression of p75NTR was found to be very low in metastatic human prostate cancer cell lines [113, 139], while p75NTR inhibits expression of uPA, MMP-2 and MMP-9 in the human prostate cancer PC3 cells [139]. This suggests that p75NTR may prevent metastasis by reducing the expression of uPA, MMP-2, and MMP-9. It was recently shown that siRNAmediated knockdown of MK2 or MK3 separately or together in different prostate cancer cell lines resulted in decreased p75NTR levels. The authors suggested that MK2- and MK3- mediated stabilization of p75NTR mRNA probably involves the RNA binding protein HuR [164]. Thus reduced MK2 or/and MK3 levels may promote metastasis of prostate tumour cells due to destabilization of p75NTR transcripts resulting in elevated levels of uPA, MMP-2, and MMP-9. Whether MK2 and MK3 levels are anomalous in metastasising prostate cancer cells remains to be examined. 4.3.2.10 p27KIP1 The cyclin-dependent kinase inhibitor p27KIP1 is a tumour suppressor that acts by regulating G0 to S phase transition [31]. In addition to its effects on the cell cycle, p27KIP1 can also regulate cell migration through the small GTPAse RhoA [12]. p27KIP1 was shown to bind RhoA in vitro and to prevent the interaction of RhoA with its activator guanosine-nucleotide exchange factor (GEF). This abrogated RhoA-dependent ROCK1 activation and increased cell motility [12]. The study by Larrea et al. [119] provide evidence that phosphorylation of p27KIP1 at threonine198 by RSK1 may facilitate the interaction of p27KIP1 with RhoA and reduce actin cytoskeleton stability. It would be relevant to examine the phosphorylation pattern of p27KIP1 in metastasising tumour cells overexpressing RSK. 4.3.2.11 p53 The tumour suppressor p53 is well known to prevent cancer progression by inhibiting proliferation and inducing apoptosis of tumour cells [209, 211]. In
62
A. Shiryaev et al.
addition, p53 mutations are associated with decreased E-cadherin expression and increased cancer invasiveness [16]. Several p53-mutant mouse models have been generated and tumours developing in these animals metastasize [148]. Another report showed that wild-type p53 is able to suppress cancer cell invasion by inducing MDM2-mediated Slug degradation. Slug is a member of the Snail family of transcriptional repressors, and is capable of repressing E-cadherin expression [214]. Recently, p53 was shown to be directly phosphorylated by MK5 at Ser37, leading to its activation in Ras-dependent senescence and transcriptional activation of p53 [198]. Thus MK5 may manipulate the function of p53 and e.g. enhance the expression of E-cadherin in a p53-dependent fashion, thereby affecting metastasis. It would be really interesting to clarify the possible involvement of MAPKAPK in the regulation of p53 activity linked to metastasis. In conclusion, a second major mechanism by which MAPKAPK may be implicated in metastasis is by increasing the expression of genes whose products are involved in metastasis. A direct proof for this mechanism was recently provided by a study identifying genes whose expression is controlled by RSK [46]. The authors found by the use of siRNA knockdown of individual RSKs and RSK inhibitors flm, BI-D1870 and SL0101 (see Table 4.2), that RSK1 and RSK2 affected the expression of 228 genes in epithelial cells derived from different tissues, predominantly through the transcription factor FRA-1. About 25% of the genes encoded proteins with established roles in motility and invasion such as uPA and UPAR, VEGF-1 and its receptor Flt-1, MMPs, CD44 which were discussed in this review. They also observed RSK-dependent TGFβ accumulation, a signalling molecule implicated in metastasis (see Section 4.3.2.5). In addition, upregulation of laminin322, integrins, RhoC, tubulin, actinin was monitored (a complete list is found in the supplementary data of the article by Doehn and colleagues). Enhanced expression of these proteins was confirmed in invading carcinoma cells. Moreover, ectopic expression of constitutive active RSK rendered the cells highly motile, while treatment of cells with specific RSK inhibitors or siRNA-mediated depletion of RSK1 and RSK2 greatly suppressed invasive migration [46].
4.4 Role of MAPKAPK in Tumour Angiogenesis Triggered by VEGF The growth and metastasis of solid tumours critically depends on their ability to develop their own blood supply, a process known as tumour angiogenesis [77]. Another role for MAPKAPK in metastasis derives from studies with vascular endothelial growth factor (VEGF). VEGF is a potent stimulator of angiogenesis, proliferation, migration and tubule formation of endothelial cells [56]. VEGF exerts its angiogenic effects through the receptor tyrosine kinases, which are expressed on the surface of endothelial cells, and whose activation leads to stimulation of various intracellular signalling cascades. One of these cascades comprises p38-MK2-LIMK1-cofilin that plays an essential role in VEGF-induced actin
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
63
reorganization, cell migration, and tube formation [105]. In particular, MK2, a major downstream kinase of p38, directly activated LIMK1 by phosphorylating Ser-323 in the consensus sequence motif for MK2 substrates. Moreover, depletion of MK2 by siRNA abolished VEGF induced activation of LIMK1 and inhibited endothelial cell migration. Accordingly, filopodium formation was reduced in MK2−/− macrophages compared to wild-type macrophages, and migration of MK2-deficient embryonic fibroblasts and smooth muscle cells in response to VEGF was diminished [110]. These observations support a role for MK2 in VEGF-triggered actin reorganization.
4.5 MAPKAPK Inhibitors The recognition of crucial roles for protein kinases in cancer has led to an exponential increase in the development of small specific inhibitors against protein kinases [69, 132]. The versatile roles of MAPKAPK in metastasis make them attractive therapeutic targets as an alternative or supplement to currently used drugs against cytoskeleton dynamics [133, 171]. Many compounds that have the potential to inhibit the kinase activity of MAPKAPK in cell culture studies have been described, but unfortunately most of them lack specificity and with the exception of one, none have successfully entered clinical trials (see Table 4.1). Several promising MK2 inhibitors have been identified [3,60,125], but none have entered the clinics [61]. The compounds developed by Anderson et al. [3] are highly potent against MK2 (IC50 < 10 nM) and >200-fold higher concentrations were required to inhibit the kinase activity of the MNK1, MNK2, MSK1, and MSK2 by 50%. The IC50 for MK3 and MK5 were 2–300 times higher depending on the compound, making them potential drug candidates for clinical trials. MK5 is the only MAPKAPK that is efficiently inhibited (90% inhibition with 10 μM EGCG) by the green tea compound (–) epigallocatechin gallate [6, 57]. Animal studies and aetiological studies have shown that tea consumption may reduce the risk of cancer [231]. EGCG is being tested by the Louisiana State University (Shreveport, USA) in a Phase II clinical trial to determine its inhibitory effect on c-Met signalling and activation of pathways that contribute to breast cancer progression and in Phase Ib and Phase II clinical trials with prostate cancer and lung cancer patients [33].
4.6 Future Perspectives Invasion and settlement of tumour cells is a complicated process that requires the participation of many proteins (for recent reviews see Chiang and Massagué [27], Kumar and Weaver [114], and Psaila and Lyden [163]). MAPKAPK seem to contribute to metastasis by two major mechanisms. They can stimulate the expression of genes whose products are implicated in the metastasis process, and they can phosphorylate proteins whose activities contribute to cell invasiveness and metastasis. So far, a function of MAPKAPK in the regulation of protein-encoding genes has been
64
A. Shiryaev et al.
appreciated as is outlined in this review. However, recent studies have identified microRNAs (miRNAs) with anti- or prometastatic properties (reviewed in Ma and Weinberg [126] and Dumont and Tlsty [51]). As miRNAs are RNA polymerase IIderived transcripts and their promoters share the same general features as those of protein coding genes [35], their expression may be regulated by MAPKAPK that modulate the activity of transcription factors involved in transcription of miRNAs. Consequently, MAPKAPK-mediated expression of miRNAs implicated in metastasis may present an additional putative mechanism of the involvement of MAPKAPK in metastasis. Activation of MAPK is a frequent event in tumour progression and metastasis (see e.g. [73, 85, 124, 169, 207]) but many studies are based on the use of inhibitors for either MAPK kinases (e.g. the MEK inhibitor PD98059) or MAPK (e.g. the p38 MAPK inhibitor SB203580). MAPKAPK act downstream of these kinases and therefore the possible involvement of MAPKAPK in metastasis cannot be excluded by the results obtained with these inhibitors. The use of specific MAPKAPK inhibitors may facilitate studies aimed at elucidating a causative role of MAPKAPK in metastasis. Thus MAPKAPK inhibitors may in the future be used as anti-metastatic drugs or in combination with other protein kinase inhibitors or chemotherapy that are presently being used or have entered clinical trials.
References We apologize to our colleagues whose work could not be referred due to space limitations. 1. Åberg E, Perander M, Johansen B, Julien C, Meloche S, Keyse SM, Seterens OM. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4. J. Biol. Chem. 2006; 281: 35499–35510. 2. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, Varnum B, Kandel ER, Heidenreich KA, Wierman ME. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase. Mol. Cell Biol. 2002; 22: 599–613. 3. Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J. Med. Chem. 2007; 50: 2647–2654. 4. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signaling. Nat. Rev. Mol. Cell Biol. 2008; 9: 747–758. 5. Arthur JSC. MSK activation and physiological roles. Front Biosci. 2008; 13: 5866–5879. 6. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003; 371: 199–204. 7. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007; 408: 297–315. 8. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. J. Cell. Sci. 2002; 115: 3193–3206. 9. Bamford MJ, Bailey N, Davies S, Dean DK, Francis L, Panchal TA, Parr CA, Sehmi S, Steadman JG, Takle AK, Townsend JT, Wilson DM. 1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK1-inhibitors. Bioorg. Med. Chem. Lett. 2005; 15: 3407–3411.
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
65
10. Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem. Biophys. Res. Commun. 2009; 384: 6–11. 11. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431–437. 12. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004; 18: 862–876. 13. Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R, Sette C. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 2008; 29: 2279–2288. 14. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AER, Charnock FML, Beck S, Dunham I, Mungall AJ, Ganesan TS. RPSKA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 2007; 26: 683–700. 15. Bourquignong LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin. Cancer Biol. 2008; 18: 251–259. 16. Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch. 1997; 431: 317–321. 17. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv. Immunol. 1999; 72: 209–253. 18. Buxade M, Parra-Paula JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci. 2008; 13: 5359–5374. 19. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC Jr. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am. J. Pathol. 1991; 139: 423–435. 20. Calderwood SK, Ciocca DR. Heat shock proteins: stress proteins with Janus-like properties in cancer. Int. J. Hypertherm. 2008; 24: 31–39. 21. Caldwell JE, Heiss SG, Mermall V, Cooper JA. Effects of CapZ, an actin capping protein of muscle, on the polymerization of actin. Biochemistry 1989; 28: 8506–8514. 22. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol. 2000; 12: 336–341. 23. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci. 2008; 13: 4258–4275. 24. Charles EE, Robert JC, Aramandla R, Francis MG, Suzanne F, Raymond D. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–1188. 25. Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback for Ras proliferative signaling. J. Biol. Chem. 2000; 275: 38973–38980. 26. Cheng TJ, Tseng YF, Chang WM, Chang MD, Lai YK. Retaining of the assembly capability of vimentin phosphorylated by mitogen-activated protein kinase-activated protein kinase-2. J. Cell. Biochem. 2003; 89: 589–602. 27. Chiang AC, Massagué J. Molecular basis of metastasis. New Engl. J. Med. 2009; 359: 2814–2823. 28. Cho YY, Yao K, Kim HG, Kang BS, Zheng D, Bode AM, Dong Z. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res. 2007; 67: 8104–8112. 29. Chrestensen CA, Eschenroeder A, Ross WG, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Sturgill TW. Loss of MNK function sensitizes fibroblasts to serum-withdrawal induced apoptosis. Genes Cells 2007a; 12: 1133–1140. 30. Chrestensen CA, Shuman JK, Eschenroeder A, Worthington M, Gram H, Sturgill TW. MNK1 and MNK2 regulation in HER2-overexpressing breast cancer cell lines. J. Biol. Chem. 2007b; 282: 4243–4252.
66
A. Shiryaev et al.
31. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev Cancer 2008; 8: 253–267. 32. Clark DE, Errington TM, Smith JA, Frierson HF Jr, Weber MJ, Lannigan DA. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 2005; 65: 3108–3116. 33. Clinical trials: http://clinicaltrials.gov/. 34. Cohen MS, Zhang C, Shokat KM, Tauton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005; 308: 1318–1321. 35. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS 2009; 4: e5279. 36. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 2007; 1773: 1358–1375. 37. Cuevas B, Abell A, Johnson G. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007; 26: 3159–3171. 38. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000; 351: 95–105. 39. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O’Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65: 7591–7595. 40. Davis T, Bagley MC, Dix MC, Murziani PGS, Rokicki MJ, Widdowson CS, Zayed JM, Bachler MA, Kipling D. Synthesis and in vivo activity of MK2 and MK2 substrateselective p38αMAPK inhibitors in Werner syndrome cells. Bioorg. Med. Chem. Lett. 2007; 17: 6832–6835. 41. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25: 9–34. 42. Desmarais V, Ghosh M, Eddy R, Condeelis J. Cofilin takes the lead. J. Cell Sci. 2005; 118: 19–26. 43. Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 2007; 26: 3097–3099. 44. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279–3290. 45. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3 -untranslated region. J. Biol. Chem. 2000; 275: 11750–11757. 46. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR, Winther O, Tauton J, Hansen SH, Frödin M. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 2009: 35: 511–522. 47. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem. 2001; 276: 20809–20812. 48. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett SM. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006; 66: 5338–5345.
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
67
49. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 2002; 3: 195–205. 50. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J. Pathol. 2000 ; 190: 190–195. 51. Dumont N, Tlsty TD. Reflections on miR-ing effects in metastasis. Cancer Cell. 2009; 16: 3–4. 52. Eliopoulos AG, Dumitriu CD, Wang CC, Cho J, Tsichlis PN. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002; 21: 4831–4840. 53. Erikson E, Maller JL. A Protein Kinase from Xenopus Eggs Specific for Ribosomal Protein S6. Proc. Natl Acad. Sci. USA 1985; 82: 742–746. 54. Eyers CE, McNeill H, Knebel A, Morrice N, Arthur SJC, Cuenda A, Cohen P. The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ. Biochem. J. 2005; 389: 127–135. 55. Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat. Cell Biol. 2004; 6: 1034–1038. 56. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004; 25: 581–611. 57. Folmer F, Blasius R, Morceau F, Tabudravu J, Dicato M, Jaspars M, Diederich M. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol. 2006; 71: 1206–1218. 58. Funding AT, Johansen C, Kragballe K, Iversen L. Mitogen-and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J. Invest. Dermatol. 2007; 127: 2012–2019. 59. Gaestel M. MAPKAP kinases – MKs – two’s company, three’s a crowd. Nat. Rev. Mol. Cell Biol. 2006; 7: 120–130. 60. Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem. 2007; 14: 2214–2234. 61. Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug Discov 2009; 8: 480–499. 62. Garcia-Closas M, Chanok S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin. Cancer Res. 2008; 14: 8000–8009. 63. Gerits N, Kostenko S, Moens U. In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice. Transgenic Res. 2007a; 16: 281–314. 64. Gerits N, Mikalsen T, Kostenko S, Shiryaev A, Johannessen M, Moens U. Modulation of F-actin rearrangement by the cyclic AMP/cAMP-dependent protein kinase (PKA) pathway is mediated by MAPK-activated protein kinase 5 and requires PKA-induced nuclear export of MK5. J. Biol. Chem. 2007b; 282: 37232–37243. 65. Gerits N, Van Belle W, Moens U. Transgenic mice expressing constitutive active MAPKAPK5 display gender-dependent differences in exploration and activity. Behav. Brain Funct. 2007c; 3: e58. 66. Gerits N, Shiryaev A, Kostenko S, Klenow H, Shiryaeva O, Johannessen M, Moens U. The transcriptional regulation and cell-specific expression of the MAPK-activated protein kinase MK5. Cell Mol. Biol. Lett. 2009; 14: 548–574. 67. Gohla A, Bokock GM. 14-3-3 regulates actin dynamics by stabilizing phosphorylated cofilin. Curr. Biol. 2002; 12: 1704–1710. 68. Goldman RD, Grin B, Mendez MG, Kuczmarski ER. Intermediate filaments: versatile building blocks of cell structure. Curr. Opin. Cell Biol. 2008; 20: 28–34. 69. Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 2008; 7: 391–397. 70. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S,
68
71.
72. 73. 74.
75. 76. 77. 78.
79. 80.
81.
82. 83.
84. 85. 86.
A. Shiryaev et al. Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153–158. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24. Hafizi S, Dahlbäck B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006; 273: 5231–5244. Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem. Sci. 2007; 32: 364–371. Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, Han J, Huang S. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J. Biol. Chem. 2002; 277: 48379–48385. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44–a molecule involved in leukocyte adherence and T-cell activation. Immunol. Today 1989; 10: 423–428. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nature Rev. Clin. Oncol. 2009; 6: 395–404. Hendrickx N, Volanti C, Moens U, Seternes OM, de Witte P, Vandenheede JR, Piette J, Agostinis P. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J. Biol. Chem. 2003; 278: 52231–52239. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 1996; 15: 507–525. Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology 2000; 36: 499–504. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol. Cell Biol. 2006; 26: 2399–2407. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 2004; 44: 195–217. Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinasespecific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J. Biol. Chem. 2000; 275: 12266–12272. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008; 27: 218–224. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J. Cell Sci. 2009; 117: 4619–4628. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O’Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C,
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
87. 88. 89. 90.
91. 92.
93.
94. 95. 96. 97.
98. 99.
100. 101.
102. 103.
104.
105.
106.
69
Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006; 66: 3987–3991. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl Cancer Inst. 1998; 90: 455–460. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1994; 1198: 165–184. Imajo M, Tsuchiya Y, Nishida E. Regulatory mechanisms and functions of MAP kinase signaling pathways. IUBMB Life 2006; 58: 312–317. Inagaki M, Matsuoka Y, Isujimura K, Ando S, Tokui T, Takahashi T, Inagaki N. Dynamic property of intermediate filaments: regulation by phosphorylation. BioEssays 1996; 18: 481–487. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 2007; 313: 2050–2062. Izawa I, Inagaki M. Regulatory mechanisms and functions of intermediate filaments: a study using site- and phosphorylation state-specific antibodies. Cancer Sci. 2006; 97: 167–174. Jang BC, Sanchez T, Schaefers HJ, Trifan OC, Liu CH, Creminon C, Huang CK, Hla T. Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J. Biol. Chem. 2000; 275: 39507–39515. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911–1912. Jongstra-Bilen J, Jongstra J. Leukocyte-specific protein 1 (LSP1): a regulator of leukocyte emigration in inflammation. Immunol. Res. 2006; 35: 65–74. Jothy S. CD44 and its partners in metastasis. Clin. Exp. Metastasis 2003; 20: 195–201. Juarez JG, Thien M, Dela Pena A, Baraz R, Bradstock KF, Bendall LJ. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br. J. Haematol. 2009; 145: 491–499. Kant LT, Vanderhoek JY. Mono (S) hydroxy fatty acids: novel ligands for cytosolic actin. J.Lipid Res. 1998; 39: 1476–1482. Kant S, Schumacher S, Singh MK, Kispert A, Kotlyarov A, Gaestel M. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. J. Biol. Chem. 2006; 281: 35511–35519. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm. Res. 2000; 49: 367–392. Kelley LC, Shahab S, Weed SA. Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer. Clin. Exp. Metastasis 2008; 25: 289–304. Khamsi F, Armstrong DT, Zhang X. Expression of urokinase-type plasminogen activator in human preimplantation embryos. Mol. Hum. Reprod. 1996; 2: 273–276. Kim HG, Lee KW, Cho YY, Kang NJ, Oh SM, Bode AM, Dong Z. Mitogen- and stressactivated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation. Cancer Res. 2008; 68: 2538–2547. Knauf U, Tschopp C, Gram H. Negative regulation of protein tanslation by mitogenactivated protein kinase-interacting protein kinases 1 and 2. Mol. Cell Biol. 2001; 21: 5500–5511. Kobayashi M, Nishita M, Mishima T, Ohashi K, Mizuno K. MAPKAPK-2-mediated LIMkinase activation is critical for VEGF-induced actin remodeling and cell migration. EMBO J. 2006; 25: 713–726. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol. Life Sci. 2009; 66: 3289–3307.
70
A. Shiryaev et al.
107. Kostenko S, Shiryaev A, Gerits N, Moens U.The roles of mammalian mitogen-activated protein kinases-activating protein kinases (MAPKAPKs) in cell cycle control. In: Progress in Cell Cycle Control Research. Chen KL (Ed.). Nova Science Publisher, Inc.: New York 2008; pp. 295–320. 108. Kostenko S, Johannessen M, Moens U. PKA-induced F-actin rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5. Cell Signal 2009; 21: 712–718. 109. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat. Cell Biol. 1999; 1: 94–97. 110. Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D, Lin LL, Gaestel M. Distinct cellular functions of MK2. Mol. Cell Biol. 2002; 22: 4827–4835. 111. Krendel M, Mooseker MS. Mysosins: tails (and heads) of functional diversity. Physiology 2005; 20: 239–251. 112. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol. Life Sci. 2008; 65: 3525–3544. 113. Krygier S, Djakiew D. Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int. J. Cancer 2002; 98: 1–7. 114. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009; 28: 113–127. 115. Kunda P, Baum B. The actin cytoskeleton in spindle assembly and positioning. Trends Cell Biol. 2009; 19: 174–179. 116. Kwong J, Hong L, Liao R, Deng Q, Han J, Sun P. p38alpha and p38gamma mediate oncogenic ras-induced senescence through differential mechanisms. J. Biol. Chem. 2009; 284: 11237–11246. 117. Landry J, Huot J. Regulation of actin dynamics by stress-activated protein kinase 2 (SAPK2)-dependent phosphorylation of heat-shock protein of 27 kDa (Hsp27). Biochem. Soc. Symp. 1999; 64: 79–89. 118. Lanzetti L. Actin in membrane trafficking. Curr. Opin. Cell Biol. 2007; 19: 453–458. 119. Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc. Natl Acad. Sci. USA 2009; 106: 9268–9273. 120. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell Biol. 2000; 20: 4265–4274. 121. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 2003; 197: 1537–1549. 122. Lemaire M, Froment C, Boutros R, Mondesert O, Nebreda AR, Monsarrat B, Ducommun B. CDC25B phosphorylation by p38 and MK-2. Cell Cycle 2006; 5: 1649–1653. 123. Liang S, Yu Y, Yang P, Gu S, Xue Y, Chen X. Analysis of the protein complex associated with 14-3-3 epsilon by a deuterated-leucine labeling quantitative proteomics strategy. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2009; 877: 627–634. 124. Loesch M, Chen M. The p38 MAPK stress pathway as a tumor suppressor or more? Front Biosci. 2008; 13: 3581–3593. 125. Lopes LB, Flynn C, Komalavilas P, Panitch A, Brophy CM, Seal BL. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. Biochem. Biophys. Res. Commun. 2009; 382: 535–539. 126. Ma L, Weinberg RA. MicroRNAs in malignant progression. Cell Cycle 2008; 7: 570–572. 127. Machesky LM, Insall RH. Scar1 and the related Wiskott-Aldrich syndrome protein, WASP, regulate the actin cytoskeleton through the Arp2/3 complex. Curr. Biol. 1998; 8: 1347–1356.
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
71
128. Machesky LM, Tang HR. Actin-based protrusions: promoters or inhibitors of cancer invasion? Cancer Cell 2009; 16: 5–7. 129. Maher P. p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. J. Biol. Chem. 1999; 274: 17491–17498. 130. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 2005; 171: 37–48. 131. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 2002; 27: 514–520. 132. Mikalsen T, Gerits N, Moens U. Inhibitors of signal transduction protein kinases as targets for cancer therapy. Biotechnol. Annu. Rev. 2006; 12: 153–223. 133. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin. Cancer Res. 2008; 14: 7167–7172. 134. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004; 16: 558–564. 135. Mounier N, Arrigo AP. Actin cytoskeleton and small heat shock proteins: how do they interact? Cell Stress Chaperones 2002; 7: 167–176. 136. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–56. 137. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 2001; 345: 833–835. 138. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930–935. 139. Nalbandian A, Djakiew D. The p75NTR metastasis suppressor inhibits urokinase plaminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clin. Exp. Metastasis 2006; 23: 107–116. 140. Nanbu R, Montero L, D’Orazio D, Nagamine Y. Enhanced stability of urokinase-type plasminogen activator mRNA in metastatic breast cancer MDA-MB-231 cells and LLCPK1 cells down-regulated for protein kinase C–correlation with cytoplasmic heterogeneous nuclear ribonucleoprotein C. Eur. J. Biochem. 1997; 247: 169–174. 141. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 1997; 71: 241–319. 142. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD, Holtmann H, Kollias G, Gaestel M. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 2002; 277: 3065–3068. 143. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, Kato Y, Parry GC, Han J. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J. 1998; 17: 3372–3384. 144. Ni H, Wang XS, Diener K, Yao Z. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochem. Biophys. Res. Commun. 1998; 243: 49249–49256. 145. O’Connell CB, Tyska MJ, Mooseker MS. Myosin at work: motor adaptations for a variety of cellular functions. Biochim. Biophys. Acta 2007; 1773: 615–630. 146. Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA, Kohleisen B. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol. Immunother. 2005; 54: 431–445. 147. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori N, Monden M. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res. 1999; 5: 2018–2024.
72
A. Shiryaev et al.
148. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847–860. 149. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis 2009; 26: 273–287. 150. Ordóñez-Morán P, Larriba MJ, Pálmer HG, Valero RA, Barbáchano A, Duñach M, de Herreros AG, Villalobos C, Berciano MT, Lafarga M, Muñoz A. RhoA–ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol. 2008; 183: 697–710. 151. Oshima RG. Intermediate filaments: a historical perspective. Exp. Cell Res. 2007; 313: 1981–1994. 152. Paavilainen VO, Bertling E, Falck S, Lappalainen P. Regulation of cytoskeletal dynamics by actin-monomer-binding proteins. Trends Cell Biol. 2004; 14: 386–394. 153. Pan MR, Chang HC, Wu YC, Huang CC, Hung WC. Tubocapsanolide A inhibits transforming growth factor-beta-activating kinase 1 to suppress NF-kappaB-induced CCR7. J. Biol. Chem. 2009; 284: 2746–2754. 154. Parry MA, Zhang XC, Bode I. Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem. Sci. 2000; 25: 53–59. 155. Pathak SK, Bhattacharyya A, Pathak S, Basak C, Mandal D, Kundu M, Basu J. Tolllike receptor 2 and mitogen- and stress-activated kinase 1 are effectors of Mycobacterium avium-induced cyclooxygenase-2 expression in macrophages. Biol. Chem. 2004; 279: 55127–55136. 156. Pawson T, Scott JD. Protein phosphorylation in signaling–50 years and counting. Trends Biochem. Sci. 2005; 30: 286–290. 157. Perander M, Keyse SM, Seternes OM. Does MK5 reconcile classical and atypical MAP kinases? Front Biosci. 2008; 13: 4617–4624. 158. Pérez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 2003; 112: 535–548. 159. Petrai I, Rombouts K, Lasagni L, Annunziato F, Cosmi L, Romanelli RG, Sagrinati C, Mazzinghi B, Pinzani M, Romagnani S, Romagnani P, Marra F. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int. J. Biochem. Cell Biol. 2008; 40: 1764–1774. 160. Pollard TD. The cytoskeleton, cellular motility and the reductionist agenda. Nature 2003; 422: 741–745. 161. Pollard TD, Beltzner CC. Structure and function of the Arp2/3 complex. Curr. Opin. Struct. Biol. 2002; 12: 768–774. 162. Pomérance M, Quillard J, Chantoux F, Young J, Blondeau JP. High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J. Pathol. 2006; 209: 298–306. 163. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009; 9: 285–293. 164. Quann EJ, Khwaja F, Djakiew D. The p38 MAPK pathway mediates aryl propionic acidinduced messenger RNA stability of p75NTR in prostate cancer cells. Cancer Res 2007; 67: 11402–11410. 165. Rådmark O, Werz O, Steinhibler D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci 2007; 32: 332–341. 166. Rakonjac M, Fischer L, Provost P, Werz O, Steinhibler D, Samuelsson B, Rådmark O. Coactin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc. Natl Acad. Sci. USA 2006; 103: 13150–13155. 167. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100–3112. 168. Rausch O, Marshall CJ. Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factorinduced hemopoietic cell proliferation. J. Biol. Chem. 1999; 274: 4096–4105.
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
73
169. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003; 22: 395–403. 170. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATRmediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11: 175–189. 171. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009; 35: 255–261. 172. Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer 2008; 8: 260. 173. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291–3310. 174. Robledo MM, Bartolome RA, Longo N, Rodríguez-Frade JM, Mellado M, Longo I, van Muijen GN, Sánchez-Mateos P, Teixidó J. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. 2001; 276: 45098–45105. 175. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005; 65: 11083–11093. 176. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, Telliez JB. The mitogen-activated protein kinase (MAPK)activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell Biol. 2007; 27: 170–181. 177. Ronkina N, Kotlyarov A, Gaestel M. MK2 and MK3 – a pair of isoenzymes? Front Biosci. 2008; 13: 5511–5521. 178. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J. 2002; 21: 6505–6514. 179. Rousseau S, Dolado I, Beardmore V, Shpiro N, Marquez R, Nebreda AR, Arthur JS, Case LM, Tessier-Lavigne M, Gaestel M, Cuenda A, Cohen P. Cell Signal 2006; 18: 1897–1905. 180. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 2004; 68: 320–344. 181. Roze E, betuing S, Devts C, Marcon E, Brami-Cherrier K, Pagès C, Humbert S, Mérienne K, Caboche J. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J. 2008; 22: 1083–1093. 182. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995; 55: 3785–3789. 183. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007; 401: 29–38. 184. Satoh J, Yamamura T, Arima K. The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astorcytes. Am. J. Pathol. 2004; 165: 577–592. 185. Schiller M, Böhm M, Dennler S, Ehrchen JM, Mauviel A. Mitogen- and stress-activated protein kinase 1 is critical for interleukin-1-induced, CREB-mediated, c-fos gene expression in keratinocytes. Oncogene 2006; 25: 4449–4457. 186. Schumacher S, Laass K, Kant S, Shi Y, Visel A, Gruber AD, Kotlyarov A, Gaestel M. Scaffolding by ERK3 regulates MK5 in development. EMBO J. 2004; 23: 4770–4779. 187. Sellers JR. Myosins: a diverse superfamily. Biochim. Biophys. Acta 2000; 1496: 3–22. 188. Seternes OM, Mikalsen T, Johansen B, Michaelsen E, Armstrong CG, Morrice NA, Turgeon B, Meloche S, Moens U, Keyse SM. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J. 2004; 23: 4780–4791.
74
A. Shiryaev et al.
189. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700. 190. Sihag RK, Inagaki M, Yamaguchi T, Shea TB, Pant HC. Role of phosphorylation on the structural dynamics and function of types III and IV intermediate filaments. Exp. Cell Res. 2007; 313: 2098–2109. 191. Singh S, Powell DW, Rane MJ, Millard TH, Trent JO, Pierce WM, Klein JB, Machesky LM, McLeish KR. Identification of the p16-Arc subunit of the Arp 2/3 complex as a substrate of MAPK-activated protein kinase 2 by proteomic analysis. J. Biol. Chem. 2003; 278: 36410–36417. 192. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005; 65: 1027–1034. 193. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, O’Meara S, Parker A, Tarpey P, Avis T, Barthorpe A, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Yuen ST, Nicholson AG, Lakhani S, Easton DF, Weber BL, Stratton MR, Futreal PA, Wooster R. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 2005; 37: 590–592. 194. Stossel TP, Fenteany G, Hartwig JH. Cell surface actin remodeling. J. Cell Sci. 2006; 119: 3261–3264. 195. Strelkov IS, Davie JR. Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer Res. 2002; 62: 75–78. 196. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem. 2003; 278: 37637–37647. 197. Suizu F, Ueda K, Iwasaki T, Murata-Hori M, Hosoya H. Activation of actin-activated MgATPase activity of myosin II by phosphorylation with MAPK-activated protein kinase-1b (RSK-2). J. Biochem. 2000; 128: 435–440. 198. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR III, Wright PE, Han J. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007; 128: 295–308. 199. Tak H, Jang E, Kim SB, Park J, Suk J, Yoon YS, Ahn JK, Lee J-H, Joe CO. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Cell Signal 2007; 19: 2379–2387. 200. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol. 1993; 5: 806–811. 201. Thakur A, Sun Y, Bollig A, Wu J, Biliran H, Banerjee S, Sarkar FH, Liao DJ. Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin. Cancer Res. 2008; 14: 4427–4436. 202. Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation–relevance in a mouse model of Parkinson’s disease. J. Neurochem. 2008; 105: 2039–2052. 203. Trivier E, De Cesare D, Jacquot S, Pannetier S, Zackai E, Young I, Mandel JL, SassoneCorsi P, Hanauer A. Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature 1996; 384: 567–570. 204. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int. J. Biochem. Cell Biol. 2006; 38: 1654–1661. 205. Vermeulen L, Vanden Berghe W, Beck IME, De Bosscher K, Haegeman G. The versatile role of MSKs in transcriptional regulation. Trends Biochem. Sci. 2009; 34: 311–318.
4
Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis
75
206. Vertii A, Hakim C, Kotlyarov A, Gaestel M. Analysis of properties of small heat shock protein Hsp25 in MAPK-activated protein kinase (MK2)-deficient cells. MK2-dependent insolubilization of Hsp25 oligomers correlates with susceptibility to stress. J. Biol. Chem. 2006; 281: 26966–26975. 207. Viala E, Pouysségur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. N. Y. Acad. Sci. 2004; 1030: 208–218. 208. Vicente-Manzanares M, Choi CK, Horwitz AR. Integrins in cell migration–the actin connection. J. Cell Sci. 2009; 122: 199–206. 209. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307–310. 210. Voncken JW, Niessen H, Neufeld B, Rennefahrt U, Dahlmans V, Kubben N, Holzer B, Ludwig S, Rapp UR. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J. Biol. Chem. 2005; 280: 5178–5187. 211. Vousden KH, Lane DP. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007; 8: 275–283. 212. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat. Rev. Cancer 2007; 7: 429–440. 213. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009a; 119: 1518–1530. 214. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, Yang PC. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 2009b; 11: 694–704. 215. Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Voudsen KH. HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 2005; 24: 1965–1972. 216. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruva-Feldstein J, Pelletier J, Lowe SW. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007; 21: 3232–3237. 217. Werz O, Klemm J, Samuelsson B, Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAPK kinases. Proc. Natl Acad. Sci. USA 2000; 97: 5261–5266. 218. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 2007; 19: 142–149. 219. Whipple RA, Balzer EM, Cho EH, Matrone MA, Yoon JR, Martin SS. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 2008; 68: 5678–5688. 220. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 2007; 26: 3172–3184. 221. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol. Cell Biol. 2002; 22: 2871–2881. 222. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 2000; 105: 1589–1594. 223. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Müller M, Gaestel M, Resch K, Holtmann H. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 1999; 18: 4969–4980. 224. Woo MS, Ohta Y, Rabinovitz I, Stossel TP, Blenis J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol. Cell Biol. 2004; 24: 3025–3035. 225. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108–1113.
76
A. Shiryaev et al.
226. Worch J, Tickenbrock L, Schwäble J, Steffen B, Cauvet T, Mlody B, Buerger H, Koeffler HP, Berdel WE, Serve H, Müller-Tidow C. The serine-threonine kinase MNK1 is posttranslationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells. Oncogene 2004; 23: 9162–9172. 227. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol. Cancer Ther. 2006; 5: 1935–1943. 228. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550–3560. 229. Xu L, Chen S, Bergan RS. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006; 25: 2987–2998. 230. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim. Biophys. Acta 2007; 1773: 642–652. 231. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009; 9: 429–439. 232. Yoshida S, Takahashi H. Expression of extracellular matrix molecules in brain metastasis. J. Surg. Oncol. 2009; 100: 65–68. 233. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, Yoshimura H, Majima M. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab. Invest. 2003; 83: 1385–1394. 234. Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W, Huang S. p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J. Biol. Chem. 2004; 279: 50446–50454. 235. Zhang Y, Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. Cell Mol. Life Sci. 2007; 64: 2771–2789. 236. Zhang H, Richter M, Greene MI. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol. Ther. 2003; 2: S122–S126. 237. Zhang J, Cao YJ, Li FY, Li J, Yao LB, Duan EK. Effects of fibronectin, VEGF and angiostatin on the expression of MMPs through different signaling pathways in the JEG-3 cells. Am. J. Reprod. Immunol. 2003; 50: 273–285. 238. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121–127.
Chapter 5
Grb2 and Other Adaptor Proteins in Tumor Metastasis Alessio Giubellino and Praveen R. Arany
Abstract Metastatic disease is a major source of cancer morbidity and mortality. Understanding the molecular basis of cancer metastasis will have a considerable impact on cancer therapy. We now understand that uncontrolled cell signaling is of great importance in oncogenesis and tumor progression. A major role in the assembly of signaling proteins into biochemical pathways and networks is played by adaptor proteins. In this chapter we describe specifically the role of these proteins in the process of tumor metastasis and the potential for cancer therapy. Historically considered undruggable targets, protein-protein interactions and adaptor proteins are emerging as rational and viable targets, as exemplified by the development of selective antagonist of the adaptor protein Grb2. Targeting adaptor proteins and cellular miswiring is an emerging and exciting cancer therapeutic opportunity. Keywords Adaptor proteins · Grb2 · Metastasis · Signaling
Contents 5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.2 Grb2 as a Paradigm for Adaptor Proteins in Oncogenesis and Tumor Metastasis 5.2.1 The Adaptor Protein Grb2 . . . . . . . . . . . . . . . . . . . . . 5.2.2 Grb2 in Cancer and Tumor Metastasis . . . . . . . . . . . . . . . . 5.2.3 Targeting Grb2 . . . . . . . . . . . . . . . . . . . . . . . . . . 5.3 Other Adaptor Proteins in Tumor Metastasis . . . . . . . . . . . . . . . . 5.3.1 Shc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.3.2 IRS Adaptor Proteins in Mammary Tumor Metastasis . . . . . . . . . 5.3.3 Other Grb Proteins in Oncogenesis and in Tumor Metastasis: Grb7, Grb10 and Grb14 . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . .
. . . . . . . .
78 79 79 80 82 85 85 86
. .
88
A. Giubellino (B) National Cancer Institute, National Institutes of Health, 10 Center Drive, Bldg. 10-CRC, Rm. 1W-5832, Bethesda, MD 20892, USA e-mail:
[email protected] W.-S. Wu, C.-T. Hu (eds.), Signal Transduction in Cancer Metastasis, Cancer Metastasis – Biology and Treatment 15, DOI 10.1007/978-90-481-9522-0_5, C Springer Science+Business Media B.V. 2010
77
78 5.3.4 Nck1 and 2 in Cell Motility and Invasion . 5.3.5 CRK and CRKL . . . . . . . . . . . . 5.3.6 NEDD9 in Melanoma and Other Cancers 5.4 Conclusions . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . .
A. Giubellino and P.R. Arany
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
. . . . .
89 90 91 92 93
5.1 Introduction Metastasis, although the most relevant and important clinical process in oncology, remain the least understood at the molecular level [21]. Despite progressive advancement in our understanding and in the treatment of cancer over the last decade, a total of 1.6 million new cases of invasive cancer are expected in the United States in 2009 and around 600,000 cancer deaths will occur, primarily due to metastatic disease [54]. Patients with metastatic disease have far less favorable survival rates when compared with tumors discovered and treated when are still confined to the primary site of occurrence. Furthermore, metastasis can insidiously appear many years after the primary tumor is removed or treated, due to the presence and growth of undetectable micrometastasis. The reported statistics highlight the substantial need for therapies targeting specifically and preventing this unrelenting disease. Current cancer treatments focus on killing the greatest number of tumor cells using cytostatic agents and targeted therapies, but these regimens offer only sporadic success, with frequent relapse. Thus, to improve survival rates for most cancers, more effective ways of treating micrometastatic disease are required. These improvements will emerge from a better understanding of the molecular basis of metastatic disease. Metastasis is a multistep process [38] in which cells from the primary tumor have to remodel cell-matrix adhesions, detach, became motile and migrate through the extracellular matrix to reach newly formed blood vessels (angiogenesis) and access the blood stream to reach distant sites through extravasation to a new location where proliferation can begin again. A number of signaling pathways are involved in this process. Blocking any stage of this process can potentially be an effective strategy to block the entire chain of metastatic events. Human proteins are typically composed of structural sub-domains that are linked in various combinations into distinct proteins and the thorough understanding of the combination of these domains in multiprotein ensembles is a major challenge to understanding cell signaling and complex biological functions and diseases [100, 101]. The detailed mechanisms that govern multiple protein-protein interactions in the formation of large signaling complexes, and how the pharmacological inhibition of those interactions interfere with complex formation, in a physiological context and in disease, are just beginning to be understood. A major role in the assembly of signaling proteins into biochemical pathways and networks is played by adaptor proteins [98]. Adaptor proteins mostly function as flexible molecular scaffolds that mediate protein-protein interactions. Consequently, they are critical players in highly controlled cellular processes due to their ability
5
Grb2 and Other Adaptor Proteins in Tumor Metastasis
79
to simultaneously interact with multiple effectors downstream of activated surface receptors. Although adaptors themselves do not contain any enzymatic or other direct effector function, they are often responsible for bringing effectors into close proximity to their targets. Specificity of such processes is achieved by the particular type of protein binding domains within the adaptor protein, the specific recognition of amino acid sequences in target proteins, the subcellular localization and proximity to the binding partners, and by their post-translational modifications. Moreover, many enzymatically active proteins also contain modular domains that allow them to serve as scaffolding proteins, performing additional functions as adaptor proteins. For example, the proto-oncogene c-Src can affect adhesion [14] and migration [58] by a kinase-independent mechanism; these observations suggest that in tumors where Src expression and activity is often deregulated, strategies to block the adaptor function of Src should be considered alongside inhibition of kinase activity [120]. Adaptor proteins are attractive and tractable molecular targets for therapy in a number of diseases, including cancer. Several reports have pointed out a critical role for adaptor proteins, including Shc [139], Grb2 [42], Nck [134] and Crk [9], in oncogenesis and cancer progression, and some adaptors have been identified among essential genes in cancer [75]. In chronic myelogenous leukemia, for example, Grb2 and CrkL are core components of the interaction network centered on the molecular hallmark Bcr-Abl fusion protein [14] and disruption of Src-homology 2 (SH2) and Src-homology 3 (SH3) domain interactions could have therapeutic potential [56]. SH2 and SH3 domains are common elements in signal transduction proteins, including proteins clearly linked to human diseases, and many of them would be novel targets for cancer therapy. SH2 domains recognize specific phosphotyrosylcontaining sequences on intracellular proteins, with additional flanking amino acid contacts responsible for generating selective binding. SH3 domains binds to prolinecontaining motifs, which often form a poly-proline type II helix (PPII) with a PxxP core consensus motif, but a growing number of binding motifs that do not fit this simple consensus motif has been reported. Other domains play a major role in cell signaling, including PH and PDZ domains. For a thorough list and description of such domains and their role in signal transduction, we refer the reader to more detailed resources [55, 100].
5.2 Grb2 as a Paradigm for Adaptor Proteins in Oncogenesis and Tumor Metastasis 5.2.1 The Adaptor Protein Grb2 The Growth Factor Receptor bound protein 2 (Grb2) is a widely expressed adaptor protein that is essential in several oncogenic signaling pathways. It has a modular structure with one Src homology 2 (SH2) domain and two SH3 domains [74].
80
A. Giubellino and P.R. Arany
Through its SH2 domain, which is a conserved sequence of 100 amino acids, Grb2 can interact directly with receptor tyrosine kinases, such as the epidermal growth factor receptor (Egfr), the hepatocyte growth factor receptor (Met) and the vascular growth factor receptor (Vegfr), and non-receptor tyrosine kinases, such as focal adhesion kinase (FAK) and Bcr/Abl [32]. The phosphopeptide motif pYXNX (where N is asparagine and X any residue) is the minimal requirement for Grb2 SH2 domain binding. The two carbonyl and amino-terminal Src homology 3 (SH3) domains, which have a conserved sequence of around 50 amino acids, bind proline-rich regions within interacting proteins. The grb2 gene is located on chromosome 17, in a region that is known to be duplicated in leukemias and solid tumors [50]. Grb2 is critical in development [20] and knock-out mice die at a very early embryological stage. To investigate the role in development, Pawson’s group has devised a hypomorphic allele strategy [113] which has shown that Grb2 is critical for epithelial morphogenesis and for processes such as cell motility and vasculogenesis. The canonical model of Grb2 function relies on the widely confirmed observation that Grb2 SH3 domains are constitutively associated with Sos1, a guaninenucleotide exchange factor that promotes GDP–GTP exchange on Ras. Upon growth factor receptor activation and tyrosyl phosphorylation, Grb2 brings Sos1 into close proximity of membrane-bound Ras, thereby activating Ras and the downstream MAPK cascade, a well-know oncogenic signaling convergence point [137]. Interactions with several other proteins connect Grb2 with numerous downstream pathways as discussed below.
5.2.2 Grb2 in Cancer and Tumor Metastasis The role of Grb2 in cancer extends beyond its role as a receptor proximal intermediate in several oncogenic signaling pathways. In chronic myelogenous leukemia (CML), the chimeric Bcr-Abl tyrosine kinase oncoprotein is able to bind the Grb2 SH2 domain through Y177 in the BCR region, linking the fusion protein to the Ras pathway [102]. Inhibition of the ATP binding site of the Abl tyrosine kinase with small molecules, such as Imatinib, is currently the standard of care, but inhibition of Grb2 could become a valid adjuvant therapy or an alternative in patients resistant to other treatments. Several reports have outlined the overexpression of Grb2 in various solid tumors. In breast cancer, in addition to its role as a proximal mediator of ErbB2/Neu signaling, Grb2 itself was found to be overexpressed in several breast cancer cell lines and breast cancer tissue samples [26, 141]. Grb2 is also important in polyomavirus induced mammary carcinoma, and grb2 gene dosage is rate limiting for the onset and development of mammary carcinomas [113], highlighting its critical role in the transformation process. Grb2 is involved in keratinocyte growth factor (KGF) induced motility in MCF-7 breast cancer cells [156] further suggesting that Grb2 can be a valid therapeutic target for pathological processes such as the spread of solid tumors through local invasion and metastasis. In the highly metastatic
5
Grb2 and Other Adaptor Proteins in Tumor Metastasis
81
cancer cell line 1-LN, Grb2 was one of the effector proteins significantly induced, together with Sos1, Shc and Raf1, through activation of the α2 -macroglobulin receptor [86]. Another group, using immunohistochemical analysis of tissue microarray from more than one thousand specimens, has reported the overexpression of Grb2, together with overexpression of Her2, in gastric carcinoma, specifically with an increase of Grb2 expression in primary cancer and nodal metastasis when compared with normal gastric mucosa [155]. Moreover, Grb2 overexpression was associated with poor survival rates, supporting a role for Grb2 in tumor cell aggressiveness. The same group has previously investigated Grb2 expression in colorectal cancers and found a significant increase in specimens derived from metastatic lesions [154]. The contribution of Grb2 to tumor cell dissemination is outlined by the several direct and indirect interactions of Grb2 with molecules involved in cytoskeleton remodeling, motility and other cellular processes recapitulated in the multistep cascade of cancer metastasis. In the early phase of the metastatic process a change occurs in the adhesion properties of potentially metastatic cells [18]. Several stimuli, such as those mediated by integrins, can induce FAK autophosphorylation, creating docking sites for proteins containing SH2 domains, including Src. Src can also activate FAK and promote phosphorylation on other tyrosine residues; one of these residues, Y925, occurs within a consensus sequence (pYXNX) for high affinity binding to the SH2 domain of Grb2 [115]. Interestingly, elevated Src activity, as observed during colon cancer progression, specifically promotes phosphorylation on tyrosine Y925, inducing changes in integrin adhesion and deregulation of E-cadherin [5], leading to an E-cadherin/N-cadherin switch [48]. This event is part of an important hallmark of cell transformation and metastasis, namely epithelial-mesenchymal transition (EMT). The interaction of Grb2 with FAK, Shc and other proteins also leads to activation of the Ras and ERK2 pathways; integrin engagement of these pathways induces cell spreading through actin cytoskeleton rearrangement. Indeed, one of the differences between ERK2 pathway activation by growth factor receptors versus via integrin receptor is that the latter requires a functional actin cytoskeleton to signal, while growth factor receptors can signal even when the actin microfilaments are disrupted by cytochalasin D, a potent inhibitor of actin polymerization [88, 116]. Grb2 interacts directly with the actin filament machinery. The interaction with WASp [121], a regulator of actin cytoskeletal rearrangement, is a well documented example. Binding of WASp with Grb2 may result in translocation of WASp from the cytosol to the plasma membrane, where it can interact with membrane bound proteins such as Rac and Cdc42 [2]. Furthermore, Grb2 links the EGF receptor to WASp protein constitutively and this interaction is enhanced upon EGF stimulation. WASp at the membrane also interacts with Nck [114], and together with Grb2, cooperatively stabilizes the actin-nucleating complex. So Grb2 and Nck, both SH2 and SH3 domain containing proteins, can link membrane receptors and membrane-bound proteins to intracellular cytoskeletal regulators, increasing their local concentrations at the membrane and facilitating enzymatic reactions and activation. Several migratory signaling pathways from the cell surface converge on the p21activating kinases (PAKs), which consequently translocate to the leading edge of the
82
A. Giubellino and P.R. Arany
cell and contributes to motility and invasion. Activation of PAKs and translocation to the plasma membrane are processes that involve the interaction with adaptor proteins such as Nck and Grb2. PAKs are important regulators of actin cytoskeletal dynamics and the role of PAKs in cancer has been widely reported in literature. Interestingly, PAK can directly and specifically interact with Grb2 through a prolinerich motif in the PAK sequence [105]. This interaction is independent of EGF stimulation, but it is increased after stimulation of the EGF receptor and EGFRGrb2-PAK1 interaction is required for EGF induced lamellipodia formation. The complexity of Grb2 involvement in actin-based cell motility is highlighted by the growing list of interacting cytoskeletal proteins, including cortactin [23] promoting the formation of lamellipodia. Cortactin is associated with an invasive phenotype, formation of invadopodia and secretion of MMPs, favoring the spread of cancer cells through tissue [22, 148]. The number of Grb2 interacting proteins involved in the actin and tubulin cytoskeleton is continuously increasing, reinforcing the idea that Grb2 is playing a fundamental role in this context. Many of the pathways in which Grb2 is involved are important in the formation of novel vessel through angiogenesis and lymphangiogenesis. Several growth factors such as VEGF, angiopoietin-1, FGF2 and HGF contribute to the development of new blood vessels in physiologic and in pathological conditions, such as tumor angiogenesis. The vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2/KDR) is phosphorylated in response to its ligand, VEGF-A, which is secreted by many tumor cells, and this activation lead to the direct recruitment of Grb2, Shc and Nck [65]. This occurs also for the VEGF receptor 3 (FLT4L). Besides the direct interaction, Grb2 can also bind indirectly through the intercession of Shc [39]. Other signaling pathways such as those driven by angiopoietin-1 and Fibroblast growth factor-2 (FGF-2) also stimulate angiogenesis through direct and indirect interaction with Grb2, via intermediate proteins such as the FGF receptor substrate 2, Gab1 and Shc [123, 131]. Another mediator of angiogenic signaling is HGF, primarily through direct effect on vascular endothelial cells. Several HGF-driven cellular events in tumor angiogenesis require the activation of multiple signaling for which Grb2 has been demonstrated to be a key intermediate [109, 110]. Besides its role as a critical effector protein in focal adhesion platforms, phosphorylation of FAK through Y925 and Grb2 binding is involved in tumor neo-vascularization. Indeed FAK activation and consequent binding to Grb2 within tumor cells induce the expression of VEGF; elevated VEGF production in tumor cells stimulate cell motility and survival of endothelial cell, without affecting cell proliferation [87]. Moreover, previous studies have demonstrated that hypoxia conditions, like those experienced inside tumors, is able to increase phosphorylation of FAK with consequent Grb2 binding [118].
5.2.3 Targeting Grb2 Several efforts to selectively disrupt the intracellular network of Grb2 confirm the importance of this adaptor protein in several oncogenic signaling pathways. The
5
Grb2 and Other Adaptor Proteins in Tumor Metastasis
83
peculiar structure of the SH2 domain of Grb2 has been the focus of intensive studies in an effort to synthesize selective antagonists. Compared with other proteins containing similar domains, the SH2 domain of Grb2 invariably prefers an asparagine at the second position downstream of the phosphotyrosine (pY+2) and requires the ligand peptide to adopt a β-bend configuration [62]. The basis of these requirements became clear when the structure of Src and Grb2 proteins became available for comparison. For the Src kinase, the peptide that binds the SH2 domain has a linear configuration because it allocates in a broad pocket that is open and elongated, while the peptide sequence that binds to the Grb2 SH2 domain is forced into a much deeper pocket and this explain the sequence requirement at pY+2 and the β-bend configuration. Using short phosphotyrosine containing peptides as starting platforms, several potent, cell permeable and phosphatase-resistant compounds have been developed over the last decade. To confer phosphatase resistance the phosphotyrosyl residue has been substituted by phosphonomethyl phenylalanine (Pmp) residue, or similar structures [18]; another approach was to use non-phosphate containing ligands [153]. More recently, Song et al. [126] reported the synthesis of potent inhibitor free of phosphotyrosine or any phosphotyrosyl mimetic, demonstrating that complete replacement of the phosphotyrosyl residue can be accomplished without significant loss of binding affinity. High affinity compounds, able to block EGFR-Grb2 interactions in intact cells [40] were derived through systematic and stepwise substitution of the backbone motif pYxN and mimicking the β-turn conformation. Starting from this platform, potent peptidomimetic inhibitors of SH2 domain interactions have been developed [15, 78]. Macrocyclization to stabilize the β-turn conformation and other modifications have been identified that increase inhibitor affinity and the potential for cell membrane penetration [17]. Using synthetic binding antagonists of the Grb2 SH2 domain, Atabey et al. [3] demonstrated their potent blockade of HGF-stimulated cell motility, matrix invasion, and branching morphogenesis in epithelial and hematopoietic target cell models. The same compounds, without affecting HGF-stimulated mitogenesis, was able to inhibit angiogenesis and vasculogenesis [127]. Testing of a prototypical antagonist in two aggressive tumor models revealed inhibition of tumor metastasis without affecting primary tumor growth in vivo, thus highlighting the critical role of the Grb2 adapter function in motility, invasion and the spreading of solid tumors [41]. The ligand binding surface of the SH3 domains of Grb2 have also been recognized as an important therapeutic target. The ligand of these SH3 domains typically occupies two pockets with two hydrophobic prolines, while a third pocket frequently interacts with basic residues, in a so called polyproline-2 (PPII) conformation [61]. The same conformation is recognized by other proline-recognizing modules such as WW and profilin domains [61], and this similarity has been the subject of several studies to better understand the selectivity of SH3 domains for target proteins. The importance of conformation over sequence for SH3 domain ligand recognition is also gaining acceptance. Although SH3 domains have long been thought to bind
84
A. Giubellino and P.R. Arany
preferentially to proline rich sequences of the form PXXP in target proteins, several exceptions to this rule have been found [82]. For example, the SH3 domains of Grb2 have also been found to bind a RXXK core consensus motif [8]. Despite doubts regarding low binding affinities reported for SH3/target protein interactions and the basis for SH3 domain selectivity [143], several progress has been made in the development of SH3 domain antagonists [34]. For Grb2 in particular, SH3 domain target selectivity may be increased through two mechanisms, one intrinsic to the SH3 domains themselves and the other through their context in an SH2 domain containing protein. For example, both Grb2 SH3 domains may interact simultaneously with different sites on a single target molecule, e.g. SOS1, thereby increasing both the apparent affinity and selectivity of Grb2-target interaction [82]. Because the Grb2 SH2 domain restricts Grb2 subcellular localization, the pool of potential SH3 domain binding partners is also likely to be limited, further increasing their apparent selectivity. Screening short peptide libraries for peptides binding the SH3 domains of the Caenorhabditis elegans Grb2 homolog Sem-5 yielded a bivalent peptide ligand with nanomolar affinity [36]. Pak1-derived peptides encompassing proline-rich sequences in that protein were found to specifically disrupt Grb2 SH3 domain-Pak1 interactions with relevant impact on growth factor mediated migration and lamellipodia formation [105]. Non-natural amino acids analogs have been substituted at the proline-requiring site of Grb2 SH3 domain ligands [92]. These have provided peptides with nanomolar affinity and reinforced the concept that proline residues may be dispensable in the design of SH3 domain binding antagonists. An adaptation of the target peptide screening approach in developing SH3 domain binding antagonists has been to systematically introduce point mutations in target peptide sequences. High affinity peptides capable of blocking the proliferation of primary blast cell cultures derived from patients with chronic myelogenous leukemia (CML) and Bcr/Abl positive cell lines have been developed using this strategy [59]. Subsequent modifications of these peptides to improve their ability to permeate cells yielded agents that more potently disrupted Grb2 signaling complexes in CML-derived cells [60]. These preclinical studies support the concept that Grb2 SH3 domain binding antagonists could provide a therapeutic alternative for CML patients developing resistance to standard treatments [35]. Enhancing the affinity and selectivity of artificial SH3 domain binding antagonists by exploiting the existence of two SH3 domains in Grb2, dimeric peptides with high affinity binding to both SH3 domains of Grb2 have been designed with the goal of disrupting Grb2-SOS1 interactions [24]. These “peptidimers” inhibited cell growth in vitro and displayed anti-tumor effects in xenograft models, and thus represent the first examples of in vivo activity for this class of compounds [44]. Introducing N-alkylated residues into both monomers of the peptidimer and optimizing the linker improved the affinity for Grb2 to the subnanomolar range [142]. Finally, non-peptidic small molecule inhibitors have also been explored. The first example is the Src signal transduction inhibitor UCS15A that disrupts several SH3 domain mediated interactions, including those of Grb2 [95]. Although target selectivity remains to be improved, this and similar chemical structures may provide
5
Grb2 and Other Adaptor Proteins in Tumor Metastasis
85
a platform for the development of small synthetic drugs that potently antagonize specific SH3 domain binding interactions. Further studies are necessary to refine our understanding of the complexity of Grb2 signaling and to better understand how Grb2 is linked to tumor metastasis in different tumor types. A promising and powerful strategy to explore target protein selectivity and mechanism of action of these compounds is the synthesis of tool compounds (e.g. modified with chemical tags, such as biotin) [43]. This and other strategies, such as the use of microarrays for the global analysis of gene expression profiles, will be extensively used to develop pharmacodynamic markers of drug action, a high priority in any modern drug development effort.
5.3 Other Adaptor Proteins in Tumor Metastasis In addition to Grb2, several other adaptor proteins have been reported to be important for triggering tumor formation and metastasis. Some of the most frequently involved in these processes will be summarized as follows.
5.3.1 Shc The role of the adaptor protein Shc (Src homology and collagen homolog) in tyrosine phosphorylation signaling pathways is well recognized. Three shc genes are known in mammals: ShcA (which is ubiquitously expressed), ShcB and ShcC (whose expression is limited to neuronal cells) [76]. The ShcA gene encodes three proteins which are produced by different promoter usage (p66) or by alternative translational initiation (p46 and p52). The modular architecture of the ShcA protein contains two distinct domains that bind phosphotyrosine containing sequences: an amino-terminal PTB domain and a carboxy-terminal SH2 domain. Human ShcA also has a central collagen homology 1 (CH1) domain with three tyrosine phosphorylation sites that transduce both Ras/MAPK-dependent (specifically recruiting the Grb2/Sos1 complex) and independent signals. The 66 kDa isoform of ShcA contains an additional amino-terminal CH-like region (CH2) [107]. Beside activation by several growth factor, cytokine, G-protein coupled and hormone receptors, Shc has been linked in transformation by Polyoma middle T antigen [16] and Bcr/Abl [104], and its hyperphosphorylation has been described in many different type of tumors [10, 130]. The involvement of ShcA in the regulation of cell proliferation, cell survival and angiogenesis clearly imply a role for this adaptor protein in tumorigenesis and cancer progression. In human breast cancer, where around one third of the patients have ErbB2/Neu overexpression or amplification, ShcA binding site on ErbB2 must be retained for transformation [28]. Similarly, several transgenic mouse models have suggested an important role for ShcA during mammary tumorigenesis. For example, mutation of the ShcA binding site